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Abstract 
Proteins are the structural supports, signal messengers and molecular 
workhorses that underpin living processes in every cell. Understanding when and 
where proteins are expressed, and their structure and functions, is the realm of 
proteomics.  Mass spectrometry (MS) is a powerful method for identifying and 
quantifying proteins, however, very large datasets are produced, so researchers rely 
on computational approaches to transform raw data into protein information.  This 
project develops new bioinformatics solutions to support the next generation of 
proteomic MS research.   
Part I introduces the state of the art in proteomic bioinformatics in industry and 
academia.  The business history and funding mechanisms are examined to fill a 
notable gap in management research literature, and to explain events at the sponsor, 
GlaxoSmithKline.  It reveals that public funding of proteomic science has yet to come 
to fruition and exclusively high-tech niche bioinformatics businesses can succeed in 
the current climate.  Next, a comprehensive review of repositories for proteomic MS 
is performed, to locate and compile a summary of sources of datasets for research 
activities in this project, and as a novel summary for the community.  Part II 
addresses the issue of false positive protein identifications produced by automated 
analysis with a proteomics pipeline.  The work shows that by selecting a suitable 
decoy database design, a statistically significant improvement in identification 
accuracy can be made.  Part III describes development of computational resources 
for selecting multiple reaction monitoring (MRM) assays for quantifying proteins 
using MS.  A tool for transition design, MRMaid (pronounced „mermaid‟), and 
database of pre-published transitions, MRMaid-DB, are developed, saving 
practitioners time and leveraging existing resources for superior transition selection. 
By improving the quality of identifications, and providing support for 
quantitative approaches, this project brings the field a small step closer to achieving 
the goal of systems biology.  
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1.1 Proteomics is the large-scale study of proteins 
Proteomics is the science concerned with understanding the role of protein 
molecules in biology, such as their function in maintaining health, causing disease 
and in development and ageing.  Proteomics techniques aim to measure and 
characterise proteins present in cells, tissues or whole organisms under a set of 
defined conditions, at a particular point in time.   
 
Protein molecules underpin living processes in every cell in every organism on 
Earth.  They provide cellular machinery to maintain life providing structural 
supports, acting as signal messengers/transducers and reaction catalysis.  Proteins 
are polymers, since they consist of many individual amino acids molecules 
covalently bonded together into long chains.  The chemical/physical properties of 
the amino acids in the chain, their position, and the cellular environment of the 
protein act together to determine how the final protein will fold up into its final 3D 
structure.  The resulting structure dictates the functional role of the protein, how it 
interacts with other biomolecules, where it is located, and the substrates it can bind. 
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Proteomics involves characterising the „proteome‟: the complete set of proteins 
expressed in a specific tissue, organ or cell type.  Unlike the genome, a DNA 
molecule that is a static string of nucleotides from birth to death, the proteome is 
highly dynamic, since proteins carry out virtually all cellular functions and respond 
to constantly changing intra- and extracellular environments.   
 
Indeed, it is estimated that there are 20,488 genes that encode proteins in the human 
body (Table 1), but the real size of the proteome depends on the measure taken; for 
example, if all splice variants are taken into account, the number of distinct proteins 
is estimated to be over 200,000 (Table 1).   
            
Table 1 Estimates of the total number of human proteins.  Data taken from (Uhlen and Ponten, 2005, 
Clamp et al., 2007)   
 
This huge variation in the composition is dependent on the individual‟s state of 
health and age, gender, as well as on genetic differences, such as race, mutations, 
and other factors.  Consequently, proteomics research (at least for now) must focus 
on characterising proteomes of very specific samples under well-defined conditions.  
Description Number of proteins 
If one protein is counted for each gene locus 20,488 
If protein fragments (such as splice variants) are counted >200,000 
If proteins that differ in post-translational modifications are counted <100,000 
If proteins that differ by small genetic variations (such as single 
nucleotide polymorphisms) 
>75,000 
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The word „proteomics‟ is an „umbrella‟ term that refers to a diverse array of 
experimental approaches; each employing its own set of niche technologies (Figure 
1).  For example, proteomics research can involve structural studies, interactomics 
and identification/ quantification of proteins using mass spectrometry (MS).   
 
The benefit of proteomics is that it is a direct method.  Compared to indirect 
measurements, such as gene expression analysis via DNA microarrays, for example, 
proteomics can reveal real changes in proteins themselves.  It is proteins that carry 
out the vast majority of functional and structural roles in cells, not the genetic 
information that underlies them. 
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Examples 
Proteins are 
chains of 
many amino 
acids, where 
the protein 
folds into a 
3D shape 
using 
molecular 
forces 
(interactions) 
between the 
amino acids, 
such as 
electrostatic 
forces.  
When there 
are amino 
acid changes 
in critical 
sites, such as 
in the active 
site of an 
enzyme, or 
in a 
structurally 
important 
region, there 
can be 
profound 
consequences 
for the 
protein‟s 
shape and/or 
function. e.g. 
Heparin 
protein, 
when lysine 
becomes  
glutamate 
(position 
531), it 
causes an 
interruption 
Modifications to 
amino acids can 
affect the 
protein‟s 
function.  e.g. 
modifications 
can change 
proteins so that 
they are no 
longer 
recognised as 
„self‟ and can 
result in attack 
by the body‟s 
own immune 
system, for 
example in 
rheumatoid 
arthritis 
(Anderton, 
2004).  
Modifications, 
such with a 
phosphate, are 
required to 
switch proteins, 
such as kinase 
enzymes, on 
and off in 
signalling 
cascades in 
cells; cigarette 
smoke has been 
shown to affect 
phosphorylation 
in proteins and 
may play a role 
in 
cardiovascular 
disease 
aetiology in 
smokers 
(Edmiston et al., 
2009). 
3D structures 
of proteins 
can reveal 
mechanisms 
of protein 
action.  e.g.  
bacterial 
proteins for 
motility (for 
understanding 
infection); 
characterising 
viral and host 
receptor 
proteins; for 
cancer 
antigens (such 
as p53); ion 
pumps and 
channels (for 
understanding 
regulation of 
heart beat); 
transporter 
proteins (how 
drugs are 
transported 
into and out 
of cells); 
enzyme active 
sites, such as 
in cytochrome 
P450 (how 
drugs are 
detoxified by 
the body).  
Drug design 
can exploit 3D 
structures for 
designing 
suitable drug 
molecules that 
will bind to 
protein 
Levels of 
specific 
proteins in 
samples 
taken from 
individuals 
can be used 
to indicate 
disease or 
health.  
Proteins 
measured in 
this way are 
referred to as 
„biomarkers‟.  
e.g. 
measuring 
levels of 
proteins, 
such as 
insulin-like 
growth factor 
protein in 
blood, is a 
way to detect 
illegal doping 
in athletes 
(Kay et al., 
2009).  
Furthermore, 
protein 
expression 
studies are a 
direct way of 
measuring 
what is 
happening in 
cells, so it is 
generally a 
more robust 
way to 
demonstrate 
to the 
regulators 
Determining 
interactions 
between 
proteins, 
peptides and 
other 
molecules 
allows a 
network of 
bio-molecules 
to be 
constructed, 
giving a 
wider picture 
of the biology 
of a system.  
This can be 
useful for 
predicting 
side effects of 
new drugs, 
or toxicity, 
for example.  
Proving that 
a particular 
protein binds 
another has 
been crucial 
for working 
out what 
happens in 
cell 
signalling.  
e.g. signalling 
cascade 
investigations 
have  shown 
cellular 
proliferation 
and  
apoptosis 
(cell death) 
are involved 
in cancer 
When the 
function of a 
protein is 
known, then 
its role in 
maintaining 
health or 
causing 
disease can 
be leveraged 
to design new 
or improved 
medicines.  
Insulin is a 
simple 
example: it is 
a protein that 
lowers the 
level of 
glucose in the 
blood.  Once 
its function 
was 
established it 
was exploited 
to treat 
patients with 
diabetes. In 
other cases, 
knowing 
which 
proteins are 
involved in 
causing a 
disease 
means 
researchers 
have a target 
for new 
medicines; 
e.g. if a 
particular 
protein 
causes a 
Bioinformatics 
can be for 
data analysis, 
data storage, 
algorithm 
design and 
routine 
infrastructure.  
e.g. some 
proteomics 
software, such 
as Mascot 
Distiller and 
X-Tracker, 
can compute 
the quantities 
of proteins in 
samples by 
extracting 
peak areas 
from MS 
spectra, or by 
automating 
spectral 
counting. 
Also, 
automated 
software 
pipelines can 
extract 
peptide 
identifications 
from 
hundreds of 
spectra in a 
single run.  
Public 
databases for 
storing 
protein data 
for the 
community 
are being 
developed and 
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Figure 1 The Proteomics Umbrella.  „Proteomics‟ describes any large-scale approach taken to investigate 
the function and properties of proteins (biology‟s molecular machines).  The „proteome‟ is the entire 
complement of proteins expressed at any one time, in a particular system, cell type or tissue under 
defined conditions, and it can be examined from very different angles to answer very different questions.  
To reflect the diversity of research activities undertaken, proteomics can be split into separate branches 
of research with its own specific toolbox of experimental approaches and methods.  The broad categories 
shown are not mutually exclusive and there are activities which do not fit in those areas shown here.  One 
of the main aims of proteomics is to discover which proteins indicate a disease state or susceptibility to a 
disease, so-called protein biomarkers.  These can be used for designing new drugs and in some cases can 
prove useful for demonstrating to the regulators that a drug works.  (Source: authors own summary)     
 
1.1.1 Proteomic mass spectrometry is an approach used for biomarker 
discovery 
The current arsenal of drugs that the pharmaceutical industry offer target only 
several hundred or so distinct proteins. Through proteomics approaches, however, 
the potential to expand on this number was widened dramatically.  Indeed, as a 
field, proteomics has grown rapidly in the last decade (see Figure 2); in the late 1990s 
to 2000s, for example, academic researchers and biotech/pharmaceutical companies 
became particularly interested in a high-throughput approach for identifying 
proteins in biological samples, namely MS-based proteomics.  This was because it 
offered a new avenue to discover biomarkers that have potentially high commercial 
value.   
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Figure 2 The number of articles with „proteomics‟ in the title or as the topic (source: ISI Web of 
Knowledge, Science Citation Index Expanded (SCI-EXPANDED) database) 
 
By comparing protein profiles identified by MS for samples from diseased versus 
healthy populations, for example, biomarkers for elucidating disease mechanisms 
and for developing diagnostics and new therapies can be identified.  These new 
targets would then be patented as new drug targets.  Conditions including cancer, 
atherosclerosis, pain, virus-induced cell transformation and many others have been 
investigated using this approach, although biomarker discovery turned out to be a 
complex task, as is explained further in Chapter 2.   
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1.1.2 Proteomics is an ‘omics’ science that is needed for systems 
biology 
Another benefit of large-scale protein studies has emerged recently, that is 
proteomics as a branch of „systems biology‟.  A major aim of biology research is to 
achieve a complete computational model of the cell: a „cell simulator‟, which can be 
used to demonstrate the effects of drugs, environment and genetics on biology to 
understand disease, human development and more.   
 
Modern drug design in the pharmaceutical industry is not as „rational‟ as scientists 
would like.  One cannot, for example, predict how a drug will affect the metabolic 
processes in a cancer cell until it is empirically tested using a cell line or animal 
model, because there are no holistic models to simulate it.  Thus, only by 
characterising the changes in molecules in time and space, using so-called „global‟ 
approaches, such as genomics (study and prediction of genes), transcriptomics 
(transcripts i.e. mRNAs which encode proteins), proteomics (protein expression), 
interactomics (molecular partners, complexes, dynamics) and metabolomics (small 
molecules and metabolites), can there be any hope of generating a mathematical 
model of a cell.  These large-scale „omics‟ approaches are required, since so many 
discrete events and interactions are happening simultaneously.  If systems biology 
ever arrives in this global form, where computational models are available for whole 
systems or even whole organisms, then the way medical research is performed and 
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demonstrated to the regulators will be totally revolutionised; changed beyond all 
recognition.   
  
Great advances have been made to get this far: for example in the 1970s, it could take 
an entire PhD project to sequence a single gene using lab-based techniques, but by 
mid-2000s it was possible to sequence the genome of a whole organism in a day 
(PressRelease, 2007i).  Compared to the biology being studied before, this scale of 
research is revolutionary.  The leap in throughput became possible, in this case, 
through the advent of: new methods in molecular biology (invention of polymerase 
chain reaction (PCR), cloning and sequencing methods); advances in 
instrumentation (automated sequencers, robotics); and computing and software 
development (sequence recombination algorithms, processing power).  The trends 
seen in the development of proteomics also relied on significant technological 
breakthroughs, as explained later.   
 
Unsurprisingly, there is much work to do before researchers can unravel what this 
new „omics‟ data really means in the context of an organism, tissue and at the level 
of the cell (Ghosh and Poisson, 2009).  Nevertheless, the desire to achieve the elusive 
systems model for biology acts as a potent stimulus for proteomics and proteome-
related computational research, including for the research presented in this thesis.   
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1.1.3 Proteomic bioinformatics exploits computers for analysing large 
datasets from proteomic MS experiments 
The promise of proteomics - to deliver biomarkers and new ways to model processes 
in biology, for example – is wholly dependent on computers, and their ability to 
manipulate large datasets in an automated fashion.     
 
When computers are applied to analyse biological data of any kind, the process is 
referred to as „bioinformatics‟.  Bioinformatics is an interdisciplinary science that sits 
at the interface between the biological and computational sciences.  This thesis 
delivers bioinformatics solutions specifically for proteome research, so the work is 
described  as „proteomic bioinformatics‟, or „proteome bioinformatics‟.  In particular, 
the work presented here is focused on delivering computational methods and tools 
for mass spectrometry-based proteomics that may be applied directly to early stage 
pharmaceutical and medical research.   
 
To put the project deliverables into context the next sections introduce some of the 
major concepts in proteomic MS and proteome bioinformatics.  The story of how 
proteome bioinformatics approaches and resources came about is presented in 
Chapter 2, and a detailed review of the state of the art in public computational 
resources for proteomics is presented in Chapter 3; however, the following section 
gives the reader a brief introduction to the field, so the contribution to knowledge 
and benefits of this thesis can be appreciated.  
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1.2 The practicalities of high-throughput proteomic MS and 
proteome bioinformatics 
1.2.1 Proteins are prepared for MS using 2D-PAGE or MuDPIT 
MS requires that peptides enter the MS in a charged and gaseous state, preferably 
only one peptide species at a time.  There are two main routes to achieving this 
(Figure 3): (1) two dimensional poly-acrylamide gel electrophoresis (2D-PAGE), and 
(2) the multidimensional proteome identification technique (MuDPIT).  The first 
approach is still practised, but is less routinely used for high-throughput studies; 
both are explained now. 
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Figure 3 Experimental flows in mass-spectrometry-based proteomics.  MuDPIT (multi-dimensional 
protein identification technology) uses two chromatography steps interfaced back to back, the advantage 
of this being band broadening and increased resolution. The capillary can also be fed directly into the ion 
source of the MS to maximise sensitivity. 2D-SDS PAGE separates proteins by two different properties: 
pl and molecular weight. Picked spots may also undergo an HPLC stage after digestion to increase purity 
and to allow automated introduction into the MS instrument. 
 
Gel-based methods separate proteins by their chemical and physical 
properties 
2D-PAGE is a gel electrophoresis approach for separating complex protein mixtures.  
It separates protein molecules by two different properties:  mass and isoelectric point 
(pI).  Protein molecules can have a positive, neutral or negative charge, depending 
on the chemical groups in the molecule and the chemical environment; pI is the pH 
value at which the net charge across the whole protein molecule is zero.     
 
To create the gel, the proteins are first separated by pI in an isoelectric focusing (IEF) 
step.  The proteins are put on a strip with a pH gradient and a voltage difference is 
applied. The proteins are free to migrate according to their charge state, moving 
towards the pole with an opposite charge until the protein reaches the location 
where its pI equals the strip‟s local pH, where it halts because its net charge is zero.    
The proteins are now separated by pI.  Next, they are separated by mass by rotating 
the strip by 90 degrees and separating using sodium dodecyl sulphate (SDS) PAGE.   
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SDS denatures proteins - straightening them all out into linear structures - and 
imparts a uniform negative charge, with the number of charges adopted being 
dependent on the protein‟s length.  To explain: when unfolded, a protein's length is 
approximately proportional to its mass, thus each protein attaches a number of SDS 
molecules approximately proportional its mass. Since the SDS molecules are 
negatively charged, the result is all proteins having approximately the same mass-to-
charge ratio as each other.  As mentioned, SDS also imparts a negative charge which 
is necessary here, because the proteins must become charged (having lost their 
charge in the IEF step) to migrate across a potential difference.  The unfolded 
proteins have to pass though the gel matrix, whereby larger proteins travel slower 
than smaller ones.    
 
Now separated by pI and mass, the proteins are stained whilst in the gel with a dye, 
the result being a canvas of spots, where each protein species has a unique position 
on the gel „map‟: its x,y-coordinates depending on its unique properties.  The protein 
spots are usually excised and then proteolytically digested into peptides.  The 
proteolytic enzyme of choice is trypsin, which cleaves the carboxy (C)-terminal of 
arginine or lysine generating peptides with at least one basic amino acid, thus 
trypsin predominantly generates positively charged peptide ions – a property which 
 16 
 
is very useful, since only charged ions can be analysed in MS, and positive ions are 
the ions of choice.  The digested protein samples are then ready for ionisation in MS. 
MuDPIT exploits high performance liquid chromatography to 
separate peptides 
2D-PAGE has a protein or peptide-picking stage, where peptides are individually 
excised from the gel and dissolved in buffer before analysis in MS; this process is 
expensive to automate, using robots for example.  In contrast, MuDPIT (Washburn et 
al., 2001) offers the advantage that it may be fully automated at relatively low cost.  
Compared to 2D-PAGE, when using MuDPIT, the IEF step (first dimension) is 
substituted by strong cation exchange (SCX) chromatography, and the separation by 
mass (second dimension) is replaced reverse-phase (RP) HPLC.  For MuDPIT, the 
protein mixture is digested into peptides first and then the pooled peptides are 
separated and purified using capillary chromatography.   
 
In chromatography, the mixture of molecules to be separated is dissolved in a 
„mobile phase‟ which is passed through a 'stationary phase‟, usually immobilised on 
a column or on beads packed into a column.  Certain molecules become separated 
from other molecules in the mixture based on differential partitioning between the 
mobile and stationary phases.  And the mobile phase moves through the column 
with the help of an HPLC pump.     
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SCX chromatography 
Ion-exchange chromatography has a charged stationary phase, thus separation of 
peptide ions is achieved by differing levels of electrostatic attraction between the 
ions and the column. Ions of the same charge state as the column and uncharged 
compounds are ejected, whereas ions with opposing charge states attract and bind, 
then must be eluted off gradually.  The SCX stationary phase is usually sulphonic 
acid polymer, as explained in (Zhang et al., 2003) for example, immobilised on silica 
particles (usually 5µm diameter).  Peptides are retained by the surface charge of the 
stationary phase because, as mentioned, most peptides derived from digestion with 
trypsin contain the basic amino acids lysine and/or arginine, so at the pH applied 
for SCX (often pH2) most peptides are cationic, with two or three positive charges.   
Furthermore, organic solvent (such as acetonitrile (ACN)) is used to strengthen the 
ionic and hydrophilic interactions, facilitating stronger retention of these charged 
peptides.   
 
To gradually elute off the bound peptides, an increase in counter ion concentration is 
needed; the pH may be increased to do this, or the salt content of the buffer may be 
increased at constant pH (e.g.pH3) starting at low concentration (e.g 10 mM) then 
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increasing (e.g. to 1M) ammonium formate, for instance.  In most cases, the mobile 
phase is usually an organic solvent, such as 5% formic acid in 20-50% ACN.   
 
RP-HPLC 
After SCX, peptides enter RP-HPLC.  RP-HPLC has a hydrophobic stationary phase 
and an aqueous polar mobile phase.  For peptide separation, the stationary phase is 
usually silica beads coated in a hydrophobic straight-chain alkyl group, C18H37 - 
referred to a „C18‟.  Peptides bind to the beads in high aqueous mobile phase, and 
elute off with high organic mobile phase (such as ACN); the peptides are usually all 
eluted by 50% organic solvent.   Since the binding of peptides to the beads is based 
on hydrophobic forces, thus retention time (RT) increases with hydrophobic (non-
polar) surface area of the peptides.   
 
In practice, peptides are separated by running an ascending gradient of an organic 
solvent over time that is then brought back to the starting concentration over about a 
specified time period.  The gradient may be performed in a linear or in stepwise 
fashion.   
 
Examples of solvents that are used are: A (aqueous, water with 0.1% acid) and B 
(organic solvent with 0.1% acid), whereby the acid (such as triflouroacetic acid (TFA) 
or formic acid) is added to improve chromatographic peak shape.  The sample 
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containing the peptides is usually dissolved into phase A.  One example of a 
gradient is starting the mobile phase with A at 98% and B 2%, then increasing B to 
60% of the total mobile phase composition and bringing it back down to 2% again 
over 60 minutes.  In this case, most peptides will elute at around 30% organic 
solvent, and if there are very hydrophobic ones these will elute nearer 60%.  The 
gradients applied in RP-HPLC are extremely variable between researchers, and often 
require optimising, but the overall aim is the same: to have distinct peptide species 
elute at discrete time points into MS.   
 
In RP-HPLC, there are many factors that can influence RT of peptides, including: 
particle size, column dimensions (length and diameter), flow rate, temperature, pH 
and mobile phase composition and gradient.  For example, C18 beads with a 
diameter of less than 2 µm can offer significant increases in throughput for peptide 
analysis (Kay et al., 2007), although beads of 2-3 µm are more routinely used in 
proteomics.  Flow rates may vary, including nanoflow (nl/min), microflow (µl/min) 
and normal flow (ml/min), depending on the column used; the advantage of low 
flow rates being that greater sensitivity can be achieved (Kay et al., 2007).  
Temperature is usually maintained at 30-40 ºC throughout separation, depending on 
the experiment.       
 
RP-HPLC is used frequently, and there are software tools for predicting theoretical 
RT of peptides in HPLC for researchers planning proteomics studies.  The 
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algorithms are based on the assumption that the chromatographic behaviour of 
peptides is dependent predominantly on their amino acid composition, so by 
summing the hydrophobic contribution of each residue, the RT can be predicted.  A 
notable example, Sequence Specific Retention Calculator (SSRCalc) (Krokhin et al., 
2004), applies a linear model that can accurately predict RT for peptides up to 
approximately 20 residues, and correction factors are specified in the prediction 
process to account for the variability in column set-up.  In addition, neural networks 
may be applied to RT datasets for the purpose of optimising models for RT 
prediction (Petritis et al., 2003). 
1.2.2 Mass spectrometry of peptides can be performed in high-
throughput 
MS was originally a method used in small molecule chemistry, since it allowed 
elucidation of chemical structures by measuring a molecule‟s m/z: mass (m) divided 
by its charge state (z).  From the m/z values one could determine the atoms involved 
and hence identify basic structures.  Over the decades, MS has evolved and can now 
routinely achieve resolutions in excess of 0.1 Daltons2 with the latest instruments 
and has become more routinely applied to analyse large biomolecules, such as 
proteins (see Figure 4 for a typical workflow). 
                                               
2 A Dalton is the same as an atomic mass unit; it is the usual way to express mass when referring to proteins 
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Figure 4 A typical workflow for proteomic mass spectrometry.  Notice that data straight from the MS 
instrument is in „raw‟, machine-readable form, meaning it usually requires MS-vendor-specific software 
to convert it to a peak list of intensities and m/z values. This conversion step often requires proprietary 
software or software libraries.  
 
There are two common modes of mass spectrometry: single MS or tandem MS (also 
referred to as MS/MS, or MS2).  The former produces a spectrum of the peptide ion 
m/z values, the latter produces a spectrum of peptide fragment ion m/z values.  
Tandem MS is the approach used most frequently for proteomic MS.  Various mass 
spectrometers are available, each setup offering different benefits and applications; 
some of these setups are explained in detail later in the thesis, such as triple 
quadrupole (QQQ) MS, and others.  The general principles of MS/MS are now 
described. 
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A tandem mass spectrometer has three components: an ion source, a mass-to-charge 
ratio mass analyser, collision cell (a type of analyser), and a detector.   
Ion source  
The ion source is at the entrance of the instrument and its function is to ensure the 
molecular species entering the analyser are charged and in the gas phase.  The most 
common ion source in proteomic MS is electrospray ionisation (ESI) (Fenn et al., 
1989), followed by matrix-assisted laser desorption/ionization (MALDI) (Tanaka et 
al., 1988).  
 
Using MuDPIT, the separation phase may be directly coupled to the MS instrument, 
whereby the continuous flow of peptide-separated liquid sample is injected through 
a fine nozzle into the instrument.  Once inside, the peptides in the liquid undergo 
ESI to atomise the peptides.  ESI is performed at the tip of a very fine nozzle 
(needle), which is heated (to around 60ºC), at atmospheric pressure, and a drying 
inert gas is applied over the tip.  The nozzle is conductive: a potential difference of 
up to 5kV is applied.  This means the positively charged peptides are pushed out of 
the needle tip, and as the liquid containing the peptide – which is more volatile than 
the peptides - dries off, the droplet containing the peptide ions gets smaller, until at 
a critical moment when the charge density destabilises the droplet and the peptide 
ions repel each other dispersing as a fine aerosol.  The vaporised ions then drift 
towards the opposing needle electrode.   
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ESI does not impart a charge on to the peptide; it is a „gentle‟ technique, whereby the 
native charge state of the molecular species is exploited.   Most peptides will have a 
positive charge if derived from tryptic proteolysis, so the technique is particularly 
suited to proteomics.  Native states of molecules are often preferred for biologists 
wishing to characterise nature.   
 
Micro and nano-spray are recent variants of ESI that are employed in proteomic MS 
studies.  The „micro‟ and „nano‟ prefix refer to the flow rates of liquid in RP-HPLC 
into the instrument; by microlitre (µl) or nanolitre (nl) per minute, respectively. 
 
MALDI is the other ionisation technique employed for proteomic MS.  It employs a 
laser, usually UV light, which is directed at a metal plate onto which a „matrix‟ with 
spots of peptide (or whole proteins) have been immobilised.  The matrix consists of 
crystallised molecules3 such that when the energy from the laser hits the matrix, the 
matrix itself becomes ionised.  Part of its acquired charge then transfers to the 
analyte molecules (the peptides).  In this way, the peptides become ionised (usually 
by addition of a proton, thus [M+H]+), but are protected from the disruptive energy 
of the laser.  MALDI usually produces singly charged ions and, in contrast to ESI, is 
usually performed in a vacuum. 
                                               
3 The most common matrix constituents are 3,5-dimethoxy-4-hydroxycinnamic acid, α-cyano-4-
hydroxycinnamic acid and 2,5-dihydroxybenzoic acid. 
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Analyser  
The analyser measures the mass to charge (m/z) ratio of ions4.  The two main 
strategies to achieve this are by using an electrical field (such as in time-of-flight 
(TOF), quadrupole and ion trap analysers), or using a magnetic field (in the Fourier 
transform ion cyclotron resonance (FT-ICR) analyser).   
 
Data from various instrumental setups has been applied to develop the novel tools 
and methods in this thesis; in particular, the quadrupole analyser data, which is the 
analyser of choice for selected reaction monitoring (SRM) (Chapter 5 and 6).  Also, 
MS instruments with ion trap and Fourier transform ICR analysers have been used 
to produce the standard datasets applied in Chapter 4, and to populate the database 
(GAPP DB) interrogated by the novel tool presented in Chapter 5.  The principles of 
these three analysers are described now. 
 
 
 
The quadrupole (Paul and Steinwedel, 1953) has four conductive, metal rods aligned 
in parallel arranged in a square (Figure 5).  An oscillating electrical field is produced 
in the chamber by the application of a direct-current and a radio-frequency 
alternating current.  When the peptide ions enter the field, they oscillate 
perpendicularly to the direction of their movement, with their progress in the field 
determined by the ions‟ charge and mass.  Only for certain mass and charge 
                                               
4 m/z means mass divided by charge, for example a peptide of 670 Da and a 2+ charge would have an m/z of 335 
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combinations will an ion successfully escape from the quadrupole, all others will 
have increasing horizontal or vertical amplitudes and will ejected before the end.  
The quadrupole can be tuned scan for a narrow or a wide range of m/z values.   
 
 
 
 
 
Figure 5 Schematic diagram of a quadrupole mass analyser.  The red arrow shows the path of selected 
ions (Source: adapted from Wikimedia Commons) 
 
Ion traps (March, 1996) are a type of ion cage that store charged particles by the use 
of an oscillating electric field (in a similar fashion to a quadrupole). An ion species is 
stored in a vacuum chamber between caps of the same polarity; there are three 
electrodes: two capping electrodes (one connected to the ion inlet and the other to 
the detector plate), and a single ring electrode that encircles the trap chamber (Figure 
6). 
  
From the ion 
source 
Detector 
– 
 
         +                + 
–  
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Figure 6 Schematic cross section view of an ion trap (Source: adapted to a schematic from the Paul ion 
trap entry at Wikimedia Commons)  
 
The ions enter the trap, where there is an applied oscillating radiofrequency 
electrical field (like in a quadrupole). This field causes the ions to shift and move 
according to the applied field, producing a compact „cloud‟ of ions that expands and 
compresses.  To dissipate the energy generated from ion collisions, an inert gas, such 
as helium, is continuously added to the chamber.  The m/z can be measured by an 
ion trap because the ring electrode potential difference sets the m/z threshold below 
which ions are expelled from the trap.  As for the quadrupole, the voltage setting 
may be configured to accept a range of m/z values.     
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The „cyclotron frequency‟ of ions is the measure used to determine m/z of peptide 
ions in FT-ICR (Figure 7); space and time measures, as for other analysers, are not 
used.  It is the highest resolution, and highest cost approach to proteomic MS 
because it requires a super-conducting magnet.   
 
The analyser is a box-type compartment with a plate on each side: encircling the 
chamber are two „excitation‟ plates (opposite to each other) two „detector‟ plates 
(also opposites), and the entrance and exit plates are the „trapping‟ plates.  When 
ions enter the magnetic field in this box, they are forced into a circular trajectory by 
the plates, thus becoming trapped inside.  An alternating current (as radio 
frequency) is applied to the excitation plates, which causes ions trapped in the 
magnetic field to become excited to higher energies, and trajectories.  At the moment 
when the current is stopped the ions decay back to their original states. The 
trajectories of the ions in the field induces an electric current that is measured by the 
detector plates.  It is this current that is measured.  It corresponds to the decay in 
kinetic energy of all ions in the trap, and may be deconvoluted into mass-to-charge 
ratios by applying the mathematical operation, Fourier transformation. 
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Figure 7 Fourier transform ion cyclotron resonance analysers use high-maintenance superconducting 
magnets (Source: Wikimedia Commons) 
 
The mass accuracy and general performance achieved by each type of instrument 
varies enormously (Table 2).  
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Table 2 Resolution of MS (Source: adapted from (Domon and Aebersold, 2006))   
Characteristic of the MS setup IT-LIT QQQ QQ-LIT FT-ICR 
Mass accuracy low medium medium very 
high 
Resolving power low low Low very 
high 
Sensitivity high high High medium 
Dynamic range low high High medium 
Throughput high medium medium medium 
Suitability for peptide identification medium low Low high 
Suitability for absolute quantitation  low high High medium 
Suitability for detection of PTMs low low High low 
 
Collision cell 
In tandem MS mode, the peptide ions are broken into smaller peptide fragment ions 
in a collision cell (or „chamber‟), which is often an ion trap or quadrupole, containing 
inert gas, such as helium or argon.  An electrical potential is applied to the cell, 
imparting kinetic energy to the particles.  This kinetic energy is converted into 
internal energy in the peptide molecular ions resulting in bond breakage and the 
release of smaller fragment molecules.  The collisions are stochastic, so even for 
replicate samples different ions may be observed. 
 
The primary mechanism of peptide fragmentation, regardless of the ion source used,  
is collision induced dissociation (CID) - also referred to as collision activated 
dissociation (CAD)5.  In CID, there are six primary ion types created during peptide 
fragmentation pathways; these are referred to as b-, y-, a-, x-, c- and z-type ions.  The 
                                               
5 Post source decay is another mechanism for peptide decay, where peptide ions spontaneously decay into 
fragments in the ion source vacuum.  It is a phenomenon specific to the MALDI ion source.     
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formation of b- or y-ions, the most common fragment ions, is shown in  Figure 8.  
The original paper describing the nomenclature and pathways is (Roepstorff and 
Fohlmann, 1984). 
  
 
 
 Figure 8 A peptide fragmentation pathway.   Frequently the peptide bond breaks to generate fragments, 
only one of which retains a positive charge and is detected in MS: either a b-ion (left, retaining the amino 
terminus) or a y-ion (right, maintaining the carboxyl group) (Source:  (Brunetti et al., 2008)) 
 
Molecular ions that retain a positive charge are fed into a final mass analyser, where 
they are focused using a magnetic field and their signal intensity measured at the 
sensor.   
 
The propensity for specific fragmentation pathways depends on the MS instrument 
in use.  Triple quadrupole MS, for example, has a bias towards detection of y-ions, 
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rather than b-ions.   Moreover, the complement of ions produced is also dependent 
on the voltage applied to the cell and pressure of the inert gas, properties which can 
be altered by the operator.  For example, „high-energy‟ CID generates spectra that 
usually from single collisions between peptide ions and the gas particles, but 
generally results in a wider range of fragmentation possibilities.  In contrast, „low-
energy‟ mode permits several collisions and hence more complex, multi-step 
cleavages  are observed, but the overall results is a greater proportion of b- and y-
ions, and fewer of the other species of ions seen in high-energy CID. 
Detector/sensor 
The detector measures either the current produced or the charge induced when an 
ion passes or directly hits a surface.  Since the volume of ions exiting the mass 
analyser at any given moment is small the signal must be amplified.  Microchannel 
plate detectors are frequently fitted in modern instruments, these are a type of 
electron multiplier.   
 
In FT-ICR and Orbitraps (modified ion traps), ions are not detected by hitting a 
detector, such as an electron multiplier, but rather are measured by passing near 
detection plates.  No current is produced, only a weak AC image current is detected 
in a circuit between the electrodes. 
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The output at the detector is a mass spectrum, usually representing the complement 
of fragment ions for a single peptide precursor ion, with m/z on the x-axis and 
arbitrary signal intensity on the y-axis (Figure 9).   
 
 
Figure 9 An MS spectrum.  Only the x-axis m/z values are applied to peptide identification using search 
engines 
 
 
Each spike represents a single fragment ion. The identity of the peptides may be 
determined manually by inspection of these product ion spectra, however, this is 
tedious and in many cases the volume of data precludes the manual approach.  
Therefore, an automated proteomic search engine is usually applied to produce 
protein identifications from MS/MS peak lists, see section 1.2.4 for details of this 
process. 
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Visibility of peptides in MS 
Not all peptides can be detected using MS with the aforementioned approach.  There 
are four aspects that determine whether a peptide will be observed or not in MS 
(Tang et al., 2006):  
(i) Chemical properties of the peptide – will the structure successfully undergo ionisation at 
the ion source?  Will it fragment in the collision cell to produce detectable product ions?   
(ii) Limitations of the peptide identification protocol, including the pre-processing of the 
sample - Is the peptide positively charged?  Is tryptic digestion complete so peptides are 
within mass range? 
(iii) Abundance of the peptide in the sample – is there enough peptide to be detected? (Of 
course, there is no PCR for proteins to amplify the sample) 
(iv) Interference with other peptides present in the sample – is there competition with 
another peptide in the identification procedure?  Is there co-elution of peptides making 
signals difficult to interpret? 
 
Some of these factors are very hard to predict, but given the data the community 
already has, it is clear that certain peptides are routinely more readily detectable 
than others, given standard MS protocols.  Peptides that are usually the ones that are 
visible for a given protein in MS are referred to as proteotypic peptides (PTPs) for 
the given protein.   
 
Given that peptides are usually measured in MS with a view to identifying the 
parent protein, in some definitions „proteotypic‟ refers to those peptides that are 
both visible and unique for a given protein.  In this EngD thesis, both constraints on 
the definition are applied: usually visible and unique to the protein.       
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 There are various computational/mathematical approaches for predicting PTPs for 
the purposes of proteomic MS.  These include: neural networks (Tang et al., 2006); 
classical pattern discovery methods (Mallick et al., 2007);   machine learning 
classification approaches (Lu et al., 2007); support vector machines (Webb-Robertson 
et al., 2008); and the Random Forest classifier technique (Fusaro et al., 2009).  These 
are valuable, because being able to anticipate which peptides will be observable in 
MS can help experimental design for targeted MS workflows, as explained in the 
following section.   
1.2.3 Proteins can be quantified using MS 
Although protein identification alone can provide valuable information about 
biological systems, there is a limit to the conclusions that can be drawn from 
qualitative experiments.  Instead, knowing how much protein is present is usually 
more valuable.  Indeed, recent findings reported by Uhlen using an antibody-based 
approach (Uhlen and Ponten, 2005) illustrate that differentially expressed proteins 
are actually rare, because most proteins in humans are expressed in all cell types, 
most of the time.; less than 1% of proteins are expressed in one tissue only (Service, 
2008a).  It is precise regulation of protein expression in space and time that results in 
tissue-specificity; thus, qualitative (present or absent) protein biomarkers are usually 
less valuable for understanding the true complexities of biology.  Indeed, many 
diseases, including asthma, arthritis, schizophrenia and heart disease, are known to 
involve very small changes in the regulation of protein expression over time, and 
diseases are complex, often polygenetic and environmentally-dependent, meaning 
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that the protein profile for healthy, susceptible and diseased states varies in very 
subtle ways; hence small changes in quantity may be important factors.     
In recent years, several techniques to quantify proteins by mass spectrometry have 
emerged (Figure 10).  
 
 
Figure 10 A summary of the approaches for quantifying proteins using mass spectrometry, adapted from 
(Lau et al., 2007) 
 
Relative approaches measure the abundance of proteins as a ratio between different 
samples, whereas absolute approaches provide a specific quantity value, such as 
ng/ml for a specific protein(s). 
 
Relative quantification of proteins (with labelling) 
An isotopic label is the marker used to distinguish two (or more) populations of 
proteins.  Heavy elements (heavy nitrogen or oxygen) or heavy amino acid residues 
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(such as heavy arginine or iso/leucine) are assimilated via cell metabolism using the 
in vivo approach.  In stable isotope labelling of amino acids in cell culture (SILAC) 
(Ong et al., 2002), for example, two cell cultures are grown up in parallel, one 
exposed to medium containing heavy amino acids, and one with standard medium.    
For higher organisms in vitro labelling with chemical reagents is performed after the 
proteins have been harvested, such as a label specific for cysteines in  the isotope-
coded affinity tag (ICAT) approach (Gygi et al., 1999) , and free amine labels with 
iTRAQTM.     
 
The assumption in all cases is that the proteins will incorporate the labels to 
completion.  Protein quantitation is achieved by comparing the MS intensity of the 
peptides derived from the two samples, which is possible since the expected mass 
shift of the ions is known. 
Relative quantification of proteins (label free) 
Label free methods include peptide/spectral counting and ion intensity monitoring.  
In spectral counting, protein quantities are estimated in distinct samples by counting 
the number of MS/MS spectrum-sequence matches found by the search engine.  The 
assumption is that protein abundance is correlated with protein coverage and the 
number of times a peptide is observed (in replicate experiments).  The size of the 
protein affects the reliability of this approach, and the assumptions are quite „loose‟.  
For the ion intensity approach, the RP-HPLC retention profile (ion chromatogram) 
for each peptide is exploited.  Chromatographic peak intensities are retrieved and 
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used as a basis to compare with peptides matched in different experiments.  When 
several peptides are matched to a common protein, each peptide ratio is used to 
measure protein fold change across the different experiments.  Peptide RT can 
present a problem for this approach; for example, when multiple peptides elute at 
the same moment peak intensity will be too high, but if peptides are separated in 
SCX not all the peptides will necessary arrive in the same peak. 
 
Absolute quantification of proteins (SRM and variants)  
The AQUA technique (Gerber et al., 2003), now more frequently referred to as 
selected reaction monitoring (SRM) (Anderson and Hunter, 2006), and QconCat 
(Beynon et al., 2005) are methods for measure absolute quantities of protein using 
tandem MS. 
To determine the quantity of a specific protein using SRM, QQQ-MS is performed as 
RP-HPLC separation is in progress.  Each peptide is analysed by selection on the 
basis of m/z using the first quadrupole (Q1).  Once separated, in a second quadrupole 
(Q2), the peptide undergoes fragmentation, generating product ions exclusive to the 
precursor, which are selectively monitored by a third quadrupole (Q3) (Figure 11).  
The two stage filtering process in SRM allows chemical background to be overcome 
by improving signal to noise ratio, and permits several transitions to be monitored 
quickly.  The observed m/z ratio of a precursor peptide and its corresponding 
product ion is referred to as an SRM „transition‟ and has a specific RT associated 
with it. 
 38 
 
 
 
Figure 11 SRM targets a specific peptide to product ion transition in triple quadrupole (QQQ) MS  
(Source: www.srmatlas.org) 
 
SRM becomes quantitative when the incoming sample is first spiked with a known 
quantity of stable isotope-labelled synthetic peptide, which is identical in sequence 
to the expected native peptide (Gerber et al., 2003).  For robust studies, calibration 
curves of serial dilutions of the surrogate are determined to produce more reliable 
measurement of the quantity of protein.   
 
To monitor a protein of interest, it must be known in advance which transition is 
most suitable.  In simple protein mixtures, a single transition may be sufficient to 
monitor a particular protein of interest, but in complex samples, such as serum, 
multiple transitions are generally required due to noise and proteins of very high 
abundance interfering with the signal (Kay et al., 2007, Keshishian et al., 2007).  
Furthermore, for very complex samples, such as whole serum, stable isotope 
standards and capture by anti-peptide antibodies (SISCAPA) (Anderson et al., 2004, 
Anderson et al., 2009) can be used to enrich the peptide targets prior to SRM to 
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further improve signal-to-noise.  With this approach, antibodies are raised to the 
native and surrogate (labelled) peptides, and are immobilised on a surface.  Prior to 
SRM, the peptides are enriched by pull down on these antibodies, thus increasing 
the sensitivity of the SRM assay.   
 
QconCat is a variation on the AQUA/SRM theme, whereby the heavy surrogate 
peptides are not synthesised artificially, but rather the surrogate peptides are 
expressed in vivo by a bacterial cell expression system.  A gene is constructed to 
encode suitable surrogate peptides (Q-peptides) concatenated in a protein (QCAT 
protein).  This protein is expressed and is digested into peptides for subsequent 
targeted monitoring (as per SRM). Q-peptides are heavy due to metabolic labelling, 
where the bacterial cells are grown in culture containing heavy amino acids, for 
example.         
 
SRM is an increasingly popular technique because it offers the option to measure 
protein regulation across many targets simultaneously, and in a quantitative manner 
examples include: (Zhang et al., 2004, Kuhn et al., 2004, Beynon et al., 2005, Unwin et 
al., 2005, Cox et al., 2005, Ciccimaro et al., 2006, Anderson and Hunter, 2006, Rifai et 
al., 2006, Wolf-Yadlin et al., 2007, Stahl-Zeng et al., 2007, Kay et al., 2007, Keshishian et 
al., 2007, Lenz et al., 2007).  It is possible to multiplex quantitative measurement of 
peptides because each transition (the pair of precursor and product ion m/zs) is 
unique for each peptide.  The assumption is made, however, that each SRM does not 
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interfere with any other in the assay, and that peptide co-elution from HPLC is 
avoided.   
 
The capability for multiplexing means SRM is often referred to as MRM (multiple 
reaction monitoring) by practitioners.  However, MRM may actually refer to either a 
set of SRM assays that are being performed for several protein targets 
simultaneously (the multiplexed approach), or may refer to monitoring multiple 
product ions (in effect, multiple transitions) for each peptide precursor ion in a 
single SRM assay.    SRM is the accepted MS nomenclature according to IUPAC 
(Murray et al., 2005), however the term MRM is still widely used in the community, 
so both are applied in this thesis, depending on the context.     
 
SRM has proven to be a successful method for discovery and validation of novel 
biomarkers  (Kuhn et al., 2004, Zhang et al., 2004, Anderson and Hunter, 2006, Rifai et 
al., 2006) and, compared to the alternatives, (such as ELISAs) it has the advantage of 
being cost effective, quicker to design and suitable for multiplexed analysis (Stahl-
Zeng et al., 2007).  MRM studies have also reported measurements down to 
attomolar concentration (Onisko et al., 2007, Keshishian et al., 2007).  Increased 
throughput is also possible with SRM, due to direct coupling of separation (via 
HPLC) to MS and, in some cases, the ability to avoid extensive sample preparation 
before analysis (Kay et al., 2007, Keshishian et al., 2007).  Furthermore, SRM requires 
a high level of ion separation, but not necessarily high resolution, meaning that the 
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instrumentation (QQQ-MS) is potentially affordable compared with the alternatives 
(Orbitrap and FT-ICR); since lower resolution MS is generally less expensive to run.   
These features suggest that in the near future SRM may become a routine assay in 
the clinic.  Indeed, transitions for monitoring blood proteins (Anderson and Hunter, 
2006, Keshishian et al., 2007, Kay et al., 2007, Stahl-Zeng et al., 2007, McKay et al., 
2007) and biomarkers for arthritis (Kuhn et al., 2004), acute liver damage (Zhang et 
al., 2004) and cardiovascular disease (Anderson and Hunter, 2006) have already been 
published, no doubt with this objective in mind.  In addition, post translational 
modifications (Cox et al., 2005, Ciccimaro et al., 2006, Stahl-Zeng et al., 2007) and cell 
signalling networks (Wolf-Yadlin et al., 2007) may also be characterised using the 
SRM technique.  
 
SRM has only recently been applied to quantify proteins, having originally being 
used to determine small molecules (Kerns and Di, 2002, Kovarik et al., 2007, Singhal 
et al., 2007) and metabolites (Gu et al., 2007) in complex sample background by the 
pharmaceutical industry.  This means much has to be learned as regards the optimal 
approach to designing transitions targeted at proteins: the major challenge being the 
decision of which peptide(s) are best to monitor, since each protein has multiple 
tryptic cleavage sites.  Moreover, some peptides and their product ions are always 
visible in MS/MS, whereas others are not detected at all because they do not ionise, 
for example (Tang et al., 2006).   
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1.2.4 An introduction to proteomic bioinformatics  
In very large volumes of data, the meaning may be hidden.  To interpret and 
understand what large datasets (such as hundreds of spectra) are showing, the data 
must first be manipulated with computers to make it understandable.  An overview 
of the types of bioinformatics tools and resources for proteomic MS is shown in 
Figure 12. 
 
 
Figure 12 An overview of proteomic bioinformatics resources for tandem MS. Note that „proteomics‟ 
repositories are distinct from „protein‟ databases; the former contains MS/MS data, auxiliary 
information (such as protocol, species, etc.) and peptide and protein identifications, whereas the latter 
contains protein sequences, and sometimes often information on protein structure, function, and other 
properties, for example. (Source: author‟s own summary)  
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Proteomic MS data has ‘peak lists’ 
Molecular ions in mass spectra are referred to as „peak lists‟.  This is a list of m/z 
values (x-axis) and intensities (y-axis).  Peak lists are not „raw data‟ direct from MS 
instruments, which is machine-readable and requires proprietary software to 
convert it to a readable/searchable form, instead they are lists of values either in text 
file form (such as .mgf, .pkl or .dta format) or encoded in XML (such as mzXML, 
mzData or mzML) (Figure 13). 
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(a) 
 45 
 
  
Figure 13 Examples of MS/MS data in peak list form, ready for analysis with a proteomic search engine.  
(a) mzData is an example of an XML-based format; (b) pkl, and (c) mgf formats are text-based. 
 
Data formats for proteomic MS came about independently and before standard data 
formats and reporting standards had begun to be established.  As a result, formats 
and repositories were autonomously designed, with no inter-change being possible: 
the European Bioinformatics Institute developed mzData and PRIDE XML; Ron 
Beavis‟ group BIOML and XIAPE; and the Institute of Systems Biology (ISB) 
mzXML, for example.  This remains an issue, because it is often difficult for users to 
convert their data into a suitable format for other labs to use.   However, barriers to 
(b) (c) 
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data sharing are beginning to come down as public data format conversion software 
is becoming increasingly easier to find (see the Appendix I for a summary), and tools 
have been specifically developed, such as PRIDE Converter (Barsnes et al., 2009) to 
ease submission to public databases.  Academics and MS instrument vendors are 
also cooperating with the Human Proteome Organisation‟s Proteomics Standards 
Initiative (HUPO-PSI) to make their native formats compatible with tools and 
databases.  Furthermore, HUPO-PSI is coordinating the development of standard 
formats for the major proteomics data-types (Table 3); for example, recently 
competing MS data formats mzData and mzXML have been replaced by a single 
new format called mzML (first release June 2008), which is expected to become the 
universal unprocessed proteomic MS data format.  Furthermore, MRM transitions 
now have TraML format.    
 
Table 3 Standard formats for proteomic MS developed by PSI.  Protein separation, interactions, and 
modifications are managed by other groups and their formats. 
   
Standards 
Work Group 
Format name Format remit 
Mass 
Spectrometry  
mzML Merges various peak list formats (not native .raw formats).  
It has experimental information (metadata).  Peak lists are 
encoded in binary to make files manageable in size 
Mass 
Spectrometry  
TraML MRM transitions  (see Chapter 6 for more information) 
Proteomics 
Informatics  
mzIdentML 
(formerly 
analysisXML) 
Peptide/protein identifications from search engines plus 
search metadata, decoy database used, etc. 
 
 
 
There are also work groups for developing standard formats for protein 
modifications, interactions and protein separation. 
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Metadata for proteomic MS 
Data that describes the MS/MS peak lists is called „metadata‟.  Metadata is usually 
required to identify proteins using an automated system (such as a search engine).  
Metadata for this purpose includes the protein search database, the mass tolerance to 
be applied in the search (which represents the level of mass accuracy achieved by the 
mass spectrometer at MS and MS/MS levels), the proteolytic enzyme used, any 
anticipated PTMs, and the expected charge state of the peptides in the experiment 
(usually 2+).  An example of a metadata entry form is in Figure 14.   
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Figure 14 The metadata required by the Genome Annotating Proteomic Pipeline, which employs the 
X!Tandem search engine and APS 
 
This form also includes „biological‟ metadata.  These are descriptions of the 
experiment, such as the name of the instrument, the cell line or tissue, disease state, 
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protocol details, such as the separation protocol used.  Having this information 
available means that the resulting identifications, when stored in a database, can be 
data-mined to reveal hidden trends.  For example data-mining can reveal the 
proteins present in certain disease states, or show that certain proteins are present 
under particular processing protocols and absent in others. 
Peptide search engines 
Proteomic search engines are central to the field of proteomic bioinformatics.  There 
are both free (X!Tandem (Craig and Beavis, 2003)) and commercial (Mascot (Perkins 
et al., 1999)) offerings, with each being based on differing scoring algorithms.  In 
proteomics „discovery‟ studies, the protein content of the sample being analysed is 
usually unknown, however, there is still some information that can be utilised to 
assign sequence to m/z.  It is known, for example, that all proteins consist of 
combinations of only 20 possible amino acid units, each having a known molecular 
weight.  It is also known that trypsin, the enzyme most often used, cuts proteins 
after lysine or arginine (if not followed by proline).  Most importantly, the target 
protein sequences are known, as database, such as a translation of the genome; thus 
information from the genome can be applied to characterise the proteome using 
search engines.  In summary, using all these sources of information, combined with 
statistical methods to assess the likelihood of matches compared to chance, various 
search-engine type algorithms have been designed. Most search engines fall into 
four types of algorithm: 
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1.  Peptide Mass Fingerprinting (PMF) matches masses (as m/z) to peptides (Figure 
15) by comparing the unknown masses to a theoretical database, generated by 
performing an in silico cleavage operation (per trypsin) on a protein sequence 
database.  With PMF, several peptides may share the same mass because 
permutations in the arrangement of the same set of amino acids will result in 
peptides of identical mass.  And certain combinations of amino acids may result in 
mass differences, which are indistinguishable at the resolution of MS. Once masses 
have been assigned to peptides, proteins may be identified as those that contain a 
number of the matched peptides.   
 
2. Tandem MS searching is the most prevalent approach.  As with PMF, the 
unknown spectrum is compared to a theoretical database, but this time the database 
is derived from in silico digestion of proteins, followed by theoretical CID 
fragmentation of the peptides (Figure 15).  Product ion masses are used, so it 
overcomes the problem seen in PMF, allowing peptides to be distinguished even if 
they have identical mass.   
 
 51 
 
MS/MS  
search database 
 
 
 
Filter by 
mass 
Enzymatic  
protein digest  
eg. trypsin 
 
Ionisation 
source MS MS/MS  
 
Peptide 
separation 
step  
eg. HPLC 
 
Primary sequence  
search database 
 
 
 
Precursor 
ion 
intensities 
Fragment 
ion 
intensities 
score 
 
score 
 
score 
score 
 
score 
 
score 
 PMF 
search 
Tandem  
MS 
search 
Peptide identification 
output, ranked by  
match confidence 
 
 
Centroided 
peak lists 
m/z m/z 
Figure 15 The principle of spectrum identification using PMF and tandem MS searches.  Scores are 
generated by comparison of experimental peak lists with theoretical peak lists in the search databases.  
For PMF, the theoretical fingerprint, which is the unique set of peptide masses generated by in silico 
enzymatic cleavage of a protein or translated genomic database, is matched to a single pass mass 
spectrum.  For tandem MS searching, the search proceeds initially in a similar way to PMF, by matching 
to the precursor ion mass, but following this, the experimental tandem spectrum is compared in a second 
round of searching to a theoretical peptide fragment spectrum of daughter ions generated for each 
candidate peptide, based on known peptide fragmentation chemistries.  It is possible to identify proteins 
by assigning MS/MS fragments only.  Note that all searches are based only on the m/z component of the 
spectra, signal intensity is only used to discriminate peaks from noise. (Source: author‟s own summary) 
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  3. De Novo sequencing seeks to use the tandem MS spectrum as the sole reference 
for deducing the sequence of the peptide it represents, it does not apply a search 
database, only knowledge of amino acids and CID fragmentation.  
 
As product ions are generated by splitting amino acids, all the information necessary 
to reconstruct a peptide sequence can exist in the ions generated, although spectra of 
high enough quality are in reality quite rare.  This technique can be performed by 
hand and is advantageous, for example, when no reference database is available, as 
in the case of organisms with an as yet unsequenced genome.   
 
4.  Peptide sequence tagging locates a peptide sequence by searching a database 
with partial sequence information, termed „tags‟, derived from the spectrum.  An 
example of a sequence tag is „[340]GLGSA[112] PK‟, where the letters denote amino 
acid sequence which could successfully be identified from the spectrum using de 
novo methods, and the numbers in brackets represent unknown amino acid 
combinations with mass equal to the values (because sequence could not be 
established from the spectrum alone for these regions).  The tag is then used to query 
the search database for possible matches.   
 
Development of peptide identification programs is a major area of bioinformatics 
research.  Table 4 summarises some popular search engines in routine use, and gives 
a synopsis of the algorithms they employ.  Due to the open source philosophy of the 
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bioinformatics research community, many tools are freely available to use and 
download; review articles provide a comprehensive overview (Sadygov et al., 2004, 
Xu and Ma, 2006, Shadforth et al., 2005a).   
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Program Ref. Type of 
search 
algorithm 
Description Free to 
use on 
web 
Free to 
download 
Website 
       
 
 
(Pappin et 
al., 1993) 
PMF, 
tandem and 
tagging 
Uses the MOWSE algorithm.  Calculates the probability 
that the match was observed by chance, and by using 
knowledge of the exact size of the search database, 
calculates the statistical significance of the match.  Some 
additional heuristics for intensity and ion ladders are 
included in the search. 
Yes  No www.matrixscience.co
m/  
       
 
 
(Eng et al., 
1994) 
Tandem  The protein database is searched to identify linear amino 
acid sequences.  A cross-correlation function is then used to 
provide a measurement of similarity between the theoretical 
mass for the fragment ions in the database and the real mass 
of fragment ions observed in the tandem mass spectrum. 
No No Sequest sourcerer and 
cluster are Thermo 
Fischer products.  
www.thermo.com 
       
 
 
(Craig 
and 
Beavis, 
2003) 
Tandem  „Dot product‟ method is used correlate theoretical spectra 
with the real one.  Performs multiple stages of searching and 
refinement to ensure efficient matching of mass peak lists to 
sequences, and to optimise for speed.  The first step aims to 
match the theoretical tryptic peptide and fragment masses 
to the real MS signal peak lists.  Then further iterative steps 
search for PTMs and point mutations, thus search space is 
decreased to a manageable size for computation, and more 
of the peaks are successfully assigned.   
Yes Yes  www.thegpm.org/TA
NDEM/index.html 
       
 
 
(Colinge et 
al., 2003) 
Tandem  OLAV algorithm.  Stochastic model, the parameters for 
which are learnt from a set of reference matches.  The 
likelihood of the match is derived from deciding between the 
null hypothesis, that the match is random, versus the 
alternative, that it is correct.  Also can identify known PTMs 
in the search. 
 
Yes No www.phenyx-ms.com/  
       
Table 4 A selection of the major protein/peptide identification search engines 
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(Ma et al., 
2003) 
De novo 
and tagging 
Determines corresponding peptide sequences without the 
use of a theoretical peptide fragment database.  All possible 
amino acid combinations are calculated and the peak lists 
are matched to these.   
No, but 
free web 
demo 
No, but 
free demo 
www.bioinformaticsso
lutions.com/products/
peaks/ 
       
 
 
(Tabb et 
al., 2003) 
Tagging Uses an empirically-derived model of fragment ion 
intensities to increase accuracy when deriving sequence tags, 
which are used to search the database.  Score of the match is 
determined by comparing the experimental spectrum and 
theoretical spectrum using the model. 
No No, license 
required 
free for 
academic 
users 
http://fields.scripps.ed
u/GutenTag/  
       
 
(Geer et 
al., 2004) 
Tandem  The Open Mass Spectrometry Search Algorithm - scores 
significant hits with a probability score developed using 
classical hypothesis testing, the same statistical method used 
in BLAST.  
 
Yes  Yes http://pubchem.ncbi.n
lm.nih.gov/omssa/ 
 
 
(Hummel 
et al., 
2007) 
Tandem  „Modified‟ dot product distance measure between unknown 
and reference spectra.  MS/MS spectra (unknown peak list, 
x, and library of peak lists, y) are compared and a distance 
between them is found using a series of steps.  The distance 
is calculated and taken as a single overall measure of the 
goodness of match between unknown and library.  To 
determine which distances are true matches a threshold is 
applied to the distances. 
Yes No http:// 
www.promexdb.org 
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Metadata is important for the accuracy of search engine results.   For example, if the 
mass tolerance window is set too large, ambiguous peptide matches may result 
leading to false peptide matches.  Other considerations are search space, for 
example, if many PTMs are specified the search may take a long time.  Having 
accurate metadata is important for the search accuracy, but also for users wishing to 
interrogate the resulting identifications later. 
 
Harnessing search engines to make large scale sets of identifications is powerful and 
widely used.  Nevertheless, despite recent advances only 10-20% of the MS/MS 
spectra analysed can be confidently assigned to peptide sequences.  Reasons for 
uncertainty come from many sources, for example: trypsin cleavage may not 
proceed to completion (depending on the protocol used); there can be inadequate 
mass resolution by the MS instrument to be certain of identity; and the search space 
can be too large to explore especially when the various possible protein 
modifications (such as oxidation or phosphorylation) are included in the search.  
Recent work by Matthias Mann‟s group is improving the situation, whereby up to 
90% of all fragmented peptides in yeast could be identified using high resolution 
Orbitrap (linear ion trap) instruments and a new search algorithm, MaxQuant (Cox 
and Mann, 2008).  In this case, the number of assignments was boosted by the 
„robust scoring‟ applied to peptides that were found to be modified versions of 
already assigned peptides.  This approach of re-searching for modified variants is 
applied in X!Tandem, and GAPP pipeline.    
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Proteomics search databases 
The search database applied for the peptide identification process is important.  
Increasingly, consensus spectra databases are being used for „pattern matching‟-type 
searches, instead of theoretical databases searches.  A consensus spectrum is a fusion 
of all available experimental MS/MS spectra for an individual peptide sequence into 
a single composite spectrum, which retains the most frequent m/z and intensity 
features.  The consensus spectra are also usually MS instrument-specific, since each 
approach favours detection of different fragment ion types.  The search process is 
analogous to methods used for small molecule identification, such as in 
metabolomics (Dunn and Ellis, 2005), whereby annotated spectrum libraries are 
searched for matches with unknown sample spectra.   
 
Since more MS/MS spectral data is available than ever before, there is now scope to 
construct this kind of database, whereas it was not an option before due to the lack 
of data.  X!Hunter (Craig et al., 2006) and SpectraST (Lam et al., 2007) are search 
engines designed to use consensus spectra for identifying peptides. These are the 
first examples, but the approach will no doubt increase in popularity as more data 
becomes available.  This is because, compared to searching a theoretical spectral 
database, consensus spectra offer faster identification speeds.  Moreover, by 
comparing real experimental (unknown) spectra to real (known) spectra, it increases 
the chances of correct identifications, because phenomena experienced in the real 
spectra will be captured in the search.  Theoretical spectra, on the other hand, may 
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capture the stochastic element apparent in real spectra, so may still have value in 
assisting identification. 
 
For the purpose of comparing the identifications derived from search engines (only 
PMF, tandem, tagging searches and limited support for de novo sequencing) there is a 
new standard data format, mzIdentML (formerly known as analysisXML) being 
developed by HUPO-PSI.  This XML-based format provides sufficient information to 
enable a subsequent researcher to run the same search using the same or another 
search engine, permitting validation of results by other scientists or reviewers.  It 
also supports enough information for tools to display the spectral evidence (if 
available) to demonstrate the peptide matches, including support for isotope 
labelling studies.  Metadata (search parameters), manual protein annotations, as well 
as the search database used are captured (but not the peak lists per se, only a 
reference to them).   
Inferring proteins from peptides  
All search engines generate peptide identifications.  Protein identifications, however, 
are made subsequently by inferring a match, given the peptides found.  In most 
cases, users first validate the peptides found; options to do this are in Figure 16.   
 59 
 
 
Figure 16 Peptide assignments from search engines may be filtered by user-specified criteria to attempt to 
remove false identifications before protein inference begins 
 
There are various algorithmic approaches to infer proteins from peptide 
identifications.  The principle of parsimony is sometimes used to overcome the 
problem of ambiguous peptides (Figure 17).   
 
 
Figure 17 The problem of protein inference.  The principle of parsimony (Occam‟s Razor) favours 
Protein A.    
 
Indeed, if the protein molecular weight and pI of the proteins are available (from the 
2D gel stage), then protein identification is made easier, however, this is usually not 
the case in high-throughput setups.  A tutorial on protein inference (Nesvizhskii and 
Pick the top scoring 
peptide and discard 
the rest
Apply an identity 
threshold (cut off at 
p<0.05)
e.g. Mascot
Use algorithms that 
calculate statistical 
confidence
eg. X!Tandem
e-value, 
Peptideprophet
probabilities 
Use a decoy database 
to estimate FPR
e.g. Mascot, 
X!Tandem
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Aebersold, 2005) suggests that peptides should be distributed using a probability-
based approach that takes the probabilities of peptide assignments into account 
(Nesvizhskii et al., 2003b).  This has an advantage of permitting calculation of 
statistical confidence measures for the protein identifications and allows estimation 
of false identification error rates resulting from filtering the data.  Indeed, 
Proteomics journal insists that for each protein identified there is a stated measure of 
certainty, such as a p-value.   
 
The identification of a single peptide is not usually deemed acceptable to confirm the 
presence of a protein; these are seen as unreliable thus are usually unacceptable for 
publication.  The more peptides are matched the more likely it is that the match is 
correct, and the protein isoform (splice variant) can be confirmed. 
Validating protein identifications 
The problem associated with automated searches is finding a means to assess the 
accuracy and hence reliability of the results, because without human interpretation 
false positive (FP) identifications may not be recognised as such.  FPs come about for 
several reasons, including unexpected enzymatic cleavage, lack of sufficient mass 
resolution, poor sample handling and background noise.  The cost of FPs can be 
substantial because such identifications can feed through into later stages of 
research, leading to, for example, phantom biomarkers or erroneous drug targets or 
erroneous conclusions about the underlying biology. 
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„Post-identification systems‟ are available to perform validation of protein 
identifications made by automated searches (Table 5).  In some cases, the validation 
and protein inference are performed by the same program as for APS in the GAPP 
pipeline, and ProteinProphet, for example. 
 
One approach to confirm identifications are correct is by taking a consensus across 
different search engines and deriving a composite score based on performance 
across the board (Alves et al., 2008, Jones et al., 2008a).  Consensus comparisons may 
be performed by Scaffold software (a proprietary offering), for example (Table 5). 
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Table 5 Post identification systems validate identifications derived from automated searches 
Program Reference Type of system Description Free to use 
on web 
Free 
software 
download 
Website 
       
 
(Searle et al., 
2008) 
Validation of 
diverse search 
engine results to 
reduce false 
positives  
Performs multiple searches on 
the same raw dataset in parallel 
and thereby compares 
independent interpretations of 
the same data, providing a 
confidence score of the 
combined results 
Yes  No www.proteomesoft
ware.com/ 
       
 
 
 
PeptideProphet 
(Keller et al., 
2002a), 
ProteinProphet 
(Nesvizhskii et 
al., 2003b) 
 
Validation of 
various search 
engine results by 
using probabilistic 
methods. Enhances 
existing search 
engine 
identification 
outputs by 
permitting 
comparison – with 
probabilities being 
on the same scale. 
 
 
 
 
 
 
 
PeptideProphet analysis is 
followed by ProteinProphet, 
which groups peptides by their 
corresponding protein(s) to 
compute probabilities that those 
proteins were present in the 
original sample.  
Yes Yes  http://peptideprop
het.sourceforge.net
/ 
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APS 
(Chepanoske et 
al., 2005), 
advanced APS  
(Shadforth et 
al., 2005b) 
Applies a threshold 
and, protein 
inference  
False positive protein 
identifications may achieve high 
scores as a result of many low-
scoring peptides. The average of 
peptide scores (APS) is 
calculated  and any proteins 
with an APS lower than a 
certain threshold is deemed 
false.  The threshold is set by a 
decoy DB search, which is  used 
to filter the hits returned from 
the target DB search (explained 
later).   
Yes, as 
part of 
GAPP 
No www.gapp.info  
Advanced 
Average 
Peptide 
Score (APS) 
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Another approach to reduce FPs is decoy database searching.  Using a decoy 
database it is assumed that the highest scoring match (between a peptide and a 
spectrum found) in the decoy search is a suitable threshold for filtering off the 
incorrect identifications found in the target search, and hence is used to eliminate 
FPs.  In this way, the decoy is exploited to test the null hypothesis; this being the test 
to determine whether a peptide was not identified in MS.  The caveats with this 
include the time consumed in searching the same dataset twice, and the difficulties 
in creating a mirrored distribution of the target without including any target 
sequences - to avoid forfeiting sensitivity.  Methods to reduce FP detection by decoy 
database searching have been published recently, including modification of 
PeptideProphet to incorporate a target-reverse proteome search (Choi and 
Nesvizhskii, 2008b), incorporation of a decoy database search option into Mascot 
and research articles such as (Elias and Gygi, 2007, Reidegeld et al., 2008).   
Proteomic pipelines  
Proteomic pipelines are the multi-step processing platforms required to seamlessly 
convert tandem MS/MS data into protein identifications by calling a specific search 
engine.  Using pipelines, thousands of spectra may be processed consistently and in 
manageable timescales; batch spectra submissions are usually possible.  In this way, 
pipelines provide a convenient route into proteomics repositories.  Pipeline steps can 
include: data format conversion, quality filtering, execution of a search engine and 
post-processing validation.  Examples include Global Proteome Machine (GPM), 
Trans-Proteomic Pipeline (TPP),  Genome  Annotating  Proteomic  Pipeline  (GAPP) 
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and others.  GAPP pipeline is applied to novel research in Chapter 4, and is also the 
basis of data analysis and capture for the tool developed in Chapter 5.   A detailed 
description of the most frequently used pipelines is presented in Chapter 3. 
 
In addition to existing pipelines, developers may use software frameworks to design 
their own bespoke, flexible workflows.  OpenMS (Sturm et al., 2008), for example, 
has a static core for download, and via this core OpenMS-specific or external 
software tools may be called (via the command line) to process HPLC-MS/MS data. 
There is a library of free packages comprising 350 classes and 100,000s of lines of 
C++ code.  The OpenMS Proteomic Pipeline (TOPP) (Kohlbacher et al., 2007) is one 
example of an OpenMS pipeline which is ready-to-use and designed to be run 
locally.   
Proteomic MS repositories 
Proteomics repositories are for storing, integrating and sharing MS/MS data.  Once 
the peptides and proteins have been identified in an experiment, their usefulness 
does not stop: by sharing and comparing the protein status of various samples, 
understanding of biology can be uncovered, for example, the proteins specific to 
certain tissues or organs (i. e. specific proteomes) can be identified by comparative 
studies.  There are many publicly accessible repositories on the internet, most with 
additional tools to make understanding the data in the repositories easier; effectively 
converting meaningless spectra and identifications into knowledge.  For example, 
the  PRoteomics  IDEntifications  database  (PRIDE)  provides  a  facility  to  generate 
  
66 
Venn diagrams to compare protein expression profiles between experiments in the 
database.  Moreover, graphical representation of the data, including clickable image 
maps of tissues where proteins have been identified are available (at the Max-Planck 
Unified Proteome Database (MAPU), for example), and dynamically generated 
spectrum views and colour shading to show significance of matches (at GPM 
database).  Programmatic querying (with API) is also available with some 
repositories, via Biomart, for example.   
1.3 Aims and objectives of this thesis  
This thesis is focused on key areas of unmet need in proteomic bioinformatics 
research and management.  For the management component, this EngD aims to 
establish the current state of exploitation of proteomic bioinformatics in public and 
commercial environments in the UK and abroad.  It looks at why the sponsor, 
GlaxoSmithKline (GSK), downsized proteomics and proteome bioinformatics 
research, and makes recommendations for future investment in proteomic 
bioinformatics products and services.   
 
The engineering research component aims to deliver computational solutions to two 
problems: first, to improve confidence when identifying proteins in MS/MS data, 
and second, to provide integrated online resources to support the next generation of 
targeted, quantitative proteomics research.  These deliverables will assist proteomics 
researchers in the community, such as those performing biomarker discovery and 
validation studies, and  will  help to  make  proteomics  research  cheaper  and  more 
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efficient, for example, by reducing the risk of false leads and saving time designing 
experiments.  Moreover, by improving the quality of identification and 
quantification of proteins, this EngD contributes to the field by moving resources a 
step closer towards achieving accurate proteome information for modelling the 
workings of biological systems in the future.   
 
The thesis is split into three parts: Part I (Chapter 2 and 3), Part II (Chapter 4), and 
Part III (Chapter 5 and 6).  The field of „proteomic bioinformatics‟ in industry and 
academia is mapped out in Part I.  In Chapter 2, for example, the question of 
whether proteomic bioinformatics is a commercially viable activity is explored.    The 
author investigates how high-throughput proteomics was funded, focusing on 
events from 1985-2009.  This is an important story that may present new lessons for 
the funding and development of new high-tech businesses in the future, and 
although there are rare examples of management literature for proteomics, such as 
(Mitchell, 2003) and a chapter in (Moody, 2004), there are no examples of 
investigations into the business history of proteomic bioinformatics, so the study will 
be unique, timely and a valuable resource for management decision-makers and 
investors in this field.   
 
In Chapter 3, a review of the freely available proteomics data repositories is 
performed.  This review highlights key data sources, which form the foundation for 
subsequent research in this thesis.  Moreover, the review represents novel research, 
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because a comprehensive overview of public repositories was not previously 
available.   
 
In Part II, approaches to improve confidence in the results from an automated 
proteomics pipeline are investigated.  Expert judgement calls cannot be made to spot 
incorrect identifications on a spectrum-by-spectrum basis using a pipeline.  
Therefore, decoy database searches may be performed to isolate incorrect 
identifications and filter them out.  In Chapter 4, therefore, the author investigates 
which decoy database design is most efficient at reducing FPR using the Genome 
Annotating Proteomic Pipeline (GAPP).    This is important research, because the 
cost of pharmaceutical R&D is rising, and by reducing FPRs the risk of pursuing 
false leads is lessened.   
 
Finally, new computational systems to support the design of quantitative MRM 
experiments are developed in Part III.  For example, designing transitions for MRM 
ab initio is challenging - it often requires empirical „discovery‟ studies and expert 
knowledge - therefore, a new algorithm is developed in Chapter 5 to speed up the 
design process.  The tool predicts the best candidates by leveraging existing public 
data resources and tools, and combines these with rules captured from expert 
practitioners.    Also, once a transition has been developed and validated in MS it 
may be reused, hence Chapter 6 describes the development of a new database 
management system for disseminating validated transitions, so researchers can 
easily re-use transitions instead of designing them from scratch, and spend less time 
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scanning heterogeneous literature for a suitable candidate.  In turn, this 
compendium will serve as a „shop window‟ to boost exposure of the data submitters‟ 
work and increase citations.   
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2 The business history of proteomic bioinformatics (1985-
2009) 
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2.1 Summary 
In this chapter, the author investigates the emergence of proteomic bioinformatics, 
the subject of this EngD thesis, and looks at the technological advancements and 
public and private funding mechanisms that enabled its development into a new 
industry of its own.  The management research performed demonstrates how 
business and science interacted to create new breeds of high-tech organisations – 
first, proteomics biotech‟s, followed by in-house departments in research and 
development organisations, and more recently niche firms focused on proteomic 
bioinformatics.  By presenting insights into how this new and specialised industry of 
proteomic bioinformatics developed, including detailed analysis of companies and 
operations in “big pharma”6, predictions are made for the future model of the 
proteomic bioinformatics market.  These recommendations are aimed at the 
management decision-makers at the project sponsor (the blue chip pharmaceutical 
company, GlaxoSmithKline), at investors in biotechs, and generally at decision-
makers and stakeholders who may be interested in exploring proteomic 
bioinformatics activities in the near future.   
                                               
6 ‘Big pharma’ generally refers to large pharmaceutical companies that have political influence.  Specific 
definitions vary but it is a widely used term in management literature.  Definitions include, for example,that  
revenue should be in excess of $2-3 billion, R&D expenditure should be in excess of $500 million, and/or the 
firm should operate in the major global markets (i.e. USA, Europe and Japan).   
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2.2 Introduction 
This chapter describes the development of „high-throughput‟ proteomics, and takes 
the reader from emergence of the science, and subsequent uptake by biotech and 
pharmaceutical companies, to the current status of the field.  It focuses on the 
interaction between the new science (proteomics and proteomic bioinformatics), 
commercial markets and public funding bodies.  As such, the resulting narrative is 
referred to as a „business history‟ of proteomic bioinformatics.   
2.2.1 The proteomic bioinformatics market is investigated using a 
business history approach  
A „business history‟ is a story about industry in the past, and can include the history 
of an individual firm, or entire business systems; often described using a specific 
time period and geographical location (Amatori and Jones, 2003).  The story usually 
includes the relationships between businesses and their political, cultural, 
institutional, social and economic contexts7.  Business history began as a discrete 
discipline at the Harvard Business School in the interwar years, with the first 
histories emerging in the 1950s8.  The business history approach is now widely used, 
and can contribute to decision-making and strategic management processes, often 
being published in journals, such as Enterprise and Society: The International 
Journal of Business History; Business History Review; and the Journal of Economic 
History.  Teaching case studies on an MBA course at Cranfield University, for 
example, are a type of brief business history, usually focused on a specific firm; and 
                                               
7 Taken from the remit for Enterprise and Society: The International Journal of Business History  
8 Examples include ‘The History of Unilever: volumes 1 and 2’ (C. Wilson, 1954, London) and ‘Pioneering in 
Big Business’ (about Standard Oil) (R.W. Hidy and M. E. Hidy, 1995, New York). 
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can be a convincing way to demonstrate business principles, stimulate ideas and 
teach strategy. 
 
The business history and analysis of the proteomic bioinformatics industry 
presented here is timely for three main reasons.  Firstly, decision-makers in big 
pharma, venture capitalists (VCs) and universities currently have no detailed reports 
regarding the business of proteomic bioinformatics and its associated technologies.  
This industry report leads the reader from no knowledge of proteomics to 
understanding the funding mechanisms, current market and wider context of 
proteomic science and informatics.  With this knowledge, better decisions may be 
made for funding proteomic bioinformatics and/or other similar technologies in the 
future.  Furthermore, the analysis presented has the advantage of being performed 
by an author actively involved in proteomic bioinformatics research, with relevant 
industry contacts and data sources to draw primary data.   
 
The second reason is that during the project (in 2005-6) GSK downsized high-
throughput proteomics in R&D.  This meant that no suitable new data were 
generated by the sponsor and hence the output of the project was not a system(s) to 
specifically meet the sponsor‟s needs, but rather relied upon publicly-available tools 
and datasets that were freely-available or from collaborators.  For the sponsor, 
therefore, this business research delivers a new account of the events that lead to the 
downsizing of proteomics as well as a description of the wider context in which 
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these events took place.  A new, independent perspective on these events is timely 
and valuable for the community to understand and learn from what happened. 
 
Finally, on a practical level, the business history and case-study-approach are 
employed, because empirical data and observations are the most accessible source of 
information on proteomic bioinformatics, which is a specialised, high-tech industry.  
It is not represented in management literature, so any other approach would not 
have been possible.  Moreover, the approach is a powerful one because by tracing 
developments over time, looking at the decisions made, funding provided and the 
players in the market, a picture of the business of proteomic bioinformatics may be 
drawn, and conclusions offered based on real evidence, rather than referring to the 
observations of others. 
 
The author believes that in spite of the downsizing that occurred at the sponsor, this 
management report (and the remainder of the thesis) demonstrates that the tools and 
techniques developed are timely and valuable for the next generation of targeted, 
quantitative proteomics research.   
2.2.2 Management hypothesis and contribution to knowledge 
The main hypothesis for this chapter is that there are links between the economics of 
proteomic/ proteomic bioinformatics and the way the science per se has developed.  
The main precept is that economic forces pushed the growth of the uptake of the 
science, not the true ability for the science to deliver valuable products and services.   
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This is the reason for the wave of investment suddenly drying up, once it was 
realised that commercially valuable protein biomarkers were not visible on the 
horizon. 
   
There are two main areas to investigate to demonstrate the truth of this hypothesis.  
Firstly, did the market for proteomic bioinformatics come about because of a process 
innovation (such as computer technology, new reagent development)?  Or, did it 
come about because of the excitement and the success of the genome sequencing 
project?  Was it scientific leaps or hype that would fuel growth and development of a 
new market for proteomic bioinformatics?  The business history presented here is a 
detailed examination of events, which will make the answer to this hypothesis clear.   
 
The contributions to knowledge of this chapter are threefold: this is the first business 
history ever to be written on the proteomic bioinformatics industry.  There are 
examples of business histories of new scientific fields, such as genetic engineering 
(McKelvey, 2000), and a review of proteomics as part of the digital revolution in 
biology (a chapter in (Moody, 2004)), however an investigation into the economics of 
proteomics/ proteomic bioinformatics per se is novel.  Secondly, the author has 
examined the two aforementioned research questions, and makes conclusions based 
on new history and case-based evidence collated specifically for this purpose; these 
data have not been described before.  Finally, this chapter represents the first 
attempt to put the business of proteomic bioinformatics into the context of the 
pharmaceutical R&D industry, and offers new recommendations about where 
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proteomic bioinformatics in this industry is going next; these predictions are new 
and unique. 
2.3 The business history of proteomic bioinformatics  
Events in the following business history are split into phases, and the funding for 
each stage of development is described.  This section serves as preliminary evidence 
for the recommendations made for potential investors in proteomic bioinformatics in 
the discussion section.     
2.3.1 The early innovators of proteomics and proteomic bioinformatics 
were publicly-funded   
It is commonly thought that proteomics came about as a result of the sequencing of 
the human genome, which took place during the late 1990s by the publicly-funded 
Human Genome Project and a parallel effort by Celera Genomics‟ J. Craig Venter.  
This is correct, since the now commonly used high-throughput approaches in MS-
based proteomics rely on search engines to identify peptides in mass spectra by 
searching a protein sequence database.  To do this, a genome sequence that is 
translated into proteins is needed, so the availability of a genome was important.  
However, the philosophy and desire to characterise the proteome in toto actually 
began years before.  According to Nicolas Wade9 (Wade, 1981) it began with the 
American pioneer, Norman Anderson, who first attempted to set up a human 
protein index project as a national objective in 1980 (reference in (Moody, 2004, Fong, 
2009)).  He failed at that time since gene-related research was the focus for funding 
                                               
9
 New York Times science journalist and author 
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agencies, however, in spite of this he and his son (Leigh) set up the first „industrial-
scale‟ protein cataloguing project in 1985.  With $1 million of US public funding and 
a team of around a dozen scientists, they began to create a database of protein maps.  
This database would contain x,y-coordinates of proteins measured on 2D-PAGE10 
gels; a technique that separates proteins on a square „canvas‟ of jelly.  The Andersons 
aimed to quantify each protein by measuring the size of its spot on the gel.  This was 
revolutionary, because it applied Henry Ford‟s conveyor-belt „brute force‟ to 
biology.  The aim was ambitious: involving creation of a catalogue of all human 
proteins and building a huge virtual repository to store the findings.    At this time, 
Edman degradation11 - a low-throughput chemical technique - was used to identify 
proteins.  This meant the project was colossal in terms of the time and resources to 
complete it; the Andersons predicted the eventual cost of their protein index to be 
$350 million over a further five years.  No one had seen protein research on this scale 
before.  Quickly it became clear, however, that they were failing to create a valuable 
catalogue.  The variability of the 2D gel approach meant that each time a gel was run 
the spots moved, making the database useless for other researchers.  Moreover, 
obtaining suitable quantities of interesting proteins was an issue, since unlike 
genomics, where PCR can be applied to amplify DNA, there is no such method to 
increase the quantity of protein.  In spite of the obstacles, the Andersons new „list-
based‟ approach to biology was revolutionary and ambitious.  They were early 
innovators, because their  ambitious  approach  was  to  characterise  the  proteomics 
                                               
10 See introduction for a detailed description of this technique. 
11 Edman degradation, named after its inventor in the 1950s, is a method of determining the order of amino acids 
in a peptide.  It is a relatively time-consuming, chemical method that pre-dates mass spectrometry for peptide 
sequencing. 
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biotech entrepreneurs a decade later.  Their work provided the first glimpse of the 
huge hype, and correspondingly large investment that would be stimulated by the 
promise of proteomics.       
 
Irrespective of the lack of continued funding the Andersons set up a company called 
the Large Scale Proteomics Corporation (LSPC) to create a proprietary proteomic 
database using their own gel platform „ProGEx‟, which could analyse “1 million 
proteins a week”12.  In addition to $1.4 million in internal funds in 1994 they received 
$1.9 million of US government‟s Advanced Technology Program: “Since no 
company...had improved ... electrophoresis since its development in 1975, sources of private 
funding for LSPC‟s efforts were difficult to find.”12.  The science was too young, and 
hence too risky, for private investors to get involved.  Several years later (1999), 
however, their technology was acquired by the Large Scale Biology Corporation 
(LSBC) and LSBC went on to release the Human Protein Index based on the 
Anderson‟s work.   
 
In Europe proteomics was also beginning to attract interest.  Oxford 
Oligosaccharides later to change its name to Oxford GlycoSystems then Oxford 
GlycoSciences spun out of the Glycobiology Unit at Oxford University in 1988.  The 
transition was managed by Oxford University‟s Isis Innovation Technology Transfer 
                                               
12 US government (NIST’s) Economic Assessment Office status report evaluating the performance of their investment in  
Large Scale Biology Corporation (formerly Large Scale Proteomics Corporation),  available at 
http://statusreports.atp.nist.gov/reports/94-01-0284PDF.pdf 
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Company13 and was directed by Raymond Dwek, who later became Head of 
Biochemistry at Oxford University (2000-06), and is now president of the Institute of 
Biology, UK.   
 
Oxford Oligosaccharides was a start-up that aimed to identify and analyse a specific 
type of protein: glycoproteins those modified with carbohydrate molecules14.  They 
were believed to play a role in important molecular interactions impacting 
reproductive biology, disease aetiology and regulation of biochemical processes in 
the body.  Initial funds for glycobiology research (£1 million per annum) were 
provided by Monsanto, then later the VCs, Advent Capital and Euro Ventures 
(Dwek, 2008).  The university, Monsanto (and Searle15, which Monsanto had then 
acquired) plus the scientists and staff were the initial shareholders.  A board of 
directors was recruited and head-hunters found the CEO – Raj Parekh, an Oxford 
postdoc.  The company became Oxford Glycosystems in October 1988 and went on 
to develop and market products for glycobiology, such as GlycoPrep 1000, which in 
1992-1994 was “purchased by nearly every major pharmaceutical company throughout the 
world” (Dwek, 2008).  However, they did not enter the MS „proteomics market‟16 
proper (as is the subject of this thesis) until they released their first product for high 
throughput proteomics in 1996.     
                                               
13 Isis Innovation Limited is the University of Oxford’s wholly owned technology transfer company.  Isis was 
established in 1988 and manages the University’s IP portfolio, working with University researchers to identify, 
protect and market technologies through licensing, spin-out companies, consulting and material sales. 
14 (Oligo)saccharide is another name for carbohydrate, hence the company name Oxford Oligosaccharides, 
which developed products related research into proteins modified with carbohydrate molecules. 
15 A company in the life sciences industry, specifically pharmaceuticals, agriculture and animal health. It is now 
part of Pfizer, the pharmaceutical company. 
16 The ‘proteomics market’ refers to businesses providing services or products for large scale proteomics, and 
specifically proteomics that is based on automated mass spectrometry workflows.   
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Another firm to embrace proteomics, Nonlinear Dynamics, started up in the UK in 
1989 in Newcastle-Upon-Tyne, and was to become one of the key players in 
provision of software for 2D gel proteomics, and is the subject of one of the company 
case studies to follow.  
2.3.2 High-throughput analysis became possible by applying mass 
spectrometry to proteins 
A critical turning point initiating the shift from expensive low-throughput protein 
identification to affordable high-throughput protein sequencing was the application 
of mass spectrometry (MS) to proteins (Barinaga, 1989, Hanash et al., 1991, 
Hillenkamp et al., 1991) (Table 6).   
 
 
83 
 
Table 6  Timeline showing key events in the development of high-throughput proteomics and proteomic bioinformatics and funding mechanisms. 
 1980s Early 1990s Late 1990s 2000s 2008-9 and onwards 
Technology 
developments 
2D-PAGE and Edman 
degradation 
„List-based‟ biology 
arrives 
Glycoprotein research 
begins 
 
 
2D gel reproducibility 
improved, 
quantification using 
spot size 
MS for peptide 
sequencing arrives 
First search engines 
arrive on internet 
Term „proteomics‟ 
coined 
 
Electrospray ionization 
(ESI) arrives – fully 
automated workflows 
now possible 
Protein biomarker 
discovery efforts using 
MS technology 
Nature warns against 
„mindless‟ high-
throughput studies 
New methods for 
quantification of proteins 
arrive (eg. ICAT) 
Validation, statistical 
approaches to increase 
quality of identifications 
derived from automated 
workflows 
Standardisation of data 
and reporting 
Journals push for data 
sharing/ dissemination 
Funding/ 
financial 
support 
US government 
funding (eg. 
Andersons) 
UK public funding (eg. 
Nonlinear Dynamics) 
Biotech funds (eg. 
Monsanto/Searle fund 
Oxford 
Oligosaccharides) 
 
 
US government 
funding 
Public funding (UK, 
USA) of research 
through universities 
 
Protein IP land- grab  
Private investment (eg. 
Oxford Glycosciences 
float, Celera stock 
offering, Geneprot 
Darier Hentsch) 
LSBC acquire 
Anderson‟s technology 
Public funds (eg. 
Imperial Cancer 
Research Fund and 
Mascot) 
 
phase 
Corporate venturing (eg 
pharma companies take on 
proteomics for 
development of workflows 
in house) 
Private investment and 
deal-making (eg. 
Confirmant: Oxford 
Glycosciences and  
Marconi, Myriad 
Proteomics) 
Oxford Glycosciences sold 
for £102 m 
Private and public funding 
(eg. Oxford Genome 
Sciences South East 
growth fund) 
 
 
Public funding of 
research  
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In the 1950s, scientists were trying to measure proteins by MS: Klaus Biemann at 
MIT in, for example, and later Howard Morris17 at Imperial College.  However, the 
problem of getting proteins to vaporise into the gas phase for entry into the MS 
instrument was to elude them and the introduction of Fast Atom Bombardment by 
Michael „Mickey‟ Barber in 1981 was the major breakthrough allowing native 
peptides to be ionised, without requiring chemical alteration.  However, MALDI18, 
the ionisation technique developed between 1987-1991 (Hillenkamp and Karas, 1990) 
delivered what is now called high-throughput proteomics, because large 
biomolecules (such as proteins) could be consistently ionised and enter the MS 
instrument.  MALDI-TOF (time of flight) MS arrived in several labs as a bench-top 
instrument for the first time in the early 1990s.  And in 1993, key ideas for applying it 
to proteins were developed.  Indeed, the discovery of the MALDI method earned a 
quarter of the Nobel Prize in Chemistry (in 2002) to Koichi Tanaka for demonstrating 
that it could be used to ionise protein.      
 
With new data becoming available from both gene sequencing efforts and new 
MALDI-derived protein spectra, proteomic bioinformatics was fast approaching.  
The first ever MS search engine, “Fragfit” (Henzel et al., 1993) performed an in silico 
digest of protein sequences, derived from translation of gene sequences, and 
compared the resulting peptide masses to MS spectra to identify proteins.  
Development of this program planted the seed for proteomic bioinformatics. 
                                               
17 He claims the first complete sequence of a protein by mass spectrometry (early 1970s) 
18 Matrix Assisted Laser Desorption Ionisation – a method to ionise and  vaporise proteins for visibility in MS. 
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Suddenly freely available software accessible via the internet arrived.  Indeed, 1993 
was described as a  „vintage year‟19 for peptide mass fingerprinting (PMF) programs, 
which improved on FragFit‟s original idea (Mann et al., 1993, James et al., 1993, 
Pappin et al., 1993, Yates et al., 1993).   
 
As a consequence of the surge in PMF tools, development of new and improved 
search algorithms began, spearheaded independently by Matthias Mann 
(Heidelberg), and John Yates III and Ruedi Aebersold (University of Washington, 
Seattle).  These two groups pioneered the first tandem MS search engines, 
Peptidesearch (Shevchenko et al., 1996) and Sequest (Eng et al., 1994), respectively.  
These new tools were the first in a new class of proteomic search engines that 
exploited fragment level information to make peptide identifications from which 
whole protein sequences could be inferred.  Another level of complexity was now 
being applied to the search; like a Google-type search engine, instead of searching 
just for webpage titles (peptide sequences), it could now include detailed webpage 
content (fragment masses) in the search.  The knock-on effect was automation of 
protein identification by combining search engines with high resolution MS 
instruments (also now becoming available).  High-throughput protein identification 
by MS would soon be affordable to many.  No biological insights of great note had 
been shown, but the technology was now viable enough to publish papers and 
present results.      Scientists were very interested, such as (Kahn, 1995, Jungblut and 
Wittmann-Lieboldb, 1995), and industry started to notice.   
                                               
19 Quoted from John Cottrell, Matrix Science, taken from a tutorial session delivered at the ASMS (American 
Society of Mass spectrometry) conference, San Antonio, Texas on June 5-9, 2005 
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2.3.3 Privately-funded biotechs competed for control during the land-
grab  
In mid-1994, the term „proteome‟ was finally coined by an Australian postdoc (Marc 
Wilkins).  Armed with a name, proteomics was ready to enter the main-stream.  The 
land-grab for intellectual property was ready to begin.  New biotech companies were 
established, each determined to be the first to identify proteins and their role in 
disease, in order to patent them and earn royalties from the pharmaceutical industry.  
Economics was driving the development of the science now.   But it was highly 
questionable whether biotech entrepreneurs were capable of moving immature 
proteomics technology from experimental labs to the wider market and be able to 
deliver knowledge to earn rents (van der Sijde et al., 2003).   
 
One of the first to cash in on the hype was Oxford Glycosystems, who in 1996 
achieved over $60m in private financing (Editorial, 1996) with Kirk Raab (formerly of 
Genentech20) as CEO.  They launched the „ProteoGraph‟ product for genome-scale 
proteomics (Editorial, 1997), and in 1997 formed the „proteome partnership‟ with 
Oxford University, changing their name to Oxford Glycosciences around this time. 
In April 1998 the company floated on the London Stock Exchange raising £30.8m 
(market cap: £103m) (Editorial, 1998).  This was achieved on their previous success in 
 
                                               
20 Now part of Roche, Genentech were the biggest biotech company in the world in the 1990s-2000s.  Set up by 
pioneers of genetic-engineering in 1976. 
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designing a drug for Gaucher‟s disease21 using glycobiology knowhow.  With the 
funds, Oxford Glycosciences invested heavily back into Oxford University providing 
a grant of £1.5m to the Glycobiology Institute to set up a proteomics facility in the 
Biochemistry Department.  They then continued in earnest with high-throughput 
proteomics, not glycobiology. 
 
The imminent arrival of electrospray ionisation (ESI) MS in 1998 further fuelled 
investment in proteomics.  ESI allowed direct coupling of protein separation to MS 
instrumentation, such that when the instrument was linked to a computer with the 
pre-processing programs (such as peak pickers) and proteomic search engine(s), the 
whole workflow from sample to identification could be fully automated.  As the 
Andersons had approached 2D gels in 1980s, now academics and companies in the 
late-1990s/2000s joined the race to perform huge scale MS-based studies to 
characterise entire proteomes before their rivals – in genome sequencing style.  
Having patented their new technologies, in 1999, Oxford Glycosciences, scaled up 
their operation building a proteomics data „factory‟ in Milton Park.  Proteomics 
facilities for biomarker discovery were now emerging in many universities and spin-
outs; the pharmaceutical industry had yet to get involved. 
   
In 1997, Geneva Bioinformatics (GeneBio) was formed by Ron Appel, Amos Bairoch 
and Dennis Hochstrasser, and became the commercial entity representing the Swiss 
                                               
21 A type of  lysosomal storage disease, a rare inherited metabolic disorder that results from defects in lysosomal 
function.  Lysosomes are organelles (sub-components) of cells in the body, which digest old organelles, food 
particles and engulf viruses or bacteria.  Symptoms may include enlarged spleen and liver, liver malfunction, 
skeletal disorders and bone lesions that may be painful, as well as severe neurologic complications. 
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Institute of Bioinformatics (SIB), providing premium versions of SIB‟s otherwise free 
data resources.  The company‟s mission was to provide high quality proteomics 
databases, software tools and services through in-house development and 
partnerships with universities, biotechs and pharma companies.  GeneBio is one of 
the company case studies described later.    
 
In London in March 1998 John Cottrell and David Creasy, both having left MS 
technology firm Finnigan (now part of Thermo Scientific), formed the first ever 
company based exclusively on a proteomic bioinformatics search engine product, 
called Mascot (Cottrell, 2003).  The product was based on the original MOWSE 
program (Pappin et al., 1993) developed at the Imperial Cancer Research Fund.  A 
later paper carefully omitted important details of the Mascot product algorithm 
(Perkins et al., 1999).  This company is an interesting case, because it has continued to 
grow in spite of the proteomics booms and busts around it.  It is one of the 
companies described in detail later. 
 
As commercial labs accelerated their efforts to catalogue all observable proteins 
using their new pipelines the editor of Nature cautioned that this may not be the 
most biologically meaningful approach (Editorial, 1999): “should funding agencies be 
pouring money into some global [human proteome project] strategy at this point?”  Nature 
was advocating the small-scale approach, where studies would lead to conceptual 
understanding of biology, rather than long lists of protein IDs.  Quality is better than 
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quantity.  Commercial labs did not take heed of this warning and huge investments 
were made to achieve the absolute opposite.     
 
Celera, for example, the company responsible for sequencing a large chunk of the 
human genome, announced their Human Proteome Project in 2000.  They intended 
to identify the properties and functions of every human protein (Butler, 2000) and 
make revenues through lucrative patents.  Craig Venter, the company president, was 
quoted in Science at the time: “We‟re going to have the biggest facility and the biggest 
database…we‟ll be working through every tissue, organ, cell” (Service, 2000).  Celera 
managed to obtain $944 million in a stock offering (Washtech@WashingtonPost).  
Venter could achieve these colossal amounts on the back of his previous success in 
sequencing the genome.  The proteome, however, is not the genome; it is something 
with more dimensions and is much harder to pin down.  Venter approached 
GeneBio co-founder, Hochstrasser, with an attempt to join forces with SIB.  No 
partnership was forged since Hochstrasser‟s view on open data access did not fit 
with Venter‟s vision.  Celera is re-visited later.    
 
In 2000 GeneProt (Geneva Proteomics) was established by the three co-founders of 
GeneBio.  It planned to set up a „proteomics factory‟ to compete with rival Celera.  
Huge investment ensued: in April 2000 the seed round of financing22 raised $4.6 
million  and  three  months  later  a  further  $40  million  was  raised  through  six 
 
                                               
22
 Funded through Switzerland’s Darier Hentsch Life Science Fund 
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additional European funds (PressRelease, 2000b).  Soon after, they spent $70 million 
with Compaq for supercomputing equipment.  A deal was then signed with the 
Swiss pharma giant Novartis, where in return for $43 million equity investment 
GeneProt would “analyse the protein profile of three human diseased tissues…and their 
healthy counterparts” (PressRelease, 2000c).  The idea was to apply the proteomic data 
generated by GeneProt to identify novel protein-based targets for use in medicine 
development.  The company was fully operational by 2001, and had an additional 
facility in USA. At the time, it claimed to have the world‟s most powerful super-
computer and proteomic discovery facility (PressRelease, 2001f).  The investors were 
leading, the science was trailing. 
 
Next Oxford Glycosciences announced (2001) that they were building „ProteinAtlas‟.  
It was to be sold on subscription basis by a company called Confirmant - a joint 
venture between Oxford Glycosciences and Marconi23- which formed just before 
Marconi went into liquidation (PressRelease, 2001c).  Their short-term aim was “to 
become the leading provider of bio-information” and long-term, to circumvent pharma 
distribution channels by developing “online, real-time diagnostics, made available to 
physicians…on a pay-per-use basis”.  In parallel to this announcement, the Anderson‟s 
Human Protein Index database was completed.  The LSBC annual report for 2000 
outlined their strategy.  Their database contained protein information for all major 
tissues so was to become: “the definitive source of information about human proteins”, 
                                               
23 Available at http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-15-
2001/0001514667&EDATE= 
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although their 2001 annual report stated a shift to “develop therapeutic products using 
our proprietary technology”. 
 
It is clear that the promises of proteomics were fuelling great expectations in the 
markets.  But the market got ahead of itself, before the science could actually 
demonstrate that it could deliver.  According to Frost & Sullivan24 in 2001, 
proteomics was estimated to grow from $700m in 1999, to $5.8bn in 2005 
(Frost&Sullivan, 2001).  Quotes from the then Director of Drug Discovery 
Technologies, Stefan Unger, suggest the high-throughput nature of proteomics, and 
the fact that the technology was in its infancy, were the drivers for the huge 
investments in proteomic biotechs:  "The main difference between the old and new 
paradigms is in the high-throughput, parallel thinking…There are no clear winners in these 
early stages of market development for proteomics, which means there is a wealth of 
opportunity".  151 different proteomics biotech companies appeared in F&S‟s 2001 
report including all areas of the proteomics market: instruments, "wet" technologies 
& supplies, lab services, and bioinformatics: "With over 40 commercial funding activities 
of various types (VC, IPO25, mergers, etc.), this is a very rapid pace for a discipline that was 
unnamed just six years ago". 
 
In 2001 Myriad Proteomics, was formed in collaboration with Oracle and Hitachi 
and headed by Nobel Prize winner Walter Gilbert (who founded Myriad Genetics).  
                                               
24 A global a strategic market research consultancy based in San Jose, CA 
25
 Initial public offering: when a company issues shares to the public for the first time. 
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The venture was valued at $185 million and aimed to “analyse all proteins and their 
interactions” (PressRelease, 2001d)26.  The business was based on collection of 
proteomics information in a proprietary database (to be ready by 2004) using 
proprietary technologies including: ProNET, protein interaction technology 
(industry-scale yeast two hybrid27) and ProSpec (proprietary MS technology for 
identifying protein complexes).   
 
Myriad‟s formation marked the ignition of the proteomic biotech bomb.  High 
profile doubters of the high-throughput approach to proteomics began to engage 
with the media.  The president of Hybrigenics28 said of Myriad‟s mission: “there‟s no 
way they‟ll come close to it!”(Pollack, 2001).  Myriad replied: they intended to look 
only at “10-12 cell types”. The famous Venter quote “there ain‟t no such thing as a 
proteome” then appeared in The Wall Street Journal (Hamilton and Regalado, 2001), 
and in The New York Times “We don‟t think there‟s much value in a general survey of 
proteins” (Pollack, 2001).  This is the key point, because suddenly everyone had 
realised there was no „value‟ in high-throughput proteomics.  The economics could 
not drive the growth anymore, because it was not there.     Celera ceased to catalogue 
proteins, switching instead to designing new drugs as a fledgling pharmaceutical 
enterprise.  LSBC also pulled out: in 2002 they reorganised stimulating both 
Andersons to resign from their life‟s work.   
 
                                               
26 Available at http://findarticles.com/p/articles/mi_m0EIN/is_2001_April_4/ai_72721585 
27 Interaction proteomics – a method to determine protein to protein binding interactions at the molecular level. 
28
  A Parisian biotechnology and pharmaceutical company 
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Oxford Glycosciences was bought by Celltech for £102 m in 2003, which was 
groundbreaking for a biology-based University spin-out.  It lead the formation of a 
new proteomics company, Oxford Genome Sciences, now called Oxford 
Biotherapeutics (one of the case study firms, see later section).  This new company 
acquired the proteomics division of Oxford Glycosciences and used this to start the 
new enterprise.  This was perhaps not ideal timing to start a proteomics company, 
since the land-grab was losing momentum and reputation of proteomics was 
diminishing.  In fact, as explained in the case study later, OGS‟s success would 
depend on how well they could exploit the potential growth for out-sourcing of 
proteomics, as the pharma companies began to downsize in-house research in this 
area in the mid-2000s.   
 
In academia, steps were being taken during the late 1990s to improve proteomics 
techniques.  One of the major drawbacks of proteomic MS was that proteins could be 
identified, but not quantified (Mann, 1999).  To address this, Aebersold and his team 
invented isotope-coded affinity tagging (ICAT) (Gygi et al., 1999).  In 2001, Oxford 
Glycosciences (before the Celltech buyout) collaborated with these inventors to 
create state of the art quantitative proteomics facilities (PressRelease, 2001e).  Protein 
interactions were also emerging as a new area of interest.  In 2000, proteomic 
„interactomics‟ arrived with yeast-two-hybrid technology being described for the 
first time (Uetz et al., 2000) (later applied by Myriad Proteomics‟ ProNET approach, 
as described earlier).  Interestingly, both quantitation and interaction proteomics 
were moving away from the principle of list-based cataloguing, which was still 
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going on in industry.  Instead, these approaches delivered detailed understanding of 
sub-sets of proteins, like traditional biochemistry, as Nature has endorsed earlier.   
 
To summarise, it appears that the development of the proteomics market was 
stimulated by the willingness of investors to believe in MS technology and 
bioinformatics analysis could deliver.  The cost-effectiveness of these new 
approaches (ability to produce huge datasets in little time) rather than scientific 
efficacy drove the boom in proteomics biotechs.  Indeed, the capacity of new 
techniques to generate value (as patents on new drug targets, for example) was 
limited in the extreme.  This clearly demonstrates that it was the economics, rather 
than the true potential of the science that stimulated emergence and growth of this 
new market. 
2.3.4 Big Pharma invested heavily in proteomic bioinformatics 
infrastructure  
In the pharmaceutical industry, heavy investment went into high-throughput 
proteomics, both during the surge in biotech funding and after biotechs began to fail.  
During the late 1990s to early 2000s productivity across pharmaceutical R&D 
organisations was declining (Prasad, 2004, Garnier, 2008).  The amount spent on 
R&D was not reflected in the number of candidates making it through the drug 
development pipeline (Dimasi et al., 1995); there was an incentive for firms to try out 
technologies to try to increase the flow.  Moreover, in the mid-2000s it was getting 
harder to convince the regulators that new NCEs  (new chemical entities)  were  safe, 
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effective and better than the existing alternatives.  A new breed of medicines, „bio-
pharmaceuticals‟, were now being developed, where large molecules, such as 
peptides and protein molecules (antibodies, as in Herceptin29, for example) were 
being designed as therapies, instead of small drug molecules.  New avenues, such as 
these, were being explored because the industry needed innovative approaches; 
proteomics and its associated bioinformatics activities would form part of this drive.  
 
GlaxoSmithKline (GSK), the sponsor of this EngD (from 2005 to 2009), is taken as a 
case to illustrate how proteomics was carried out in R&D-based pharmaceutical 
firms at the time30.  Prior to the merger in 2000, both Glaxo Wellcome (Glaxo) and 
SmithKline Beecham (SKB) were using some tandem MS to identify proteins in 
samples from humans and model organisms, with both companies having labs in the 
US and UK.  High-throughput proteomics, however, began only after the merger.    
Pre-merger Glaxo joined forces with Cellzome for proteomics  
With several new proteomics-based biotech companies already trading, Glaxo began 
proceedings to set up its own independent spin-out company called the Cell Map 
Incubator (CMI).  CMI was based on the biotechnology expertise within Glaxo at the 
time, and planned to study protein-protein interactions on a large-scale.  The CMI 
company would recruit its scientists from Glaxo, including Walter Blackstock (cell 
biologist, mass spectrometrist and co-founder of the earlier  cell  map  unit  in  Glaxo, 
                                               
29 Trastuzumab is a breast cancer treatment.  It interferes with the HER2 protein receptors, which regulate cell 
growth, survival, adhesion, migration, and differentiation – all processes affected in cancer. 
30 Information on amounts invested could not be released.  Instead, the information presented is taken from 
public sources, such as press releases, and from interviews with remaining GSK employees in bioinformatics. 
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1998), and it would specialise in generating and analysing proteomic MS data.  In 
exchange for their investment, Glaxo would receive proteomics services at a 
discounted price from CMI in the future.   
 
However, regrettably for CMI, the merger with SKB happened just before it began 
trading.  As a result, several key players pulled out.  Some experts remained at GSK, 
but most moved elsewhere (Malcolm Ward and Helen Byers for example, who 
joined a new proteomic MS company, ProteomeSciences – listed on the AIM stock 
exchange in 1995).  Blackstock joined Cellzome UK soon after, in 2000.   
 
CMI‟s business model was based on the expertise, skills and knowledge of its 
scientists, so after haemorrhaging their most important resource, it was forced to 
collaborate with an external third party.  After deliberation, they chose Cellzome 
(PressRelease, 2001a).  This was a compelling choice, because Cellzome had links 
with the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. 
 The partnership meant that Cellzome could provide bioinformatics services, and 
CMI would perform MS in the UK to generate data.  This setup appeared to be 
working until 2006, when Cellzome dropped the MS function, in line with other 
major downsizing of MS in big pharma.  This down-sizing is described now. 
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Post-merger GSK invested in proteomics workflows and IT 
infrastructure in the UK and USA 
After the spin-out of CMI, a „home-grown‟ proteomics facility was established at 
GSK.  Workflows were set up to analyse samples using most types of proteomic 
analysis; in particular, high-throughput MS to discover biomarkers for a variety of 
diseases in easily accessible samples, such as serum.   
 
There was a „buzz‟ surrounding proteomics at the time.  Scientists believed that 
proteomics would be capable of providing a supply of new biomarkers; so GSK 
invested heavily in proteomics capability.  Indeed around 2002, a major focus was on 
large scale phospho-proteomics studies, since GSK was aiming to understand how 
chemical modification of proteins (with phosphate groups) affects biological 
pathways and cell signalling (Annan, 2002) thus developing new ideas to design 
drugs to target kinases31. 
   
By 2001/2, the six CEDDs32, instituted by CEO Sir Richard Sykes and his successor J-
P Garnier were up and running, each investigating a different therapeutic area in 
GSK‟s portfolio.  Feeding the CEDDs with new candidates were the drug discovery 
„research‟ organisations: discovery research (DR) and genetics research (GR). These  
                                               
31 Kinases are ‘druggable’ enzymes that catalyse phosphorylation reactions in the body.  Druggable refers to 
their ability to be targeted successfully with medicines.  Kinases are phosphotransferases that transfer phosphate 
groups on other molecules, and are involved in cell signalling.   
32 Centres for Excellence in Drug Discovery.  These are smaller centres in R&D, each focuses on a specific 
disease area.  They were set up after the merger to improve the efficiency of research in such a large 
organisation like GSK. 
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carried out research typical to a “classical proteomics department” (Annan, 2002), 
including comprehensive high-throughput experiments.  Organisationally, the 
bioinformatics group for proteome research was aligned to GR, performing the 
occasional ad hoc project for DR.   
 
Large investment was put into instrumentation (Roland Annan Head of Proteomics: 
“We have…one of everything here” (Annan, 2002)) as well as hardware and software 
solutions to capture, store, analyse and report huge amounts of data being generated 
from DR and GR workflows.  In the early 2000s, software suites that could pipeline 
data into a searchable repository were scarce and were either too specific or too 
generic.  GSK built a bespoke, adaptable infrastructure for data analysis, working 
with a number of third parties, in particular Matrix Science.  The result was a system 
called „Proteominer‟, directly integrated with the Mascot result files.   
 
Collaborations with academia in proteomics were ongoing, including in 2002 links 
with Ray Deshaies at the California Institute of Technology (CalTech).  No corporate 
partnerships were in place, however, as was the case for rivals like Novartis, who 
joined with GeneProt.  GSK had greater in-house expertise, for example in genomics, 
so needed to rely less on third parties (Annan, 2002). 
Proteomics was downsized at GSK  
The turning point came in 2005.  Previously (in 2002), the head of proteomics at GSK 
(Roland Annan) had stated that “upper management here thinks that [proteomics] can  
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make an important contribution to all aspects of drug discovery...applications for proteomics 
are still evolving.” (Annan, 2002).  Management were changing their view.  Annan‟s 
comment on applications of proteomics was telling.  It shows that investment has 
been driven by economic grounds, not based on what science could deliver to GSK.  
GSK could not find a place for proteomics to add value. 
   
By this time, however, the volume of MS/MS data generated had grown, so too had 
spending on Mascot licenses and Blade servers.  The board had begun to notice that 
the cost-benefit profile of proteomics was not acceptable.  There had been no impact 
on the drug discovery pipeline; a scenario that was encountered by many labs in 
industry, as well as their academic counterparts: “...there are no clear success stories in 
which discovery proteomics has led to a deployed protein biomarker”(Rifai et al., 2006).   
 
Technology platforms were prioritised at this stage, and compared with other 
emerging technologies, such as transcriptomics and high-throughput screening 
(HTS)33, proteomics‟ impact on the drug discovery was noticeably inadequate, as 
was the case for GSK‟s rivals.   Consequently, in winter 2006 all proteomics activity 
was stopped.  The remaining proteomics research activities would be very small or 
                                               
33 A method of drug discovery that involves testing hundreds of thousands of compounds against a particular 
target – so all permutations of the problem are tried to find a match, rather than undergoing rational design.  
HTS is an automated process  involving  modern robotics, sophisticated control software, advanced liquid 
handling and detection methods. The hits generated during HTS can be used as the starting point for a drug 
discovery effort. Many pharmaceutical companies are screening between 100,000 and 300,000 compounds per 
screen to produce approximately 100 to 300 hits. Usually only 1 or 2 of these hits become lead compounds for 
further development. Occasionally, screens of over 1 million compounds are required to generate a sufficient 
number of lead compounds.   HTS can also be used in safety studies, to screen for compounds with undesirable 
activity. 
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outsourced.  This inevitably prompted disposal of MS instruments and an exodus of 
MS scientists, several moving to biotechs and back to academia34.    
GSK has a new CEO and proteomics does not feature in his 
plan 
Since 2006, proteomics and related research has remained absent from GSK.  Current 
CEO, Mr. Andrew Witty, consulted the firm's shareholders after taking his post in 
May 2008.  Many were discontented with years of underperformance, thus, 
demanded "more growth with less risk” (PressRelease, 2008c). This suggests that the 
consumer goods part of GSK‟s business will grow, not the more risky R&D-base in 
which proteomics and bioinformatics sit (Russell, 2008).  Interestingly, Witty‟s 
background, unlike previous GSK CEOs, is in economics not science or medicine.   
 
Witty‟s role as CEO is to mediate between innovation in R&D and the overall 
business strategy of the firm.  As such, he has the central role in the ultimate 
outcome for GSK.  To bridge the market and innovation in R&D, he plans to 
outsource R&D activities to contract research organisations (CROs); implying that if 
proteomics were to prove valuable in the future, it would be bought in not grown. 
 He is simplifying the structure of R&D and intends to encourage competitiveness, 
as in small biotechs, by setting up teams that must compete for up to $1 billion in 
annual funds from a „Drug Discovery Investment Board‟.  This board will include 
VCs and an external (biotech) firm's senior executive. The idea of this role-play is to 
                                               
34 For example, Arthur Moseley who is now the Director of Proteomics for the Institute for Genome Sciences & 
Policy at Duke University’s School of Medicine.   
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simulate the pitching process of a university spin-out, to ensure that R&D‟s activities 
can only proceed if the proposed strategy fits with the current, highly competitive 
marketplace.  This may help, although if the investments made previously by 
biotech investors in this space are exemplary of the decisions made by the market – 
then these can also be amiss, presenting Witty with a no win scenario. 
2.4 Current status of the proteomic bioinformatics market 
In this section the most topical areas of funded academic research in proteomic 
bioinformatics are described and following this, the current state of the proteomic 
bioinformatics industry is presented with case studies for firms operating in the UK, 
continental Europe and North America.  In this section, the author demonstrates 
how the research work for this EngD thesis is relevant and timely, given the status of 
the field.   
2.4.1 Proteomic bioinformatics research is publicly funded again 
Proteomic bioinformatics research has continued to receive small amounts of public 
funding in the UK.  Funding awarded between 1998 and 2008 for England is shown 
in Figure 18 (details of each grant are available in Appendix II).   
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Figure 18  Distribution of BBSRC funds in England for bioinformatics research for proteomic MS 
between 1999 and 2008
35
.  Only grants for software and computational hardware for proteomics were 
considered.  See Appendix II for information on each grant.  From this sample, the Wellcome Trust 
appears to be the most engaged in funding bioinformatics projects for proteomics, such as the PRIDE 
(Proteomics IDEntifications database) grant (PressRelease, 2005d).  The figure illustrates a sample only, 
other possible funding sources are available, but not reported here due to data access issues.   
 
To obtain a snapshot of public spending globally is more challenging, since there is 
no easy way to search awarded grants in specific areas, such as via the NIH 
(National Institute of Health, USA).  However, activity in proteomics can be traced 
indirectly using a major public proteomics repository, The Global Proteome Machine 
Database (GPMDB), because it provides detailed statistics on hits by country (an 
example is shown in the Appendix II).  It shows the global proteomics „hot spots‟ are 
                                               
35 Information taken from BBSRC Oasis database of awarded grants.  Only research grants are considered, not  
teaching  or fellowships.  The database can be found at  http://www.bbsrc.ac.uk/science/grants/index.html 
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Seattle and the South East UK.  Seattle is home to the Institute of Systems Biology, 
and the UK has the European Bioinformatics Institute – major hubs for data in 
proteomics.       
Ideally, large-scale proteomics would now be a commercially viable activity earning 
rents through with private funding.  Instead, it has come full circle.  The early 
innovators (Andersons, Mann and Aebersold) were publicly funded and after the 
tsunami of biotech and pharma investment, it has now dried up again leaving the 
field in a funding situation as per the 1990s.  This suggests that the economy is still 
waiting for proteomics to deliver on its potential.  Private funding and interaction 
with financial markets will resume if investors believe in the science of proteomics.       
2.4.2 Company case studies illustrate the current market for proteomic 
bioinformatics products and services 
Despite general disinvestment, proteomic bioinformatics companies are still trading.  
To illustrate the current status of the market, key players have been examined.  Case 
studies are used to examine how businesses were funded over their whole life cycle, 
and to see if there are any patterns which support or contradict the overall industry 
summary and the conclusion that too much investment was made too early.   
Funding routes are varied, and different funding providers have very distinct 
expectations as regards the return on the investment they provide.  VCs, for 
example, expect quick and large returns on their investment, as this is the nature of 
their business model.  Government agencies and charities, however, do not usually 
demand returns in the short term, but rather invest with a view to obtaining revenue 
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opportunities and societal benefits in the longer term.  This difference in priorities 
must be applied when interpreting the case studies in this chapter. 
Only firms that generate revenue from MS-based proteomics software or software-
related products and services36 are considered. MS-instrument vendors are therefore 
excluded because they provide proteomics software as part of larger product 
bundles, and it would be virtually impossible to consider the two revenue streams 
separately.  This may cause a bias, since the MS vendors (such as ThermoScientific, 
Agilent, Waters, Bruker, Shimadzu and others) represent large providers of software 
products for MS-based proteomics.  In some cases, the innovative elements of the 
software products sold by these vendors originated from university research or R&D 
in niche bioinformatics companies and the software is incorporated into MS 
instrument vendor bundles at a later stage: through licensing agreements, for 
example.  Specific examples include the Sequest search engine which was previously 
freely available (developed by John Yates III et al (Eng et al., 1994)), but is now 
exclusively available from ThermoScientific.  In this way, the two types of company 
are linked.     Examples of niche firms that have been left out include GenoLogics 
Life Sciences Software (USA) and Accelrys Software Inc. (Canada); which both have 
software platforms for proteomics, but their products are not exclusively in this area.  
Bioinformatics Solutions Inc.  (Canada)37 are not included, although they have a 
search engine product for de novo sequencing peptides from MS/MS spectra, because 
too little information was available to include them.  
                                               
36 Gel-based proteomics software is also included in some instances.  This is acceptable since in practice, gel 
studies are often linked to MS experiments. 
37
 See www.bioinformaticssolutions.com 
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CASE STUDY 1: Oxford Biotherapeutics Ltd. 
This start-up company was incorporated in November 
2003 and began trading 18 months later.  The 
opportunity to start a new proteomics company came 
about when Oxford GlycoSciences (OGS) and the newly formed company, 
Confirmant (a joint venture between OGS and Marconi) were acquired by Celltech 
plc in 2003.  At the point of purchase, OGS had three core areas of business: 
oncology drug development, inherited disease drug development and proteomics 
services.  The latter two were of significant value to Celltech, offering precious IPR 
for potentially lucrative drugs.  Proteomics, as a research service, did not.  This 
meant that Christian Rohlff (OBT‟s current CEO) and other senior members of the 
proteomics division at OGS could strategically acquire technology, infrastructure, IP, 
bioinformatics and data that Celltech did not want (PressRelease, 2003a), including 
OGAP® (The Oxford Genome Anatomy Project) (Rohlff, 2004).  OGAP is a unique 
database of high quality protein data derived from (formerly) state of the art 
proteomics facilities at Oxford Glycosciences, one of the largest in the world at that 
time.  This was not a management buy-out; instead a completely new company was 
started up.  Proteomics was going to be their business, but by retaining a familiar-
sounding acronym „OGeS‟, it meant that the company could maintain continuity 
with existing clients and exploit Oxford Glycosciences‟s good reputation.  Five years 
later - in November 2008 - OGeS became Oxford Biotherapeutics (OBT) to better 
reflect its expertise in proteomics. 
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Initial funding for the firm was provided by the South East Growth Fund, part of the 
UK government agency SEEDA38 in July 2004. Investors in this fund included GE 
Commercial Finance, Barclays, The Royal Bank of Scotland, the European 
Investment fund, Berkshire Pension Fund and the DTI (Smart Awards Scheme) 
(PressRelease, 2005b).  The company‟s pitch was to perform biomarker discovery 
and evaluation using high-throughput proteomics and bioinformatics.  Later the 
fund invested further (March 2005) (PressRelease, 2005b) as part of a larger 
investment round including the venture capital firm, Oxford Capital Partners 
(PressRelease, 2005f).  This second tranche of financing was for the move to larger 
custom-built facilities, the largest of its kind in Europe.  In February 2007, Catapult 
Growth Fund invested £1,200,000 (PressRelease, 2007f).  This is private equity firm 
funded by the UK government‟s Department for Business, Enterprise and 
Regulatory Reform and local authority pension funds.   
 
OBT is still privately held and based in Abingdon, Oxfordshire, with an additional 
site in San Jose, California.  It has 16 employees.  The firm‟s income comprises 
approximately 50% government grants and 50% commercial contracts, see Table 7 
for the financial performance information.  Grants include schemes such as the DTI‟s 
Smart Awards and TSB39 competitions, in return for which OBT must match the 
donated funds 100% - providing documentation and attending quarterly meetings.  
The remaining revenue stream is bespoke projects for pharmaceutical companies.  
                                               
38 South East England Development Agency  
39 The Technology Strategy Board.  Government agency which has a budget for 2008-2011 of £711 million plus 
aligned funding from the Regional Development Agencies of £180 million and at least £120 million from the 
Research Councils.  
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Since the majority of big R&D-based pharmaceutical companies have downsized 
internal proteomics research activities, OBT is presented with potentially lucrative 
opportunities to sell contract research services, allowing their clients to avoid 
expensive internal headcount.   
 
Table 7  OBT‟s financial performance (source: Companies House, UK) 
 
 
 
 
The contract services offered include protein biomarker discovery, the “bread and 
butter” 40 of the business (approximately 60% of contract revenue), and proteomic 
assay development, including design of MRM (40%).  Both of these services involve 
significant expertise in proteomic bioinformatics and data analysis, and they rely 
heavily on exploitation of OBT‟s most valuable asset: OGAP.  This is OBT‟s source of 
competitive advantage, because it provides the value-added elements to the 
discovery and development services they offer.  The database includes clinical and 
SNP41 information along with protein expression data on an enormous scale, 
containing over a million peptide sequences from over 50 different tissues involved 
in 58 diseases, including 5,000 cancer membrane proteins42.   This  means that  when  
                                               
40 Quoted from Martin Barnes, Head of Bioinformatics, OBT  
41 SNPs and haplotypes are the genetic differences between populations or individuals that can affect 
susceptibility to certain diseases. 
42
 Membrane proteins are often the preferred targets for drugs 
Year Turnover (£) P & L (£) 
2006 427,342 -546,484 
2007 0 -1,265,168 
2008 not available until 
October 2009 
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biomarkers are to be discovered many possible clinical implications can be 
accounted for, allowing evidence-based multi-marker assessment – an attractive 
proposition to big pharma.   
 
OBT have partnered with Medarex, a specialist in antibody technology.  OBT license 
Medarex's proprietary transgenic mouse43 technology to generate antibody 
therapeutics against cancer proteins that OBT identify using OGAP.  OBT retain 
worldwide rights to the antibodies generated, and Medarex has the right to receive 
license fees, milestone payments and royalties on commercial sales of any products 
that may result from the agreement: all on a 50:50 cost and profit share basis 
(PressRelease, 2007g).  Medarex would have liked to purchase OGAP outright, but 
greater value could be leveraged by OBT by retaining it.   
 
In 2006, OBT partnered with BioSite (San Diego), a company specialising in 
commercialisation of protein-based medical diagnosis (PressRelease, 2006a).  This 
strategic partnership improves OBT‟s position in personalised medicine. There is 
also a three-way agreement with Biosite and Medarex, where Medarex provide 
access for Biosite to transgenic technology, and Biosite carry out early stage antibody 
generation on behalf of OBT for OBT‟s programs. Amgen also collaborate with OBT 
to develop and commercialise antibody therapies (PressRelease, 2007a), where OBT‟s 
                                               
43 In this case, transgenic mice are genetically modified mice, which are used to generate antibodies that are 
suitable for human therapeutic use, for example to treat or diagnose cancer.  The mice produce ‘humanised’ 
antibodies, which are less likely to cause an adverse immune system reaction in humans 
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role is to provide novel druggable44 protein targets to which fully human antibodies 
can be raised by Amgen‟s proprietary Xenomouse® (transgenic mouse) technology. 
 
Going forward, OBT wants to commercialise components of OGAP via vendors of 
MS instruments and associated software packages.  MS vendors offer very attractive 
routes to consumers and could greatly expand OBT‟s market by exploiting their 
huge network of existing research laboratory clients.  At present, however, OBT is 
„too resource-constrained‟ to invest in product development to prepare OGAP for this 
kind of proposition.  Of course, OBT‟s market position is based on OGAP, so they 
will need to be very careful if they want to share even parts of it with such powerful 
organisations. 
  
                                               
44 Implies that the protein can be targeted by a chemical compound (medicine).  This type of protein is most 
suitable when designing a new drug.  
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CASE STUDY 2: Matrix Science Ltd. 
Matrix Science Ltd. was set up by John Cottrell and David Creasy, 
experts in scientific software /analytical hardware for protein MS, who had prior to 
their venture worked for Finnigan, now part of Thermo Scientific - a major MS 
vendor.  The company was launched initially in collaboration with the Imperial 
Cancer Research Fund (ICRF), with the original idea for the product, the molecular 
weight search (MOWSE) algorithm (Pappin et al., 1993) from Darryl Pappin, head of 
the Protein Sequencing Laboratory at ICRF.  Cancer Research technology, the 
technology transfer subsidiary of this fund, licensed the rights to MOWSE to Matrix 
Science.  To further develop the program into a viable product, Matrix Science 
partnered with BioVisioN (of Hannover, Germany), a peptidomics45 company.  
BioVision had lab-based research expertise, which could be combined successfully 
with Matrix Science‟s bioinformatics knowhow.  The company was officially 
incorporated on 24th March 1998, making it a very early entrant into the proteomic 
bioinformatics market.   
 
The company started with shareholders‟ funds of less than £40k and is still privately 
held, with the major partners also being active in running the business.  As Cottrell 
stated in 2003 “Starting a software company is not as expensive as starting a hardware 
company, so we did not have to get outside investment, which has given us a certain amount 
of freedom” (Cottrell, 2003). 
                                               
45 Peptidomics is essentially the same as proteomics, the difference is that only the peptide sequences are 
characterised; you do not go the extra step to identify the proteins that gave rise to the peptides. 
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The company began distributing the Mascot search engine product a year after the 
company was started.  Despite having only seven employees (six in UK, one in 
USA), MatrixScience has a healthy P&L46 account, reporting +£1.67m in March 2007 
and +£1.89m in 2008.   
 
Mascot has been around the longest of all the commercial search engines, so many 
labs and individual researchers are loyal to the product.  Commercial data capture 
and analysis pipelines have incorporated Mascot, via licensing agreements, so it is 
difficult for customers to switch products easily.  Also the target consumer, the 
research biologist, generally is attracted to a well supported „black box‟ analysis 
platforms, which are easy to use: Mascot fills this niche.   
 
Revenue streams include the sale of licensing agreements to commercial partners for 
integration of Mascot into their systems, for example with NonLinear Dynamics, 
IBM, LabVantage‟s Sapphire, National Institute of Health (NIH), Proxeon and 
Thermo Scientific.  The sale of licenses for their software platforms directly to clients 
is another major stream.  Their products are all related to Mascot and perform 
proteomic MS data analysis in some form (Table 8). 
 
 
 
                                               
46 Taken from abbreviated accounts at Companies House, UK.  A cash flow statement is not included, so no 
turnover information is available. 
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Table 8 A summary of Matrix Science‟s products 
Product Description Approximate retail price 
Mascot 
Server 
Hardware and software for protein 
identification 
Entry level £4,250
47
 up to 
£21,800 for eight processors 
Mascot 
Distiller 
Workstation 
Analyses data from multiple vendors 
includes novel algorithms for peak detection 
and quantitation 
£1,500 plus £750 for each 
toolbox (e.g. Daemon or 
quantitation) and £6,000 for 
Distiller Developer 
Mascot 
Integra 
Scalable solution for managing and 
automating proteomics research, based on 
Proteominer, which was developed for GSK 
in the early 2000s 
Entry level £20,000 
Mascot 
Cluster 
“Turn-key solution” for high throughput 
protein identification, exploiting parallel 
computing 
Price depends on specification 
 
In additional to the revenue from these products there are also rents earned in the 
form of support contracts (30% of license fee per year).  A final minor revenue 
stream is the sale of Mascot training courses, which are hosted in various cities 
across the world and in-house on request.  Arguably most proteomics labs in 
industry and academia, at least in Europe, are Matrix Science customers.  In addition 
to direct sales and marketing, MS instrument vendors perform marketing on their 
behalf, Bruker Daltronics, for example.   
 
Since 2004, the company has been expanding its Japanese customer base 
(PressRelease, 2004b) with the establishment of a sister company, Matrix Science KK, 
which was assisted by The Japan External Trade Organisation (JETRO), a 
government-funded organisation that promotes inward investment. 
 
                                               
47
 Prices were by quotation and exclude VAT 
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CASE STUDY 3: Nonlinear Dynamics Ltd. 
Incorporated in Newcastle-Upon-Tyne, UK, on 9th 
October, 1989, Nonlinear Dynamics is a privately 
owned company specialising in analysis and data-
mining tools for 1D and 2D electrophoresis gels and for MS.  Nonlinear is a family-
backed business with former „directors‟ including William, Sheila and Alfred Dracup 
and the current CEO is Will Dracup. 
 
Currently with 29 employees and an additional office in North Carolina, USA, 
Nonlinear is one of the larger companies in this market.  The firm was financed 
initially through bank loans (e.g. £15,000 in 1993), followed by equity investment by 
British Coal in 1995.  Funds from the Smart Awards scheme48 were granted, but the 
majority of investment was provided by Northern Enterprise49.  NEL Captial Fund 
Managers also have Nonlinear in their investment portfolio50.  In 1995, the first 
distribution contract was signed and in early 2000 Nonlinear launched their most 
successful product, Progenesis. The end user price for this software increased from 
£4.5k to £80k and the company headcount grew suddenly as a result, growing from 
just 25 to 100.  However, revenue streams dried up in more recent years and 
redundancies ensued (Figure 19).   
 
                                               
48 Smart Awards were given to individuals and small and medium-sized companies  (<250 headcount) by the 
Department of Trade and Industry.  The last one was awarded in 2003 NEWSLINK (2003) ‘Smart’ companies 
get their rewards Newcastle University's Newslink.. 
49 From Will Dracup’s blog at http://www.ifwecanyoucan.co.uk/Entrepreneurs/Will-Dracup/my-story 
50
 NEL is a VC company investing  in high growth businesses in North East England http://www.nel.co.uk 
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Figure 19  Nonlinear Dynamics financial performance
51
 
 
Nonlinear‟s customers are universities and academic institutes and also Novartis 
and BioMerieux.  They are also a distribution partner for GeneBio, distributing 
Phenyx globally (PressRelease, 2008e).  For a summary of their products see Table 9.   
  
                                               
51
 As reported in the Fame database 
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Table 9 A summary of Nonlinear Dynamics‟s products 
Product Description Approximate retail price (in $) 
Progenesis software for 2D gel, DIGE, LC-MS and 
biomarker screening 
22,000 
Progenesis 
SameSpots 
2D and DIGE analysis platform 24,000 
Progenesis 
Stats 
multivariate statistical analysis tool for 2D 
and LC-MS 
Unknown 
Progenesis 
PG600 
biomarker discovery using MALDI TOF MS 
analysis 
Unknown 
TL100 quantitation and calibration of 1D gels 999 
TL120 analysis tools for quantitation, calibration 
and band pattern matching 
3,000 
 
Nonlinear has two wholly owned subsidiary companies: Nonlinear EBT Limited and 
Phoretix International Limited, and has distribution partners in Korea (Chayon 
Laboratories Inc.) and Japan (SCRUM Inc) (PressRelease, 2007e).  In August 2004, 
Nonlinear sought collaboration with Matrix Science Ltd.   Under this agreement, 
Nonlinear‟s protein informatics system was integrated with the Mascot Server 
product.  They also have agreements for distribution with Perkin Elmer, who have 
proteomic gel imaging products (PressRelease, 2005e).   
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CASE STUDY 4: GeneBio S.A. 
Geneva Bioinformatics (GeneBio) was founded in 
1997 by three professors from the University of 
Geneva: Ron Appel (Department of Computer Sciences and Executive Director of the 
Swiss Institute of Bioinformatics52 (SIB)), Amos Bairoch (Department of Structural 
Biology/ Bioinformatics and head of the SWISS-PROT53 database group at SIB) and 
Denis Hochstrasser (director of the Clinical Pathology and Vice Dean of the Faculty 
of Medicine).   
 
The current CEO, Nasri Nahas, took the role in 2001 having acquired experience in 
the biotech industry at Genset SA, which specialised in genomics54 and was the 
second largest biotechnology company in Europe in 1999, and also ValiGen SA, a 
EuroAmerican functional genomics55 company.  Former director, Prof. Robin Offord 
(1998-2000) came from GeneProt.  GeneBio was funded predominantly by Index 
Ventures, a pan-European VC firm focused on the life science and information 
technology markets (PressRelease, 2001b).   
 
                                               
52 SIB is an academic not-for-profit foundation established on 30th March, 1998.  It coordinates research and 
education in bioinformatics and provides bioinformatics services for various areas of biology to international 
research communities via the internet. 
53 SWISSPROT is a protein sequence database hosted at SIB, which was first created in 1986 by Amos Bairoch 
during his PhD.  It is a manually-curated database which means it provides a high level of annotation (such as 
the description of the function of a protein, its structure, chemical modifications and variants).  It has little 
redundancy, making it more compact than other protein databases available in the public domain.  It also has 
links to relevant external data resources. 
54 Genomics is the study of genomes, where a genome is the entire DNA sequence of an organism. 
55 Functional genomics aims to understand the function of the genes that make up the genome, so includes 
research into on the dynamic processes such as gene transcription and  translation – which leads to protein 
production in cells. 
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In 1998, GeneBio became the exclusive commercial representative for the Swiss 
Institute for Bioinformatics (SIB), the developer of key proteomic tools and protein 
databases like SWISS-PROT, PROSITE56 and SWISS-2DPAGE57.  In May 2004, 
GeneBio expanded into Japan (PressRelease, 2004a).  In 2005, another company was 
founded called Current BioData, Ltd (CEO Ian Tarr) as a joint venture between 
GeneBio and the Current Science Group (London).  The company would focus on 
the further development, promotion, and distribution of the ProXenter product.  
Current BioData set up a research site in Wales in 2008 (PressRelease, 2008a).      
 
Financial performance information is unavailable for this firm.  The company‟s 
products (Table 10) are priced on an individual basis. 
 
Table 10 A summary of GeneBio's products 
Product Description 
Phenyx MS data analysis platform released in 2004.  It is sold as PhenyxServer, with 
a CPU-license (set price per CPU) and as PhenyxOnline with an annual 
subscription the price of which depends on the “user profile” (i.e. number of 
monthly submissions, size of peaklist files,etc.) 
SmileMS Metabolomic MS data analysis 
Melanie 2D gel analysis which is sold as a user-license (price per user number) 
Aldente For PMF sold as a PC-license (price per PC) 
MSight For graphical exploration of huge MS datasets 
e-proxemis Bioinformatics learning portal (launched 2005) 
Premium 
versions of the 
SIB Databases 
User license (with a set price per user number) 
ProXenter Web-based information portal (released as a joint venture with Current 
Science Group) 
 
                                               
56 PROSITE is a manually-curated database of protein families and domains hosted at SIB. It was set up in 1988 
by Amos Bairoch.  
57
 SWISS-2DPAGE is a database of annotated 2D and 1D PAGE gels hosted at SIB, set up 1993.   
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GeneBio‟s key customers are academic institutions, such as the Biozentrum at the 
University of Basel (PressRelease, 2007b) and the proteomics group at Utrecht 
University (PressRelease, 2009).  They are well-connected with partnerships 
including Nonlinear Dynamics, GE Healthcare, Bruker Daltonics, Genedata, 
Amersham (PressRelease, 2003b); Wiley-VCH (PressRelease, 2005g); Sage-N 
Research (PressRelease, 2006e); Insilicos (PressRelease, 2006b); Genologics 
(PressRelease, 2006c); Proteome software (PressRelease, 2007c); Institute of Systems 
Biology, Seattle (PressRelease, 2007d); Protagen AG (PressRelease, 2008f); and 
Proxeon (PressRelease, 2008b).  GeneBio has international partnerships including 
KOOPrime Pte (Singapore) (Summary, 2005); BIGG (The Bioinformatics Institute for 
Global Good (BiGG), a research institute in Tokyo, Japan) and Hitachi Software 
Engineering Ltd. (PressRelease, 2005c); Proteomic Solutions (France) (PressRelease, 
2005a); and Proteome Systems (Sydney, Australia) (PressRelease, 2000a). 
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CASE STUDY 5: Proteome Software Inc. 
Mark Turner and Brian Searle58 started Proteome Software 
Inc. in 2004 in Portland, Oregon, USA.  Mark Turner's 
background is in information technology and previously (1994-1996) established a 
successful start-up called Noetix based around views for visualising data in 
commercial Oracle databases.  Brian Searle was originally trained in chemistry, but 
then later moved into proteome informatics research and software programming.  
The company was initially funded internally and has since been funded entirely on 
sales. 
 
Before forming their company, Searle and Turner had worked together at Oregon 
Health and Sciences University under Srinivasa Nagalla, MD59.  Here they 
developed proteomics software called OpenSea (Searle et al., 2004, Searle et al., 2005) 
to interpret peptide de novo sequencing data.  OpenSea was intended to be Proteome 
Software's first product but IP issues complicated the spin-out process.   
 
Instead, the first year was spent developing an alternative software product called 
Scaffold.  This software package helps scientists interpret results from proteomics 
search engines such as Sequest and Mascot in a consistent and reliable manner.  To 
achieve this, they  re-implemented  and  pipelined  strategies  from  the  proteomics 
                                               
58 Brian Searle was interviewed by the author on 15th July, 2009, Cambridge, UK.  This case study text has also 
been edited directly by Brian Searle (31st August, 2009). 
59 Founder and CEO of Diabetomics, a medical diagnostics company.  He is a pioneer in application of genomic 
and proteomic technologies for medical diagnostics. 
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literature, most notably PeptideProphet (Keller et al., 2002a) and ProteinProphet 
(Nesvizhskii et al., 2003b) for determining peptide and protein identification 
probabilities.   
 
Once the product was ready for market, the company hired Mark Pitman as a 
primary sales lead.  Turner took on management and product testing responsibilities 
and Searle took technical development.  Searle admits to using Matrix Science as a 
model for setting up and maintaining a profitable proteomics software company.  
Proteome Software has gone on to specialise in developing tools to make complex 
data analysis easier for lab-based researchers.  
 
In 2009, the company is still privately held and employs just nine people: one 
manager, three software developers, two sales leads, two customer service 
managers, and a software tester.  The company has a modest list of specialised 
products that are sold to industry and academic labs worldwide, but predominantly 
in the USA and Europe (Table 11).   
 
Table 11 A summary of Proteome Software's products 
Product Description 
Scaffold 2 Interpreter for MS/MS based proteomics that combines and compares 
multiple samples and database search engines into a single experiment-wide 
view 
Scaffold Q+ Relative quantitation tool for MS/MS based proteomics 
MassQC Online service that stores, analyzes and displays performance metrics for LC-
MS/MS based proteomics for quality control 
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Sales are made directly, or via resellers, such as Mass Solutions Technology in 
Taiwan, Software4Labs, UK, and Matrix Science KK, Japan.  Proteome Software do 
not publish accounts.  The funding structure, however, is known to be based on 
reinvestment of profits, for example into new product development, rather than 
requiring external investment – at least for now. 
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CASE STUDY 6: Sage-N Research Inc. 
Sage-N Research‟s CEO is David Chiang, a member of the Sand 
Hill Angels60, an early-stage venture and mentor capital firm.  He 
is an inventor and engineer, educated at MIT, and before founding Sage-N Research, 
he was employed by Xilinx, Inc., the world leader in the Field Programmable Gate 
Array (FPGA) industry61.  Before this, he was a Senior Design Engineer for Altera 
Corporation, as well as for the Research Laboratory of Fairchild Semiconductor. 
 
The company was incorporated in 2002 and is in San Jose, California, and Shanghai, 
China (since December 2005).  The Silicon Valley connection is unique in the 
proteomic bioinformatics field, and Sage-N plays this to its strength with its major 
product being the only integrated data appliance for proteomic MS-based research.  
It also boasts the biggest names in proteomics on its advisory board, including 
Zubarev, Aebersold, Gygi and Yates.  Sage-N‟s major revenue stream is the 
development and sale of platforms for high-throughput proteomics data analysis 
(Table 12). 
 
 
 
 
                                               
60 http://www.sandhillangels.com/ 
61
 Information is from the Infotrac Company Profile for Sage-N, dated 5
th
 Dec 2008 
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Table 12 A summary of Sage-N Research's products 
Product Description 
Pattern Match 
Accelerator 
Hardware and software that are as powerful as a computational cluster 
but are a single machine 
Sorcerer 2 Software that supports continuous high throughput proteomic data 
analysis.  It is extensible, accommodating Open Source as well as 
proprietary analysis algorithms.   
Sorcerer XT Rack mounted server version 
Sorcerer Enterprise Scalable version for large research centres, designed for Linux 
platforms 
Sorcerer's Shield Subscription program (for continuous updates and zero down time) 
renewed on a yearly basis for up to five years ($5500/year) are 
additional add-on lines 
 
Sage-N have an agreement with Proteome Software Inc. (PressRelease, 2006f) for 
distributing Scaffold as part of the Sorcerer bundle. In 2007, they were also granted a 
sublicense from ThermoFisherScientific to sell SEQUEST® search engine 
(PressRelease, 2007h, PressRelease, 2008g).  Other partnerships include VM Ware, 
IBM, Institute of Systems Biology (PressRelease, 2005h); Rosetta BioSoftware 
(interoperability between Elucidator® and Sorcerer) (PressRelease, 2006d) and 
GeneBio (Sage-N can distribute GeneBio's Phenyx platform together with Sorcerer) 
(PressRelease, 2006e).  Sage-N‟s customers include universities, institutes and 
private companies in USA, UK, Israel, Canada and Singapore. 
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2.5 Discussion  
Proteomic bioinformatics is a new field of science.  The chapter so far has explained 
how it developed and how it was funded.  In the discussion, the business history 
and case studies are interpreted, and recommendations are made to fragment the 
proteomics value chain.  This will increase efficiencies in R&D spending on 
proteomics in big pharma and, in turn, will generate further growth potential for 
niche proteomic bioinformatics companies.     
2.5.1 High-throughput proteomics is a typical ‘hype cycle’ technology  
Gartner‟s technology hype cycle offers a useful model for interpreting the series of 
events seen in proteomics (Figure 20).  The x-axis is time, and the y-axis is „visibility‟, 
which represents private funding and the level of interaction with financial markets 
in general.  The model shows that there is a direct connection between the way 
science is funded with how it evolves.  
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1985 protein catalogue using Edman 
1987-91 MALDI,  
1998 ESI 
1993 MOWSE (Mascot precursor) FragFit 
1996 PEPTIDESEARCH 
1999 Mascot paper, ICAT 
2004 ProNET, 
ProSPEC 
2000 Yeast 2 hybrid 
1990s human genome sequencing 
1994 SEQUEST 
Early 1990s   MALDI-TOF 
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Figure 20 Gartner‟s technology hype cycle applied to proteomics.  The green star marks the current 
location of high-throughput proteomics technology (MS/MS and associated bioinformatics) in pharma; 
the blue star represents the location of academia and other publicly-funded research organisations.  
Process innovations are annotated on the curve by the year(s) they emerged.  Gartner is a large, US 
market research firm for high-tech and IT.   (Source: images from Wikimediacommons, Matthias 
Mann‟s MaxQuant website and http://www.sttammany.lib.la.us) 
 
Phase I: The technology trigger came from publicly-funded 
research 
Prior to proteomics taking off in industry, two developments had begun in publicly-
funded organisations: (1) in the late 1980s and 1990s researchers began large-scale 
cataloguing of proteins using existing low-throughput methods; then (2) new 
technology (MS and proteomic search engines) was invented which could increase 
the throughput of cataloguing, meaning proteins could be measured on an industrial 
scale. 
 
These catalogues were effectively proteomics „taxonomies‟, where the aim was to 
record and measure every human protein.  This was an obvious thing to do first: like 
explorers, or alchemists, endeavours were made to carefully characterise the 
landscape and give the new field boundaries.  An effort to create such a catalogue is 
perhaps unlikely to create commercial value in the short term, but the public funders 
appreciated that this was unchartered territory and they were willing to support it.  
Indeed, funding of fundamental research like this is justified by governments by 
referring to “indirect but important long-term benefits to society”, with the division of 
labour with firms coming later once technical advancements have been made 
(McKelvey, 2000).      
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Phase II: Industrial scale proteomics was possible and investors 
believed the genomics ‘superstars’ could deliver   
The transition from publicly funding to private investment came about because: 
1. There was a technology push: industry-scale proteomics was now possible, specifically via 
MALDI (1993) and ESI (1998). 
2. IP was potentially available using the new technology; there was a desire to increase the 
effort for protein biomarker discovery in pharma and biotechs.    
3. Genomics was developing high-throughput science ‘superstars’, who attracted the attention 
of investors. 
 
During the land-grab, a boom began for companies to create their own catalogue of 
proteins and mark their territory in the form of IP.  This was fundamental 
exploration of the science way before commercial viability had been demonstrated.  
During the 1990s, the greatest taxonomy yet - the human genome project - was 
almost complete.  The sequencing effort for genes began in 1990, a draft was 
available of the entire genome in 2000, and by 2003 it was complete.  And in contrast 
to proteomics, high-throughput sequencing of genes created commercial value 
almost immediately, in the form of low cost microarray products for measuring gene 
expression using the sequences taken direct from the genome sequence.  In 1997, for 
example, the first miniaturised microarray was created (Lashkari et al., 1997), with 
commercial versions coming soon after: Affymetrix62 in 1994, Agilent63 in 1997.   
 
                                               
62 Scientists at Affymetrix invented the world's first high-density microarray in 1989 and the company was the 
first to market with a DNA microarray. 
63 Agilent is a Hewlett Packard spin out .  In 1997 as HP, it introduced its first microarray product  (the 
GeneArray Scanner) for analysing GeneChip probe arrays from Affymetrix. 
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As a result of the incumbent success of genomics in the mid to late 1990s, the new 
breed of genomics biotech „champions‟ (as defined in (Markham, 2002)), like Venter, 
Hochstrasser, Gilbert and Raab - who had been highly visible figures in gene-related 
enterprise - were powerful, well-connected and respected in both commercial and 
scientific spheres.  They effortlessly attracted the confidence of investors when they 
set out to launch proteomic biotech companies.  However, the land-grab did not 
succeed.  Expectations were artificially high; compared to genomics, the problems 
being addressed were more complex: “the proteome is analogue, the genome is digital” 
(Moody, 2004).  The human proteome, as a concept still is not fully defined, whereas 
it took less than ten years to have the idea and complete the entire sequencing of the 
whole genome.  The number of genes is 20,488 (Clamp et al., 2007), but there are 
more than 200,000 proteins including variants and possibly up to ten million if all 
somatic DNA rearrangements are included (Uhlen and Ponten, 2005).   
 
For evaluating the potential of biotech companies, JP Morgan suggest that three 
requirements need to be satisfied (Figure 21): people, IP and science (Berry, 2002).   
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Figure 21  Investors weigh up biotech start-ups using three main criteria: people, IP and science (Source: 
JP Morgan in (Berry, 2002)) 
 
It could be argued that the proteomics biotechs of the late 1990s easily met the 
people criterion that investors were looking for, but the IP rights and the science 
were notably absent; spelling their downfall.  The reputation of the „genomics 
superstars‟ sold the idea of high-throughput proteomics, despite the „experts‟ having 
specialised knowledge derived from a distinct field.  One of the challenges facing 
middle/senior managers is how to determine the economic value of the new 
technologies and knowledge they have or promise to deliver (McKelvey, 2000).  At 
the time, it was impossible to understand the proteome in enough detail to patent or 
just apply elements of it to patents or product development.  Fishing for marketable 
biomarkers in the „spectral soup‟ was hindered by the technical  difficulties,  such  as  
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background noise, orders of magnitude differences in protein expression and issues 
with reproducibility.  Sophisticated tools were needed to integrate and interpret 
proteomics data, and many different groups needed to coordinate to get the job 
done.   
 
There was not a public policy issue to prevent IP for protein biomarkers.  Indeed, 
despite President Clinton and Prime Minister Blair announcing in 1999 that gene 
sequence information should be made freely available, thus not patentable (Hencke 
et al., 1999), by spring 2000, Clinton had clarified the statement: “if someone discovers 
something with a specific commercial application, they should get a patent” (Pilling, 2000).  
And in any case the genomics market had grown on the back of technical microarray 
products, not just gene leads per se.  Protein sequences and information could in 
theory be patented, as demonstrated by Oxford GlycoSciences who successfully 
patented 800 proteins associated with human disease in 2000 (Firn, 2000), it was just 
that there were very few leads to patent, because the technology could not deliver 
them.  In summary, the IP dimension of the triangle (Figure 21) was not to blame.  It 
was the science criterion of the model, there was a problem.  Since industry-scale 
research of proteins became possible, it was automatically deemed worthwhile 
doing it, but “technology should not be about higher throughput,...but a means to provide 
insight...of the biology...under investigation” (Naylor et al., 2007).  The science was not 
ready to deliver knowledge with economic value.     
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Phase III: The peak of inflated expectations - proteomics was 
driven by hype and rivals in corporate pharma 
Corporate pharma entered the market for proteomics relatively late.  There was 
increasing pressure to be seen to be investing, since “... not doing anything is generally 
not a real option for firms engaged in fast-moving environments...[it] means being left behind 
and out of business” (McKelvey, 2000).  By investing in high-throughput proteomics, 
GSK could demonstrate that it was not missing out in the technology potentially 
delivering value to their rivals. Operations in proteomics were at full speed (at GSK, 
for example) at the very tip of the wave (Figure 20).   
 
Companies, like GSK, have a history of „punting‟ on several new technologies in 
parallel in R&D and then assessing the value added by each after a period of time.  
For them, proteomics and its associated bioinformatics activities was just another 
component in a very large „machine‟ (Garnier, 2008).  Unlike the biotechs, it did not 
spell bust, because there were other elements of the business that could keep the 
machine running.  However, proteomics is an example of how technology alone is 
unable to cure the inefficiencies in R&D: “without true understanding of ...new 
technologies...and the ability to interpret the complex and massive datasets that are 
produced...how can we expect [technology] ...to cure...all [the pharma industry‟s] 
woes?”(Naylor et al., 2007).  
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Phase IV: The trough of disillusionment – proteomics has no 
interaction with the financial markets  
Industrial proteomics in the mid to late 2000s was noticeably absent from the 
headlines, with no interaction with the financial markets: “Once the poster child of the 
biotechnology revolution... seen as the next technological gold rush, proteomics has gone very 
quiet.” Russ Swan64, 22nd July 2008.  Given the very steep increase in investment seen 
in the wave, proteomics may be considered the victim of its own successful 
marketing.  However, “...much of the data generated by proteomics groups over the past 
decade is junk.” (Service, 2008a).  The plasma proteome project, for example, was “a 
big disaster” (John Yates quoted in (Service, 2008a)) because of the lack of quality 
control and reproducibility obtainable with MS.  Moreover, downsizing cost 
scientists (and middle management) their jobs, morale and credibility.   
 
As a hit back, the Nonlinear Dynamics CEO, Will Dracup, is leading the Fixing 
Proteomics Campaign65 (2007) to protect the marketplace (including his own 
company‟s) and to „bring together the people in proteomics who want to tackle the growing 
frustration and unfair perception that proteomics hasn't delivered‟.  How „unfair‟ the 
perception is can be debated, since as yet there are still no commercially valuable 
biomarkers derived exclusively from proteomics (Rifai et al., 2006). 
                                               
64 Editor of the Laboratory Talk Blog (http://www.laboratorytalk.com) 
65
 http://www.fixingproteomics.org/ 
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Phase V: The slope of enlightenment – a new technology trigger 
or consolidation of existing techniques? 
In spite of the difficulties, proteomics still has the potential to become a big market.  
Unlike genes, proteins are the physical targets of drugs; they carry out the biological 
process in all cells in all organisms, so there is great potential for leveraging 
understanding about them to create commercial value. “The lure of proteins was 
undeniable” (Service, 2008a) and it still is.  For now, however, high-throughput 
proteomics is in the trough, albeit higher on the y-axis than when it started out 
(orange arrow, Figure 20).  Possible options for escape are the arrival of a new 
technology trigger, or revisiting existing techniques applying learning from 
mistakes.  For the first scenario, the limits of MS and current database searching 
techniques must be overcome.  It may be that investors will need to see totally new 
technologies that have been proven, to lift the market out of the dip and start a new 
cycle.  Given the poor track record for proteomics, funding will only be made 
available if scientists can reliably substantiate their claims.  Furthermore, given the 
economic crisis in the financial industry during 2008-9, governments and private 
companies have contracted budgets further; President Obama, however, appears to 
be backing fundamental scientific research with $1.1 billion already promised for 
research funding to NIH and other bodies (Mundy, 2009).  However, there is a 
noticeable absence of „superstar‟ scientists to lead the cause this time, so 
revolutionary new techniques may be even harder to sell.     
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If, in contrast, high-throughput proteomics is revisited in a concerted effort, then 
best practice and standards must be set and adhered to.  This is the route of escape 
that the author believes is happening now.  For example, since January 2006 the US 
National Cancer Institute has been running the Clinical Proteomic Technologies for 
Cancer (CPTAC)66 programme: a five year initiative to develop standard operating 
procedures (SOPs) for high-throughput proteomics (PressRelease, 2008d, Blow, 
2008).  The program will cost $104 million; and they have already spent 
approximately $35.5 million.  Five labs are involved in setting SOPs for unbiased 
biomarker discovery and biomarker verification with MRM including bioinformatics 
analysis.  A new tool for MRM transition design, for example, was funded by 
CPTAC (Skyline from the MacCoss lab (Prakash et al., 2009)) (personal 
communication, MacCoss, June 2009).  Furthermore, recent news articles hint that 
leaders in proteomics research, such as Matthias Mann, Mathis Uhlen and Amos 
Bairoch, are forming a plan to undertake a new full-scale human proteome project 
(HPP) (Editorial, 2008a, Service, 2008a), estimated to cost in excess of $1 billion and 
take 8-10 years.  This may not happen just yet, as European-wide funding is harder 
to coordinate.  Nevertheless, a pilot study is being considered for mapping the 
proteins expressed by genes on chromosome 21.   
 
Indeed, it seems that the profile of high-throughput proteomics is improving.  €12 m 
over five years (2008-2013) has just been awarded by the EU framework 767 to the 
                                               
66 http://proteomics.cancer.gov/about/CPTC_milestones_508.pdf 
67 Seventh Framework Programme of the European Community for research, technological development and 
demonstration activities (http://cordis.europa.eu/home_en.html) 
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PROSPECTS (PROteomics SPECification in Time and Space) project (Cottingham, 
2008), and the Science magazine 2008 „Breakthrough of the year‟68 runner up was 
Matthias Mann and co-workers‟ with work in large scale proteomics.  Mann et al. can 
now identify the complete yeast proteome “in one shot-in just a few days” using tuned 
MS (Service, 2008a) and new software, MaxQuant (Cox and Mann, 2008); a feat 
which in 2003 would have taken months five years earlier.  Their strategy is truly 
like a gene sequencing facility – running samples constantly in a fully automated 
fashion.  The difference this time is that the cataloguing approach has impact on 
science.  For example, they can measure all of the proteins expressed in cells lines 
and knock-outs, which are used by the pharmaceutical industry to test new 
medicines.  Specific biomarkers are not here yet, but reproducible platforms are 
emerging.     
 
Phase VI: Plateau of productivity – routine and affordable 
proteomics technologies are needed 
For the technology to plateau, the technology must become routine and affordable.  
To this end, efforts like CPTAC, and Mann‟s work brings the field a step closer to an 
affordable method to map the proteome and exploit it to examine global changes in 
protein expression for delivering biomarkers.  For proteomics to see growth, like 
genomics, the industry needs a single, affordable technology platform to tell 
researchers all they would like to know about proteins.   
                                               
68
 http://www.sciencemag.org/cgi/content/full/322/5909/1768 
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From the viewpoint of the author, high-throughput proteomics is now beginning to 
ascend the slope of enlightenment, but has not yet reached an acceptable plateau.  
The aforementioned efforts work towards the formulation of SOPs and best practice 
(CPTAC, Mann, et al.).  Furthermore, the author argues that the tools and resources 
developed in this EngD add to the progression of this upward slope.  For example, 
by increasing confidence in automated searches (in Chapter 4) higher quality is 
established in high-throughput analysis workflows; it acts as a way to establish best 
practice and suitable reporting guidelines for protein identifications derived from 
pipelines.  Indeed, new statistical techniques and methods to increase the quality of 
identifications are topical right now (Elias and Gygi, 2007) (Nesvizhskii et al., 2007) 
(Choi and Nesvizhskii, 2008a, Käll et al., 2008, Tabb, 2008). 
 
Furthermore, the computational resources for MRM (developed in Chapter 5 and 6) 
are important steps towards the future of proteomics, because it is highly likely that 
MRM will feature in the final toolbox of SOPs for proteomics, and in routine clinical 
proteomics practices on the plateau.  The MRM tool and database developed in this 
thesis fit with CPTAC‟s aims to improve the quality of biomarker validation using 
targeted and reliable, and quantitative approaches - not high-throughput shot-gun-
style proteomics seen previously.  In fact, the MRM tool published as part of this 
thesis was released before the CPTAC offering (Skyline), showing the timeliness of 
the efforts presented by the author. 
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2.6 Proving the management hypothesis 
The hypothesis for this investigation was that the economics was leading the true 
value creator: science and technology.   
 
The business history of proteomics showed clearly that despite the advent of 
genome sequencing (leading eventually to the development of the first search 
engines), scientists like the Andersons, were aiming to catalogue proteins years 
before a genome was available.  So proteomics started out in the absence of 
genomics.  It started, like other sciences, as publicly-funded exploratory science.  
Only when it became possible to perform large-scale proteomics, through 
technologies such as bioinformatics (now using genome sequences) and high-
throughput LC-MS set-ups, did private investors get involved.  When they did, it 
was frenzy and a new market was rapidly cultivated.  It was a technology push 
scenario, where the improvements in technological ability to analyse proteins fuelled the 
investment in proteomics and bioinformatics, rather than a market pull where 
technical improvements were made in response to a perceived market demand for 
protein analysis.   
   
In contrast, however, pharmaceutical companies had declining productivity in R&D 
and were looking for ways to fill their drug pipelines with new targets.  Proteomics 
was one of many new technologies offering potential use for biomarker discovery so 
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it fitted the bill.  In contrast then, a market pull was driving the investment and 
growth in proteomics in corporate pharma and indirectly affected biotech growth.      
 
Did the market for proteomic bioinformatics come about because of process 
innovation, or did it come about because of the excitement and the success of the 
genome sequencing project?  It is true to say that the excitement and the success of 
the genome sequencing project helped to fuel the growth in commercial proteomics 
in biotechs and big pharma in the late 1990s- early 2000s, in that this era produced 
the genomics „superstars‟ who caught the eye of investors and hence, socio-economic 
interactions ensued. However, availability of genome sequences per se, had little 
effect on the growth in proteomics at this time.  Since when one search engine was 
developed to demonstrate the principle of applying genome sequences to 
proteomics that was it.  Search databases did not change significantly after this; 
instead developments were made in instrument design and software algorithms.  It 
was the reputations of individuals from the genome sequencing era that were more 
responsible for the growth in proteomics, than the improvements in genome 
sequences themselves. 
 
The author argues that increases in processing power, new algorithms (such as 
Mascot), and capability of MS as a technique, did have an impact on the 
attractiveness of proteomics and hence the emergence of proteomics and proteome 
bioinformatics as a new market in its own right. But, by the boom in the market in 
the late 1990s, the science could not keep up with the demands of the market.      
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2.7 Recommendations for investors and funding bodies for 
proteomic bioinformatics 
The hype cycle demonstrated that proteomic bioinformatics is a high-tech industry 
with close parallels with the IT industry.  Indeed, the dot-com bubble (1998–2001) 
was happening at the same time as the boom in high-throughput proteomics 
biotechs.  By 2001, the IT industry was in crisis, but it picked up quickly afterwards 
with success stories like Microsoft and Google, and more recently Skype and 
Facebook.  So, for investors looking to invest in the next phase in proteomic 
bioinformatics, what recommendations can be made?   To answer this, the trends in 
funding mechanisms are analysed, and suggestions made given the author‟s 
interpretation of the results of the analysis.       
2.7.1 Funding high-tech can be a springboard for growth or a futile cycle 
The typical funding stages for high tech companies are shown in Figure 22.  High-
tech is a high risk, potentially high-growth industry, so VC funding is usually 
required.  Funding is multi-stage and exit routes (of interest in particular to the VCs 
involved) are: a buyout, for example by a larger corporate firm; flotation on the stock 
market; or (in the worst case) a cycle where start-ups require further government 
support to continue development and trading (blue arrow, Figure 22).      
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Figure 22  Usual funding stages for high-tech start-ups, with buy out or public floatation as the final 
stage.  The blue arrow is atypical, but observed in some of the proteomic bioinformatics companies in this 
chapter, such as Oxford Biotherapeutics where government funds are still needed to fund day-to-day 
operation.  Grants at the start are usually at the university stage, but may be in collaboration between a 
university and company.  (Source: author‟s own summary) 
 
Looking in detail at the business history and case studies, three types of business 
emerge based on the funding route taken (Table 13), these are: 
 Type I: ‘ideal’ rapid growth, VC-funded, successful exit 
 Type II: ‘lifestyle’ profitable, small, stable, perpetual 
 Type III: ‘marginal’ pre-revenue, need continued support with public grants   
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Table 13  Funding summary for the proteomic bioinformatics case studies.  Oxford Oligosaccharides is taken as an example for comparison with the proteomic 
bioinformatics companies (the case studies).  * - at the grant stage, companies must usually match the funds „in kind‟ (i.e. by teaching time, resources etc., bank 
loans or individuals investing).   
 
Type of 
business 
Company Grants*/ funds 
from academic 
projects 
Private funds Angels 
investors 
VC Corporate 
venturing 
Final or next 
move 
Type I 
Success – 
usual funding 
route 
Oxford 
Oligosaccharides 
(predecessor of OGS 
and then OBT) 
Yes (Oxford 
Uni) 
Yes (£60m) No Yes (Advent 
Cap. And 
Euro 
Ventures) 
Yes 
(Monsanto, 
Searle) 
Floatation (mkt 
cap £103m) 
Type II 
Stable 
 
Matrix Science Yes Yes (shareholders 
funds) 
No No No No change 
„lifestyle‟ 
business 
 Proteome Software  No Yes (director 
invested initial 
capital) 
No No No Reinvest profits 
in developing 
more products 
Type III 
Marginal 
Nonlinear Dynamics Yes (smart 
awards, 
northern 
enterprise, 
Yes (bank loans) Yes (British 
Coal) 
Yes (NEL) No Unknown 
 Oxford Bio-
therapeutics 
Yes Yes (small amount 
of shareholders 
funds) 
No Yes No Government 
funding, reinvest 
any profits 
Unknown, 
likely 
marginal 
GeneBio Yes ?  Yes (index) ? ? 
Unknown Sage-N Research ? ?  Yes (Sand 
Hill) 
? ? 
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Overall, there is no common funding model followed by proteomic bioinformatics 
ventures.  OBT‟s original company, Oxford Glycosciences was floated on the public 
markets (market cap: £103m, 1998) then it bought by Celltech for £102m in 2003, thus 
provides an example of how it can proceed.  In proteomic bioinformatics ventures 
there is no example of type I.  The most successful businesses in proteomic 
bioinformatics (Matrix Science and Proteome Software) are type II: stable, not fast 
growing, not requiring VC or Angel funding (as described by (Brush et al., 2001)).  
This is consistent with the market characteristics, being specialised and too small to 
support the kinds of investments that were seen in the late 1990s and early 2000s: 
“Good database search software is not a word processor; it‟s not a spreadsheet. There aren‟t 
millions of customers.” Cottrell, Matrix Science co-founder (Cottrell, 2003).  So, the 
antithesis is that these firms are certainly high-tech, but unlike high-tech seen before 
they are not suited to VC funding rounds.  It appears proteomic bioinformatics 
companies are a new breed of „bio-high-tech‟ firms, unlike IT and unlike typical 
biotechs.        
 
Type III is the „marginal‟ group.  They do not demonstrate a clear pattern, but 
appear to be „thinking bigger‟ in terms of their strategy than they should.  Nonlinear, 
for example, had a workforce of a hundred and turnover at £4m, but profits were 
never higher than Matrix Science, a tiny firm of seven people at its height.  The type 
IIIs show no tangible links with private financial organisations, despite high 
ambitions for growth – only government backed funds, such as Catapult Growth 
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private equity fund.  They appear to have invested, anticipating growth that the 
market could not support.  The P&Ls quoted for Nonlinear and OBT for 2006-07 are 
negative, and this was in comparatively good times, when public labs were receiving 
more funding from the research councils in the UK, before the economic downturn 
seen in 2008-9.   New P&L information is not yet available, but in the short term, the 
losses may be greater as fewer customers have the ability to buy their products as a 
result of spending cutbacks. 
    
The case study businesses did not take part in corporate venturing with big pharma 
or established IT companies, for example (Table 13).  This may be because “an 
imbalance in the power relationship between a high-tech firm and its network partners makes 
the high-tech firm vulnerable” (van der Sijde et al., 2003).  There are, however, strategic 
links and agreements between smaller biotechs and specialist equipment vendors 
across all the firms examined in the case studies.  Indeed, collaboration for small 
players in this high-tech market is essential, because of the complexity and changing 
needs of the client: a single entity is unlikely to work flexibly enough to 
accommodate the changes, but by offering expertise in one specific area, they 
become an attractive proposition for partnering with other experts to deliver an 
optimal package.  Moreover, other firms may have useful routes to market, which 
are hard to establish for small start-ups.   
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Other evidence is provided by the cases (Table 14), for example, the trend for 
expanding operations into the Far Eastern countries confirms the high-tech nature of 
proteomic bioinformatics companies.  Generally, branding is not an important 
feature for these companies, because the unique selling points of each software 
product are sufficient for sales, not usually brand recognition.  There are limited 
options in each niche, because the field is so new, so there is less need to advertise.  
Matrix Science‟s Mascot product is perhaps an exception to this, because there are 
multiple search engines available both public and proprietary, yet Mascot is a 
trusted „brand‟ amongst the proteomics research community.        
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Table 14 Comparisons between the company case studies 
 
 
Similarities between case studies  Differences between case studies 
Small start-ups Ambition – Non Linear have highs and lows, Matrix Science is steady 
low-level growth „lifestyle‟ business.   
Technical individuals as senior management and advisors  (scientists, 
software programmers) not „business/commercial‟, not high-profile 
individuals as seen in other industries, such as finance or biotech (such as 
the biotech „champions‟ defined in (Markham, 2002)) 
Matrix Science‟s Mascot is the only established „brand‟ across the 
board.  Most citations in literature. 
Major revenue streams are from software licensing, they all have similar 
product types 
Funding routes are diverse (refer to Table 13) 
Small niche, high tech firms– cutting edge researchers are their main 
customer base (industry or academia).  Not easy for customers to weigh up 
the quality of the products before purchase because the field is not well 
established, so there is less to benchmark and little choice. 
Hardware as a bundle in the bioinformatics products  – Sage-N 
product is distinct, offering the Silicon Valley USP  
Partnerships, collaborations and agreements with many other 
companies/institutes.  Classic cases of resource sharing seen within 
collaborative networks – see later subheading regarding  the balance 
between vulnerability and collaboration (van der Sijde et al., 2003) 
 
Technology push-based projects – MS technology means there are high-
throughput approaches – all the products on offer have emerged to fill the 
unmet need for complex analysis 
 
The companies are in the trials, deals and further research stages.  Growth 
ideally needs to be fast enough to be fundable by further VC rounds (Berry, 
2002).  This is not the case for these firms; they have stagnated. 
 
Expansion/distribution into Asia-Pacific region, especially Japan and China.    
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2.7.2 Specialise for success: the contract research model is 
recommended 
Pharmaceutical companies have removed many core research activities in recent 
years to try to reduce R&D spending (Prasad, 2004) and CROs have profited from 
this trend (Sahoo, 2006).    
 
Analysis of the proteomic bioinformatics market suggests that the value chain 
should be split into individual elements for the range of proteomics research 
activities for the short-to-mid term (see Figure 23).  This process is effectively 
reorganisation of vertical supply chain relationships (McMillan, 1994). 
    
Figure 23 Suggested concept of fragmentation of the proteomics value chain.     
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This is a phenomenon where firms shed some the activities they would normally 
perform in-house, so switch from „making‟ to buying.  For example, in the „usual‟ 
value chain for an R&D-based pharma organisation, proteomic bioinformatics 
would have formed part of their own research base, but it is now suggested that 
small niche firms operate to do this directly for customers, not via another 
organisation.  The net result is that firms reduce headcount and the economy 
becomes more sophisticated in terms of relationships and specialisms (McMillan, 
1994).   
 
The evidence for this recommendation is that proteomic bioinformatics services 
alone, as provided by Matrix Science for example, appear to be much more 
commercially successful when they are independent of proteomics data capture 
facilities.  The overheads involved in experimental work are too high; demonstrated 
by the fruitless land-grab phase and subsequent bust.  Too many different areas of 
expertise had to integrate for success, when each area alone needed to grow and 
mature independently first.   
 
CROs, such as Quotient BioResearch (a significant collaborator for this EngD) 
demonstrate the growth in CRO‟s business.  They have rapidly expanded their 
contract research with pharmaceutical companies, since big pharma now outsources 
a large proportion of routine experimental work.  This trend for outsourcing 
activities has been seen in many other industries, such as telecoms and 
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manufacturing, and is already taking place in clinical research for big pharma.  The 
author, with others, such as (Arlington, 2007), forecast outsourcing to increase in 
scope in pharmaceutical R&D.  By 2020, for example it is predicted that „specialist 
firms‟ focussing specifically on discrete areas of drug development, such as testing 
biological pathways, and proving mechanisms of drug action, will be more prevalent 
(Arlington, 2007).  Proteomics research will most probably be part of this trend.   
 
As the era of the blockbuster drug is over, to replace it there will be a wider array of 
more targeted medicines.  Similarly, big pharma organisations will get smaller and 
will perform more „virtual‟ research through targeted partnerships with smaller 
expert business and groups in academia, outsourcing large portions of their research 
operations, such as proteomics research and bioinformatics analysis.  Indeed there is 
already a virtual CEDD (CEEDD) at GSK based on this idea.   
 
R&D efficiency must increase, by these (and/or other) means, because new 
innovative medicines are desperately needed to cure the chronic illnesses such as 
diabetes, neurodegeneration, cancer, obesity and heart disease.  Costs need to be 
better managed, by making the right decisions in R&D, and more candidates 
exhibiting novel mechanisms of action must be found. 
 
These predictions bode well for the aforementioned „marginal‟ companies, such as 
OBT,  Nonlinear  and  Matrix  Science.    They  are  suitably  placed  to  soak  up  the 
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demand for contract research, as proteomics becomes more developed with SOPs 
and best practice.  A key requirement, also, is the adaptability of these companies: 
how quickly they can embrace new techniques as the field settles into maturity?  
Will they be able to get funding to do this?     
 
Moreover, will biomarkers and the opportunity for IP see growth soon?  For the 
moment, it is not likely since the best source of easy-access biomarkers is blood and 
blood proteins remain problematic, because they are expressed in quantities that 
vary by ten orders of magnitude; thus, it is difficult to measure interesting, low 
abundance proteins using current MS-based techniques (Service, 2008b).  More 
focused techniques, such as using N-linked glycopeptides that fish out the 
interesting proteins, have potential to improve the promise of biomarkers, but 
overall consensus is that timescales for these developments could be years or even 
decades. 
 
In summary, the recommendation is to hold off private investment in proteomic 
bioinformatics companies until the SOPs and platforms become routine.  To develop 
routine technologies, public agencies will provide, and are already providing, the 
majority of the funding.  Big pharma should look further into networking and 
building relationships with niche CROs, such as the companies discussed in this 
chapter.   
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2.8 Conclusion 
This chapter has given a detailed account of the development of a new science and 
the high-tech industry of proteomic bioinformatics.    
 
The business history showed that proteomics was born out of publicly funded 
research, carried out in the late 1980s, and 1990s.  Once high-throughput could be 
achieved with new MS-related inventions, industry got involved with a view to 
patenting newly sequenced proteins for developing therapeutics.  This was a 
disaster, as the technology did not generate reproducible results, dogged by 
technical failings and complexities of the proteome.  Divestment ensued in both 
biotechs and pharma.   
 
The story followed closely the technology hype cycle, where over-enthusiasm for 
high-throughput proteomics technology was followed by commercial 
disappointment. The slope of enlightenment and plateau of productivity are still to 
be reached for high-throughput proteomics, because trust for the technique was lost 
and the technology has yet to be shown to be reproducible and value-adding.  
 
For now, the market is small and is still immature, supporting only niche companies 
of a very technical nature.  Given the data presented in the cases, these companies  
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fall into two types:  small, profitable and stable companies who have kept headcount 
to a minimum; and marginal companies, who aimed for higher growth, and now 
rely on public funds to survive, partly as a result of a previous miscalculation of the 
size and expected growth of their marketplace.   
 
Analysis of the players in the market suggests that proteomic bioinformatics is 
indeed a commercially viable activity when executed in a small, specialised 
company that keeps overheads to a minimum and growth slow and steady.  This is 
in contrast to other equivalent high-tech examples, such as IT, where accelerated 
growth and several rounds of VC-funding usually ensue.   
 
For corporate pharma, proteomics and associated bioinformatics is unlikely to ever 
become a large core function, since there will be an increasing trend towards 
outsourcing technical aspects of R&D to keep costs to a minimum without 
compromising quality of research.  In this future, niche companies will have a 
refined core competency in the field, so will offer superior quality for less cost than 
setting up the equivalent research and data analysis infrastructure in-house.   
 
In summary, the author believes that the market for proteomic bioinformatics 
products and services will not grow significantly until standards are developed, and 
the value added by the technologies can be clearly demonstrated to new investors.  
As a result of the problems in the past, investment  in  a  high -throughput  approach 
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may be harder to obtain, but the fact remains that proteins are the molecular 
machines of the cell.  Only by understanding these can a radical breakthrough be 
made to improve drug design processes and deliver understanding and targeting of 
the most elusive diseases.  
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3 Review of public repositories for proteomics  
 
 
 
 
 
 
 
Review of public  
repositories for proteomics  
 
 
 
 
 
 
“To hoard is human; to share, divine.” 
From (Wells et al., 2008) 
 
 154 
 
  
 155 
 
 
3.1 Summary 
Since the withdrawal of high throughput proteomics at GSK (2005-6), and given that 
there are no in-house labs producing proteomic MS data at Cranfield University, a 
major source of data for the research in this EngD project was public data.  This is 
data deposited into public proteomic repositories on the internet, usually the 
product of publicly-funded research projects and may be downloaded by anyone for 
free.   
 
The problem with using public data, however, is that new data appears frequently 
but is not usually announced through traditional routes, such as research papers, 
and developments in the repositories themselves are frequent.  For this reason, there 
is an urgent need for a single document detailing all available resources, so 
researchers can leverage the most value from the systems and data available to them.  
Thus, for both practical purposes and to add to state of the art, this chapter presents 
a review of the major public data repositories, the data they contain and the 
pipelines that populate them.   
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3.2 Introduction 
3.2.1 Definition of a public proteomics repository 
As explained in the introduction public proteomics repositories can store and 
disseminate proteomic MS datasets.  In this way they are distinct from the freely 
available laboratory information management systems (LIMS) such as PROTEIOS 
(Garden et al., 2005), PRIME69, YASSDB (Thomsen et al., 2007), Labkey.org‟s CPAS 
(Rauch et al., 2006) and the Proteomics Experiment Data Repository (Taylor et al., 
2003). This is because LIMS systems typically store much more diverse data such as 
gel images, plate barcodes and protocol information, and are primarily intended for 
local data analysis and archiving, rather than for public data sharing over the 
internet; however, some do also facilitate secure data sharing across geographically 
distant collaborating groups.  As mentioned in the Introduction, proteomics 
repositories are also distinct from protein databases, because they store data 
pertaining to MS/MS experiments, not data pertaining to proteins per se.  
Commercial products for proteomics data capture and storage are not described 
here, because they are not relevant for this EngD project.   
3.2.2 Benefits of public repositories  
As proteomic MS has increased in throughput, so has the demand to catalogue the 
increasing number of peptides and proteins observed by this technique. As in other 
'omics' fields, this brings obvious scientific  benefits  such  as  sharing  of  results  and 
                                               
69 http://prime.proteome.med.umich.edu 
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prevention of unnecessary repetition, but also provides technical insights, such as 
the ability to compare proteome coverage between different laboratories, or between 
different proteomic platforms (Figure 24). 
 
 
Figure 24 A summary of the benefits and potential uses of public proteomic MS repositories 
 
As well as offering direct benefits, proteomic data repositories have also catalysed 
developments in other areas of proteomics research (Figure 25); for instance, the 
availability of large volumes of data - only possible by combining efforts from many 
labs - means research can now be performed and biological conclusions drawn 
which otherwise would have been impossible. A specific example is PTPs: only 
when redundant data is available can PTPs be identified, and the benefits of 
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knowledge of PTPs be gleaned, such as design of PTP-based search engines 
optimised for speed, like X!P3 (Craig et al., 2005), or software suites for MRM 
transition design, like in TIQAM (Lange et al., 2008). Furthermore, with access to 
large amounts of data the limitations of the MS method per se are brought to light, 
for example redundancy in the peptide identification data can effectively 
demonstrate the limited range of visibility of peptides using current techniques 
(Nesvizhskii et al., 2007) – stimulating the community to look for improved 
alternatives for detecting the elusive peptides. 
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Figure 25 The emergence of public proteomic data repositories has stimulated the development of a huge 
array of public bioinformatics resources, including pipelines and diverse data analysis tools.  The 
concentric dashed ellipses show the progress of the field, with the central ellipse showing the completed 
areas of work, the next showing areas of work in progress, to the outermost area, which describes 
anticipated future developments in the field.  Text which overlaps a boundary means that the work 
transcends both areas.  (Source: author‟s own summary) 
 
Another advantage of availability of public datasets is that advanced data-mining 
and visualisation tools can be developed.  These programs, which sit at the „front 
end‟ of some public data repositories, can highlight important trends in data that 
would otherwise remain hidden; for example, tools to collate and display 
differentially expressed proteins, peptides and PTMs, or data-mining programs that 
use Gene Ontology (Ashburner et al., 2000) categories to compare shifts in cell or 
molecular functionality across datasets. Such tools can be used by researchers to 
analyse their own data, possibly in the context of data from other groups, and as the 
amount of data in the repositories increases, so does the possibility of new 
discoveries being made purely using existing public data. 
3.3 An overview of the public repositories 
The main public repositories are the Proteomics IDEntifications database (PRIDE) 
(Jones et al., 2006), the Global Proteome Machine database (GPMDB) (Craig et al., 
2004), PeptideAtlas (Desiere  et al., 2006), Tranche at ProteomeCommons70, the 
Genome Annotating Proteomic Pipeline (GAPP) (Shadforth et al., 2006), and Human 
Proteinpedia (HPP) (Mathivanan et al., 2008). 
 
                                               
70 Falkner, J. A., Andrews, P. C., HUPO Conference 2006, Long Beach USA, poster presentation 
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Smaller scale repositories include the Max-Planck Unified Proteome Database 
(MAPU) (Zhang et al., 2007), PepSeeker (McLaughlin et al., 2006), and SwedCAD 
(Falth et al., 2007).  And even more specialist offerings include the Yeast Resource 
Center Public Data Repository, the BiblioSpec Library (Frewen and MacCoss, 2007), 
the Open Proteomics Database, the Proteomics Data Center at the Resource Center 
for Biodefense Proteome Research (Zhang et al., 2008), SWISS-2DPAGE (Hoogland et 
al., 2004), and Biodemo; these are not covered in this chapter.   
 
The main repositories are now described briefly, followed by more detailed 
information of the features for the six databases deemed relevant for this EngD, 
namely: PRIDE, GPMDB, PeptideAtlas, Tranche, GAPP and Human Proteinpedia.   
3.3.1 PRIDE 
PRIDE71  is not limited to identifications; it also includes peak 
list data for download, journal article links and associated 
tools, including data-mining, visualisation and ontology-
assisted data conversion tools (Jones et al., 2008b).  With close links to HUPO PSI, 
PRIDE aims to be compliant with agreed community standards, in terms of 
reporting (MIAPE) and standard data formats (mzML and mzIdentML), as soon as 
they become available.  PRIDE does not include an analysis pipeline and as such 
stores data from any appropriate MS/MS analysis workflow.  This repository has a 
facility for pre-publication data storage to assist the peer review process. Notable 
                                               
71 http://www.ebi.ac.uk/pride/ 
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datasets in PRIDE include the acid mine drainage extract, HUPO liver (HLPP), 
HUPO plasma proteome (HPPP), HUPO brain and human CSF, and the Cellzome 
dataset.  
3.3.2 GPMDB 
GPMDB72 celebrated its 50,000,000th peptide 
identification on 16th May, 2008.  It was created by Ron 
Beavis and co-workers, and was originally designed as a 
web-interface for the X!Tandem Spectrum Modeler search engine (Craig et al., 2004), 
but it has been developed significantly, now allowing comparison between 
experimental results and the best results that have been previously observed by 
other scientists.  It is the first repository to apply analytics tools to map the number 
of visits, and has recently developed new features: for example, it has expanded the 
number of eukaryotic species supported (as NCBI builds) and shifted to collecting 
annotated spectral files for improved searches, as well as a new compressed data 
format (called Common, .cmn).  A peer-to-peer grid computing system, called 
Tornado, has also been released which speeds up searches tenfold (for human, 
mouse and rat) by determining which server on the grid is least busy and sending 
the search to X!Tandem there.  In addition, there are new ways to access and view 
the data, such as a new view that allows protein lists to be explored by chromosome 
number73 or those derived from mitochondria or transposons, also there is an MRM 
                                               
72 http://gpmdb.rockefeller.edu/ 
73 http://gpmdb.thegpm.org/go/index_chr.html 
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worksheet that uses consensus spectra to select transitions for MRM (Walsh et al., 
2009).   
3.3.3 PeptideAtlas  
PeptideAtlas74 is a project of ISB, Seattle,and as such its creators 
place an emphasis on its application to systems biology research.  
It is described as a “platform to select and validate MS targets” (Deutsch et al., 2008) and 
is separated into „builds‟, which represent all peptides mapped to a single reference 
Ensembl genome.  This allows protein identifications to be viewed from within the 
Ensembl browser as a DAS track (Dowell et al., 2001, Shadforth and Bessant, 2006).  
Current species builds include human, human plasma, Drosophila, Drosophila 
Phosphopeptide, yeast, mouse, halobacterium and Streptococcus pyogenes.  The 
Ensembl and IPI accession numbers are supported and PeptideAtlas is also home to 
the Human Plasma Proteome Project Data Central (Omenn et al., 2005) with various 
links to project-specific articles and identification data.  
 
MS data is made available as peak lists by submitting laboratories, from which TPP 
(Trans Proteomic Pipeline) (Keller et al., 2005) extracts peptide IDs to populate the 
SBEAMS (Systems Biology Experiment Analysis Management System) proteomic DB 
module.  Furthermore, PeptideAtlas has released a raw data repository for MS/MS 
dataset posting, acting as a data provider for others, including the spectrum library 
at NIST and the PepSeeker database (McLaughlin et al., 2006). 
                                               
74 http://www.peptideatlas.org/ 
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To derive a quantitative perspective on protein expression, for generation of system 
models and simulations, PeptideAtlas has developed an MRM transition prediction 
tool, TIQAM (Lange et al., 2008), and a database of yeast MRM transitions, 
MRMAtlas (Picotti et al., 2008). 
3.3.4 Tranche at ProteomeCommons  
Tranche75 aims to solve the problem of data sharing in 
proteomics by supporting transfer and dissemination of 
very large datasets in a secure fashion across the internet.  It has huge volumes of 
distributed disk space for backing-up of proteomics datasets, facilitating long term 
data storage to ensure data is not lost through changes in staff or funding.  It also, 
like PRIDE, has a facility for pre-publication (private) data storage.  It is a storage 
platform not a relational database, so does not provide powerful querying 
functionality.  The system had 5,502 projects and 11.1 million individual files 
corresponding to 3.1 terabytes on June 26th, 2008.  Notable datasets include The 
National Cancer Institute (NCI) Mouse Proteomics Technologies Initiative (MPTI) 
project and Kislinger and co-workers‟ ascites study into ovarian carcinoma 
biomarkers (Gortzak-Uzan et al., 2008).  PeptideAtlas data repository is also mirrored 
here.  Tranche has an average of 70 website visits per day (reported on April 22nd, 
2008).   
 
 
                                               
75 http://tranche.proteomecommons.org/ 
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3.3.5 GAPP 
GAPP76 is a data analysis pipeline, the results of which are stored 
in GAPP DB.  Like PeptideAtlas identifications can be viewed as 
an Ensembl DAS track (Shadforth and Bessant, 2006). Much of the 
data in GAPP is taken from other repositories, and has been reanalysed to allow 
direct comparison between different datasets. 
 
GAPP has undergone significant developments since creation on a previous EngD 
project, and in its current state it is a critical element required for the novel research 
work presented in this thesis.  New graphical visualisations and data-mining 
functionality have been developed for GAPP by others in the Bioinformatics Group, 
as well as simplification of data submission using data-entry forms.   
3.3.6 Human Proteinpedia 
HPP77 is a repository of diverse proteomic 
datasets including data from MS/MS, co-immunoprecipitation MS/MS, 
immunohistochemistry, yeast two-hybrid and other platforms.   It is the best 
repository in terms of consistent reporting of all necessary metadata to reprocess the 
raw datasets accurately; routinely reporting mass and fragment tolerances, for 
example. Its data content is steadily increasing, with 71 labs regularly submitting.     
 
                                               
76 http://www.gapp.info 
77 http://www.humanproteinpedia.org/ 
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The HPP repository is complemented by The Human Protein Reference database 
(HPRD) (Mishra et al., 2006): a database of literature-derived information, compiled 
at the level of the individual protein.  HPRD shows, for example, characterised 
protein domains, PTMs and interactions, and allows users to explore the meaning of 
their data, submitted via HPP.  Each protein in HPRD is annotated with peptide 
information and the sample of origin (and where relevant as an HPP „HuPA‟ 
identifier). 
3.3.7 MAPU 
MAPU 2.0 78 a database of 
organellar, cellular, tissue 
and body fluid proteomes was released in 2006 by the Max-Planck-Institute of 
Biochemistry in Martinsried, Germany (Zhang et al., 2007).  The system is a family of 
discrete proteome databases, which its creators believe will eventually provide 
reference proteomes for biomarker discovery studies.  It has a notebook-style design 
with tabs to navigate around the site, and like PeptideAtlas and GAPP, it has 
genome annotating functionality viewed as a DAS source.  Furthermore, transcript 
annotations are also accessible via a graphical chromosome view, similar to GPMDB.  
The proteomes available at MAPU 2.0 include mouse adipocyte and liver, and for 
human, there are body fluid proteomes: urine, tears and seminal fluid.  MAPU 1.0 
also includes the human plasma and cerebrospinal fluid proteomes.   
 
                                               
78 http://www.mapuproteome.com 
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3.3.8 PepSeeker 
PepSeeker79, unlike other repositories, aims to increase the 
understanding of peptide fragmentation chemistries and 
the effect of peptide sequence on visibility in MS (McLaughlin et al., 2006).  It is led 
by Simon Hubbard at the University of Manchester, UK and it stores peptide 
identifications and corresponding fragment ion details used to identify that amino 
acid sequence. The argument for such a system is that the peptide sequence 
composition determines the presence or absence of certain ions in the resulting 
spectrum, so by harnessing this information, development of more sophisticated 
peptide identification algorithms should be possible in the future.  Improvements to 
query functionality have been made (now via Biomart), and it has contains a „gold‟ 
database instance comprising only the highest scoring peptides.   
 
3.3.9 SwedCAD and SwedECD 
SwedCAD80 and SwedECD81 are databases of high 
resolution, high mass accuracy MS/MS spectra 
derived from collision associated dissociation (CAD) and electron capture 
dissociation (ECD) MS, respectively.  One aim of the repositories is to provide 
reference  spectra  for  use  as  search  databases  for  peptide  identification, since  all  
                                               
79 http://www.nwsr.manchester.ac.uk/cgi-bin/pepseeker/pepseek.pl?Peptide=1 
80 http://www.bmms.uu.se/CAD/ 
81 http://www.bmms.uu.se/CAD/indexECD.html 
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datasets may be downloaded for local use.  Arguably, the main aim, however, is to 
provide a repository that can offer unique insight into fragmentation pattern 
aetiology, such as exploring the phenomenon of neutral loss, looking at the 
frequency and nature of missed cleavages, and the effect of certain motifs, such as 
terminal „RR‟ (Falth et al., 2007).  The systems are able to do this because they 
provide both CAD and ECD spectra for the same samples, namely human milk, 
lysates of human cell lines (K562 and A-431) and E.coli proteins.       
3.4 Data upload, download and format support  
New standard data formats for MS are available, as outlined in Chapter 1, but they 
must become “the norm” in order to be useful to the community.  To achieve this, 
the analysis tools and databases must support them, thus encouraging their use.  In 
the short term, however, diverse data formats remain in existence so knowing which 
system supports which formats is necessary – thus is described here.  Long-term, it is 
envisaged that the standards will prevail across all public MS resources. 
3.4.1 PRIDE 
PRIDE supports private data submission, generating anonymous login details to 
grant access to the uploaded dataset. This anonymous login can be sent to reviewers, 
providing confidential access to the details of the proteomics experiment supporting 
the manuscript before publication.  The Proteome Harvest PRIDE Submission 
Spreadsheet is available for small-scale submissions of data to PRIDE (Jones et al., 
2008b) supporting conversion to PRIDE 2.1 XML and applies an ontology look-up 
 169 
 
service (OLS) (Côté et al., 2006) to apply controlled vocabularies to data annotations.  
Data may also be submitted via the MASPECTRAS pipeline (Hartler et al., 2007), or 
via PrideWizard (Siepen et al., 2007) (for Mascot files), which both create PRIDE 
XML output.  The method of choice, however, is the new PRIDE Converter (Barsnes 
et al., 2009), which can be used for large or small datasets, accepts various input 
formats, and has a „point-and-click‟ graphical interface.       
 
Once registered, users may submit data to PRIDE as individual XML files (PRIDE 
XML or mzData/mzML), or as a zip archive of multiple files.  Submitting data in 
this way can be impersonal; however there is access to a curator at PRIDE if 
submission is difficult.  For bulk data submissions, PRIDE also supports secure FTP 
upload of datasets.   
 
In PRIDE‟s case, public mzData/mzML and PRIDE XML datasets may be 
downloaded.  The files are downloaded as zip files directly from the website or 
alternatively the FTP server82.  The only exception to this is where experiments have 
been submitted without MS/MS spectra, in which case mzData/mzML is not 
available. 
                                               
82 ftp://ftp.ebi.ac.uk/pub/databases/pride/ 
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3.4.2 GPMDB 
Adding data to GPMDB is possible via the search pages in public or restricted mode.  
To submit data for analysis and storage a species (referred to as a „boutique‟) is 
selected and the details for the search are entered on the Tornado search form.  Only 
the top 50 most intense ions are applied from the peak lists (Walsh et al., 2009). 
 
GPMDB‟s new compressed format is Common (.cmn), and there is a tool provided to 
compress/decompress MS/MS data files (such as .mgf, mzXML, mzData, .dta and 
.pkl) to/from .cmn.  MS/MS files may still be submitted in more familiar formats, 
however .cmn files have the scope to support analysis of files that would previously 
have been too large to submit.  Furthermore, .cmn files can be made available to the 
data archive83.  GPM also provides protein lists derived from specific tissues, as part 
of the Normal Clinical Tissue Alliance84.  Both processed data and the raw MS/MS 
files are available, the former via GPMDB interfaces in the usual way, and the latter 
via an FTP site85.     
3.4.3 PeptideAtlas  
MS/MS spectra are accepted in either native (.raw) format or in mzXML, with the 
latter being preferred.  There is a web application for data submission, and to access 
it the administrators must be contacted. As part of PeptideAtlas‟ pipeline, the Trans-
Proteomic Pipeline (TPP), there are several free tools available.  For data submission, 
                                               
83 ftp://ftp.thegpm.org/data/msms 
84 http://wiki.thegpm.org/wiki/Normal_Clinical_Tissue_Alliance 
85 ftp://ftp.thegpm.org/projects/ncta/release_1/data 
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for example, there is a program86 to convert .wiff87 format files to mzXML.  If 
desired, a date can be entered for when the raw data becomes available to the public.  
„Minimum public access‟ submissions still appear on the site with the institution 
name, the contact, date, organism and cell type, but data is only available when it 
becomes public.  To download unprocessed datasets and lists of identifications, there 
is a Data Repository88 - by clicking on the zip files they may be saved locally.  
Accompanying journal paper links are also provided.  
3.4.4 Tranche  
Tranche is based on peer-to-peer data sharing.  To upload data, a Tranche account 
must be requested and any data format is accepted.  The administrators also offer a 
data submission service with data on USB hard drives.  An easy way to download 
data is via the website89, where there is a long list of the available datasets.  The free 
Java downloader package manages the download, and also executes the security 
check for private datasets.  Tranche applies industry standard encryption protocols 
for security.  In the current system, data annotations can be made by anyone 
uploading data - a separate username and password is not required.   
3.4.5 GAPP 
As GAPP is primarily an analysis pipeline rather than a repository, it accepts mass 
spectra not identifications, and does not provide data for download.  To submit data, 
                                               
86 http://tools.proteomecenter.org/wiki/index.php?title=Software:mzWiff 
87 Proprietary raw data format used by Applied Biosystems 
88 http://www.peptideatlas.org/repository/ 
89 http://www.proteomecommons.org/data.jsp 
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users must register and login, then create a dataset-specific „data profile‟, which is an 
electronic form for metadata.  Data may be submitted in .mgf, .pkl or mzXML 
format, and can be submitted privately.  Privately submitted data is not visible to 
any other users at any time, including via the data-mining tool, MRMaid, described 
later in this thesis.  GAPP DB (the current version) captures and analyses only the 
100 most intense ions. 
3.4.6 HPP 
A comprehensive list of meta-annotations is required to submit data to HPP.  The 
submission process exploits ontologies where necessary and guides the submitter by 
providing drop down menus.  Format is not specified, with currently available 
datasets including .pkl, .mgf, mzXML and .raw.  To submit, users must first register 
and login.  All data is visible to the public and is stored in triplicate across 16 servers.  
HPP employs the Tranche Java application for download of raw datasets and 
identifications. 
3.5 Data-mining and visualisation 
3.5.1 PRIDE 
There are two ways to mine data in PRIDE: by „browsing experiments‟ (Figure 
26(a)), or by querying with Biomart.  The former is a „flat file‟ table view with 
hyperlinks, whereas the latter is based on the programmatic web service framework 
(Jones et al., 2008b) offering flexible searching and quick retrieval of user-specified 
relevant data.  Half of all downloads from PRIDE are via Biomart.     
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Since PRIDE accepts identifications that are derived from searching different protein 
databases, querying across all datasets exploits the Protein Identifier Cross-
Reference Service (PICR) (Côté et al., 2007), which is cross-referencing tool to map 
identifiers across 60 different databases.  Thus, PRIDE may be queried by the users‟ 
accession numbering system of choice.  Furthermore, PRIDE has been incorporated 
into EBI‟s new metasearch, „EB-Eye‟ – a search tool that collates data from multiple 
EBI resources. 
 
PRIDE also has graphical de novo sequencing spectrum views (Figure 26(b)) and a 
tool to dynamically generate Venn diagrams to compare identifications from up to 
three datasets (Figure 26(c)). 
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(a)
 
(b) 
 
 
 
 
 
 
(c) 
 
  
 
Figure 26 PRIDE data 
visualisation options       
(a) dataset download 
page; (b) manual de novo 
sequencing tool; (c) Venn 
diagram for comparing 
identifications across 
experiments 
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3.5.2 GPMDB 
For each protein entry in GPMDB, all the experiments in which the protein was 
identified are listed with a schematic representation of the protein sequence with the 
individual red „peptide blocks‟ for observed peptides, and green blocks for regions 
that are predicted to be difficult to observe in MS/MS (Figure 27).   
 
Figure 27 GPMDB's experiment view with assigned peptides shown as blocks along the protein sequence.  
Each row represents a single experiment.  Red blocks are PTPs, green are predicted to be not visible in 
MS 
 
Statistical significance of identifications is also illustrated graphically, by the shade 
of red, and there are three possible ways to view identified proteins: gene view (G), 
protein and observed peptide sequence view (P) and the X!Tandem view (X).  X is a 
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collapsible view of the algorithm‟s output, which breaks down to the details, 
including the x,y-coordinates of the original peak list. Graphics are implemented in 
SVG. 
 
As in PRIDE, different protein database accession systems can be searched, however 
GPMDB has implemented automatic conversion of identifiers (for Ensembl, IPI, 
HGNC or MGI gene symbols, NCBI genes and Swiss-Prot/Uniprot) without 
requiring repeated searches.  The „note keywords‟ search allows querying of 
submitter‟s notes (that accompanied the uploaded datasets), and there is batch 
querying where a list of peptide sequences is queried.  In addition, when searches 
have been performed against the Ensembl database (for human, mouse, rat or yeast) 
the results may be viewed as a KEGG (Kyoto Encyclopedia of Genes and Genomes) 
pathway by sorting proteins into metabolic pathway categories using ontologies.  
3.5.3 PeptideAtlas  
Peptide and protein information may be browsed, where each peptide entry has a 
list of properties (like pI, sequence, accession number and SSRCalc (Krokhin et al., 
2004)-derived hydrophobicity) (Figure 28).  Each protein entry has a genome view, 
which shows observed peptides and predicted domains, such as membrane 
spanning regions determined by TMHMM (Krogh et al., 2001).  As in GPMDB‟s 
view, peptide regions that are predicted to be unlikely to be visible in MS/MS are 
highlighted (Figure 28).    
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Figure 28 PeptideAtlas maps peptides on to the genome using a DAS track. 
 
PeptideAtlas has the Cytoscape (Shannon et al., 2003) plug-in linked to each protein 
entry, which allows peptides to be viewed as a network with associated proteins.  
The proteotypic score reflects the likelihood that a peptide is proteotypic, this is also 
shown in the protein view.  Hyperlinks to external resources, like Ensembl or IPI, are 
also provided. 
3.5.4 Tranche  
The data available via Tranche is listed on a single page (linked via the „data panel‟ 
shown in Figure 29).  A simple search form is available for specifying the search 
criteria, such as, project status, journal, and researcher name. 
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Figure 29 Homepage for Tranche at ProteomeCommons.  Latest datasets are shown in the centre.  
 
3.5.5 GAPP 
GAPP now provides three options for querying: by experiment, by protein, or by 
„differential view‟.  The experiment view lists all experiments processed and stored 
in GAPP by displaying headline information about each.  By selecting a single 
experiment, metadata for the experiment and lists of identified peptides and 
proteins are displayed in a collapsible view. The protein view allows users to search 
for a protein of interest by Ensembl accession number and displays a breakdown of 
information for this protein, including peptide coverage, GO categories, number of 
experiments in which it was seen and PTMs, where found. 
 
The differential view allows protein expression to be compared between 
experiments in a table. These experiments may be selected manually, or according to 
metadata (e.g. tissue type, disease state or instrument type). As the list of proteins in  
 179 
 
such a comparison can be large, proteins can be filtered according to GO category 
(Figure 30(a)), and a pie chart (Figure 30(b)) illustrating the breakdown of protein 
identifications is generated dynamically for the selected experiments.  
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(a)  
(b)  
Figure 30 GAPP's differential view shows (a) a comparison of the protein content between experiments 5, 
6 and 7, and (b) the proteins found in the experiments broken down into GO „biological process‟ 
categories. 
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3.5.6 HPP 
There are three search avenues: genes/proteins, annotations and MS platform.  
Ontologies are implemented and the user may select from lists of agreed terms using 
the query form.  For gene or protein searches, entries that identified the query gene 
or protein are listed, and under each contributor‟s and experiment information there 
are the peptides that contributed to the identification with associated modifications, 
charge state, precursor mass and HuPA identifier.  Complete datasets may be 
downloaded with corresponding metadata (Figure 31). 
 
Figure 31 Human Proteinpedia's download page.  Raw datasets, protein identifications and meta-
annotations may be downloaded for some experiments, for other just identifications and metadata are 
available. 
 
Although there is comprehensive search functionality at HPP, arguably more 
powerful biological querying may be performed using the reference database, HPRD 
(Mishra et al., 2006), which is directly linked to HPP and also contains peptide 
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sequences derived from the PeptideAtlas and PRIDE repositories.  HPRD can be 
queried using gene symbols or various accession numbers including RefSeq, OMIM, 
Swiss-Prot, HPRD and Entrez Genes. Several different parameters may be queried 
simultaneously as well as via a BLAST search tool.  There are also links to curated 
pathway information and visualisations.    
3.6 Data content of repositories is varied 
Since each repository fits a particular niche and the developers have different 
collaborators, the data present in each system can vary.  This section highlights the 
differences in data volume (Table 15). 
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Table 15 A summary of data content of the major public repositories.  Values were reported on 26th June 2008, except PeptideAtlas where values were taken from 
(Deutsch et al., 2008),  and PRIDE where values were taken from a lecture (Phil Jones, 4
th
 December 2008, Cranfield University).  a) denotes that the value is not 
readily obtainable on the website or recent paper; b) referred to as „projects‟; c) these values are based on the gene level, with values indicating distinct 
identifications at the gene level ; d) high confidence proteins; e) two Salmonella typhimurium datasets are counted so identifications may overlap; f) includes post-
translationally modified and different splice variant peptides, for the other values in this column it is assumed that they are counted but not stated explicitly in the 
data sources.   
 
Repository Species No. spectra No. experiments Protein identifications All peptides Distinct peptides 
PRIDE all 16,564,434 7,969 (all) 1,949,593 8,523,790 986,473 
GPMDB 
 
all 
 
?
a) 
 
? 
 
(all) 8,585,612  
(distinct) 491,070
c)
  
52,748,666 
 
1,150,085 
 
PeptideAtlas all 74,600,000 471 (distinct) 40,456 ? 285,000 
 human 49,000,000 219 (distinct) 12,141 ? 97,000 
Tranche all ? 5,502
b)
 ? ? ? 
GAPP DB human 130,152 146  (distinct) 2,171
)
 649,366
 f)
 66,655 
f)
 
Human PP human 4,567,235 2,695 (distinct)15,231 1,851,124 ? 
MAPU 2.0 mouse ? ? (all) 5,497d
d)
 ? ? 
 human ? ? (all) 2,926
d)
 ? ? 
SwedCAD/SwedECD All 15,897 15,897 n/a 15,897 15,897 
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In most repositories public data submissions outnumber private ones; in PRIDE, for 
example, 84% of data submissions were public, and 16% private in December, 2008.  In 
general, submission rates are increasing; see Figure 32 for PRIDE submissions as an 
example.   
 
 
 
 
 
 
 
 
  
Figure 32 Increase in data submissions to PRIDE repository (Source: Phil Jones „Proteomics Standards 
Development: Progress & Tools‟ Lecture, 4th December, Cranfield University) 
 
This increase has most probably been stimulated by the recommendations from journal 
editors that, upon publication, proteomic MS data should be made public (Table 16).   
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Table 16 Journals that recommend deposition of MS-based proteomics data into public repositories (autumn, 
2008) 
Journal Requirement for submission to public repositories 
 
Journal of Proteome Research  
 
Molecular Cellular 
Proteomics 
Authors encouraged to provide access to raw MS data 
using group websites and public repositories 
Nature Methods  Strongly recommends deposition of data before 
manuscript submission.  PRIDE and HPP are 
mentioned (Editorial, 2008b)   
Nature Biotechnology  Recommends proteomics data be posted in public 
repository before manuscript submission.  PRIDE is 
preferred (Editorial, 2007) 
Proceedings of the National 
Academy of Sciences 
Proteomics data is required to be submitted to a 
publicly accessible database and accession numbers 
must be provided. Access must be available at the time 
of publication.  
Proteomics States protein identification results, expression data 
and MS peak lists should be deposited in a public 
database.  Gives PRIDE as an example. 
Rapid Communications in MS Encourages public dissemination of raw files 
supporting identifications (Taylor and Goodlett, 2005) 
 
  
3.7 Standalone versions of some public repositories are available 
Some pipelines and their accompanying databases can be installed as standalone 
versions for local processing and warehousing of in-house data.  However, in contrast 
to web-based versions, which are relatively easy to use and universally accessible, 
standalones require computing expertise to set up; for example, GPMDB90 is available 
as a standalone, and a complete local PRIDE system (core and the web interface) is 
available91 as creation scripts for Oracle or MySQL.   
 
                                               
90 ftp://ftp.thegpm.org/projects/GPMDB/current_release 
91 http://sourceforge.net/projects/pride-proteome/, requires two components: PRIDE core 
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PeptideAtlas is based on SBEAMS92 which can also be downloaded, but it is complex to 
install because the core biolink module, interface software and proteomics module must 
be configured individually, and the bundle does not contain all the required Perl and R 
libraries.  Also, the setup files are written for Sybase (proprietary DB system), so it can 
be difficult to set up a MySQL version, for example.   
3.8  Pipelines feed GPMDB, PeptideAtlas and GAPP DB with 
identifications 
There are two routes of data entry into public repositories: by direct submission of peak 
lists and identifications by users, or via an analysis pipeline.  Pipelines, as defined in 
Chapter 1, perform multi-stage processing to assign identifications to peak lists, as well 
as other processing steps in some cases.  The resulting identifications and peak lists are 
stored in a repository („back-end‟).      
3.8.1 GPM 
X!Tandem Spectrum Modeler (Craig and Beavis, 2003) is the heuristic search engine in 
the GPM pipeline.  The algorithm produces theoretical spectra for peptide sequences 
using known relationships between intensity of mass peaks and amino acids, and then 
matches these with the unknown experimental peak lists using a dot product.  This is a  
 
                                               
92 http://www.sbeams.org/download/ 
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„descriptive‟ approach, because it is based on mechanistic prediction of how peptides 
fragment (Sadygov et al., 2004).  
 
X!Tandem performs multiple stages of searching and refinement to ensure efficient 
matching of mass peak lists to sequences, and to optimise for speed.  The first step aims 
to match the theoretical tryptic peptide and fragment masses to the real MS signal peak 
lists.  Then further iterative steps search for PTMs and point mutations.  This way, the 
search space is decreased to a manageable size for computation, and more peaks are 
successfully assigned.  
 
Also, a new option to „use sequence annotations‟ creates a search file detailing the 
proteins and their potential modifications (referred to annotations) for searching in a 
more PTM-specific fashion.  The files are created using UniProt and GPMDB as sources 
of annotations; and human, mouse, rat, chicken and yeast are currently supported.    
 
Furthermore, users can now select „decoy search‟ on the form to reduce FPs.  Users are 
not restricted to X!Tandem; there is also a consensus spectral search engine X!Hunter 
(Craig et al., 2006)  and a PTP-based search engine, X!P3 (Craig et al., 2005). 
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3.8.2 TPP 
In TPP, spectra are searched against sequence databases using SEQUEST (Eng et al., 
1994), or (the recently added) X!Tandem (Craig and Beavis, 2003).  The peptide 
identifications are converted into probabilities using PeptideProphet (Keller et al., 2005) 
and protein identifications, also with probabilities, are derived from the PeptideProphet 
results by applying ProteinProphet (Nesvizhskii et al., 2003a).  The recent addition is the 
next SpectraST (Lam et al., 2007) stage, which offers a second round of searching and 
scoring using a spectral library, followed by Peptide- and ProteinProphet as before.  The 
addition of this search produces more identifications compared to the original TPP 
alone, and with a low error rate.   
 
The SpectraST search is against an MS/MS library created by combining high scoring 
spectra to create a database of consensus reference spectra, each one representing an 
individual peptide.  As in X!Hunter, the consensus reference spectrum is compared to 
the unknown.  Individual searches can be performed via the website, where users enter 
peak lists and mass tolerance.  The resulting match of unknown to reference is shown as 
a comparison view with the x-axis as a „mirror‟ where the consensus spectrum points 
up and the unknown query peaks are mirrored below the x-axis, facing down.  The 
main drawback with SpectraST is that it is only applicable for the PeptideAtlas builds 
that have sufficient data to create a library.   
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3.8.3 GAPP 
GAPP (Figure 33) is the most important pipeline for this thesis, because the work 
presented in Chapter 4 and 5 is based on it.   
 
 
Figure 33  An overview of the Genome Annotating Proteomic Pipeline 
 
As in GPM, GAPP performs peptide scoring using X!Tandem (Craig et al., 2004).  
Advanced APS filtering (Shadforth et al., 2005b) is then performed to produce high 
quality protein identifications.  GAPP is parallelised, where the process of matching 
spectra to peptides, using X!Tandem, is split across 16 separate PCs (nodes), which are 
all connected to a master node with the MySQL database for collating the results from 
each node.  The X!Tandem scores are converted to APS (average peptide scores) values 
by summing the score for each peptide and dividing by the number of peptides found 
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for each protein identification.  A reversed proteome search is performed (in composite 
with the target) and the maximum APS found in the reverse decoy is used to filter the 
target protein identifications found.  For a detailed description of APS, see Chapter 4, 
where GAPP is applied to determine the optimal decoy database design to reduce false 
positives. 
 
There are splice variant and PTMs loops in GAPP (Figure 33); these aim to increase the 
proportion of spectra that are successfully assigned to peptides.  The pool of unassigned 
spectra in a given run are filtered by accepting only spectra with „quality‟ higher than 
the worst „quality‟ spectrum that was successfully assigned.  The quality metric is the 
sum of the peak intensities divided by the number of peaks, which is usually 100, since 
only the top 100 peaks are processed by GAPP.  The unassigned spectra that pass this 
criterion are re-searched with X!Tandem against smaller search databases that 
correspond to the proteins already found in the first round of searching (those in the 
„hitlist‟ table of GAPP DB).  The first database is the relevant splice variants for the 
proteins in the hitlist table (an exon boundary “Pexon” database), and the second is a 
database of all possible PTM variants (30 of them) for the proteins in the hitlist table.  
These searches are faster than the original search because the search space is smaller.  
The Pexon database is created for each target database used in GAPP (human and 
others) using a Perl script created by Ian Shadforth on a previous EngD project 
(Shadforth, 2005).   
 191 
 
In summer 2008, peptide mass fingerprinting (PMF) functionality was added to GAPP, 
allowing MS as well as MS/MS data to be analysed, with both results being deposited 
into GAPPDB.   
3.9 Repositories for quantitative proteomics are emerging  
Although application of quantitative proteomic MS techniques, such as ICAT, iTRAQTM 
and SILAC, is growing, there is still very little quantitative data available in the public 
domain.  This may be attributed to quantitative data not being supported in public 
systems.  Some public offerings are beginning to support quantification. For example, 
when a complete LC/MS run is uploaded (as a single mzData query file) to ProMEX 
(Hummel et al., 2007), one of the public pipelines, an entry for each protein/peptide is 
generated including how often it was identified.  The cumulative sum of spectra per 
peptide and protein may be taken as similar to spectral counting, and spectral counting 
has been shown to be related to protein abundance, so effectively enables semi-
quantitation (Lau et al., 2007).  PeptideAtlas also claims to give an approximate estimate 
of absolute abundance of proteins in biological samples, determined by spectral 
counting and averaging of the many datasets analysed by its pipeline, the TPP (Deutsch 
et al., 2008).  This information indicates the quantity of surrogate peptide that should be 
spiked for SRM, for example.  Also, after the peptide identification stage of TPP, 
XPRESS (Han et al., 2001), ASAPRatio (Automated Statistical Analysis on Protein Ratio) 
(Li et al., 2003) or Libra may be invoked to perform quantitation on suitable data.   
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However, quantitative data is not available via the public PeptideAtlas repository 
interface, so is only possible when TPP is installed and run locally.   
 
A major hindrance to the development of repositories to support quantitative data is the 
lack of formats for its capture, storage and exchange and the variety of strategies 
available (Lau et al., 2007).  Furthermore, best practice in protein quantification has not 
yet been established, compounding the problem.  However, in-roads are being made 
with iTRAQ reporter ion ratios forming part of the extended PRIDE XML schema 
(Siepen et al., 2007), and mzML format is expected to support quantitative data, 
although is unlikely to do so in the first releases.  Encouragingly, a recent addition is 
Quantitative proteomics repository (QuPE)93, a database and algorithmic framework 
implemented in Java and the Spring framework.  It stores proteomics data and 
metadata from assorted quantitative approaches, such as SILAC, in a consistent fashion, 
also offering tools for statistical analysis.  The resource is accessed via the web interface 
(after login), which is implemented using Echo2 web framework and has an Ajax-based 
rendering for graphics.   
3.10  Discussion: proteomics data quantity, quality and usage 
In summary, the outlook for public proteomics repositories is positive.  They continue 
to grow in content and functionality.  However, there  is  still  no  complete  collection of 
                                               
93 At http://www.cebitec.uni-bielefeld.de/groups/brf/software/prose_info/index.html.  QuPE was previously called 
‘ProSE’     
 193 
 
all publicly available data in one place, despite the ProteomExchange Consortium 
(including PeptideAtlas, Tranche, GPMDB and PRIDE) being set up to work towards 
this goal (Hermjakob and Apweiler, 2006).   
 
In general, repositories with the largest amount of data are most useful, because large 
quantities of data are necessary for meaningful data-mining, deriving consensus 
libraries for searching, and to improve significance of conclusions derived from the 
data.  However, large file sizes can themselves present a problem for the pipeline-based 
repositories; GAPP, for example, has an upload limit of ~200MB per submission, 
although files are routinely much larger, given increased sampling frequency with new 
MS protocols (to increase sensitivity).  Moreover, files are especially large after merging 
multiple runs for the same experiment.  As a result, establishing the best way to submit 
data is a formidable challenge for the pipeline-based repositories.   
 
In addition, the quality of submissions is an issue for public systems.  For spectral 
quality, research into new methods to assess quality is ongoing (Nesvizhskii et al., 2006), 
but at present no repository claims to limit public submissions based on any measure of 
quality.  In fact, the move to consensus spectral searches (such as using SpectraST in 
TPP and X!Hunter at GPM) aims to overcome this issue empirically by averaging across 
many submissions to account for noise and variability amongst individual  spectra 
assigned to the same peptide.     
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It is hoped that proteomics repositories may be useful for answering challenging 
questions such as: Who has observed a set of proteins similar to the set I have 
observed?, or Can I perform global comparative proteomics using their datasets?  To 
answer the former, the PRIDE Venn diagrams may be used, for example, or GAPP‟s 
differential view, or indeed the iSPIDER94 integration service (Siepen et al., 2008), which 
enables users to search and view the identifications made by other groups that are 
stored in different databases in an internal format called spidyXML.  The combined 
results are then displayed using software clients and specialist viewers.   
 
To answer the latter, global comparative studies are, by definition, only possible if 
whole proteomes are made publicly available.  Examples exist of this scenario:      such 
as Martiens et al. who compared protein identifications from brain proteome project 
(BPP) and three other proteome studies (plasma proteome project (PPP), human platelet 
proteome and the mouse proteome) (Martens et al., 2006).  For now, however, the 
heterogeneity of data submitted by various labs hampers the process of whole 
proteome comparison, since sample type, MS instrumentation, identification algorithm 
and search database can vary.  With efforts, such as CPTAC (Blow, 2008) and the Fixing 
Proteomics Campaign, addressing the issues of reproducibility of data, it is hoped that 
comparative proteomics will become feasible via public repositories soon. 
 
                                               
94 http://www.ispider.manchester.ac.uk/cgi-bin/ProteomicSearch.pl 
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Finally, it is likely that in the mid- to long-term future new functionality will lead to 
better integration between proteomics and other „omics‟ data, such as interactomics and 
metabolomics.  This could deliver holistic understanding of biology and the workings 
of the cell, with implications for improved approaches to biomarker discovery. 
3.11  Conclusion  
This review described two main types of repository: the analysis pipeline-based 
repositories (GPMDB, PeptideAtlas and GAPP), and the data warehouse repositories 
(e.g. PRIDE, Tranche and HPP).  It represents novel research that was adapted to form 
two review articles that were published by Proteomics journal (see Appendix III).   
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4 Optimising the design of decoy search databases using 
the Genome Annotating Proteomic Pipeline (GAPP) 
 
 
 
 
 
Optimising the design of decoy  
search databases using the Genome 
Annotating Proteomic Pipeline (GAPP) 
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4.1 Summary 
False positive (FP) identifications can be costly for high-throughput proteomics as they 
can lead to futile follow-up studies, for example, or erroneous conclusions about the 
underlying biology.  Indeed, inaccurate identification performance provides a reason 
for investors to continue to be suspicious of high-throughput proteomics, and can lead 
to problems for those developing new tools to mine the data, once it is stored in 
proteomics repositories (as is the case for the MRMaid tool developed in Chapter 5).   
 
To remove FPs decoy database searches are routinely applied, the decoy acting as a null 
model to test if the score of the peptide match is true.  Threshold scores, for filtering out 
FP identifications, are usually set to the highest score achieved by the decoy database 
search in a given MS/MS data analysis run. Various methods have been published for 
generating decoy databases, but there is debate about which decoy design is „the best‟.  
This chapter addresses this question by performing an evaluation of nine diverse decoy 
designs using public MS/MS datasets from samples of known composition and GAPP 
pipeline.  
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4.2 Introduction 
Proteomics pipelines are automated, high-throughput workflows that extract protein 
identifications from m/z peak lists, usually by tandem MS database searching.  As 
already described, one way to assess if the identifications are correct is to apply a decoy 
database search to filter out false positive (FP) identifications from the target database 
search results; for example, by taking the highest score achieved by the decoy to siphon 
off the low scoring peptides in the target search results.  Using reversed sequence 
searches for this purpose is well documented (Peng et al., 2003, Cargile et al., 2004, Qian 
et al., 2005, Kapp et al., 2005).  However, a reverse decoy database may be simple to 
generate (literally reverse the sequences end to end), but it may not be the optimal 
choice as regards to false positive rate (FPR) it can achieve; in fact, “there is no clear 
consensus ... as to which method for generating a decoy database is best” (Käll et al., 2008).     
 
To answer the question of which decoy database is best for reducing FPRs, therefore, 
nine different decoy database designs were systematically investigated, searched in 
both composite and in parallel to the target proteome.  The peptide and protein 
identification performance was examined for each decoy using Cranfield University‟s 
GAPP pipeline.  Unlike other studies to investigate decoy designs (Higdon et al., 2005, 
Elias and Gygi, 2007, Käll et al., 2008, Reidegeld et al., 2008), the data used in this 
investigation is a standard protein mixture analysed by multiple laboratories, each of 
which processed the sample using MS without knowing its composition. It therefore 
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represents a real-life scenario, taking into account inevitable variability between 
different experimental setups and researcher experience.   
4.3 Method 
To perform a decoy optimisation study, a peptide identification pipeline is required so 
that many searches can be performed in an acceptable period of time.  The methodology 
applied in this study is summarised in Figure 34, and is explained in more detail in the 
following sections.   
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Figure 34 Overview of the approach used to investigate the best decoy database design performed in this 
chapter.  The GAPP-APS pipeline was applied to ABRF standard MS/MS datasets, and performance of the 
decoy was measured as FPR 
   
4.3.1 Standard datasets with suitable metadata were selected 
A prerequisite for the standard data analysed in this study was the availability of 
accompanying metadata, such as details of the protein content of the samples, chemical 
treatment, MS instrumentation and the number of spectra: 
 Chemical treatment information relates to search parameters, such as variable 
modifications to include, enzyme regular expression and others 
 Instrument type indicates the necessary mass tolerances for the search.  
 The number of spectra provided confirmation that all intended spectra from each lab 
had been downloaded in completeness    
 
The two main contenders, based on fulfilment of these criteria, were the Aurum dataset 
of 246 human proteins (Falkner et al., 2007) and the ABRF sPRG2006 49 human protein 
mixture (Andrews et al., 2006); for a full summary of the publicly available datasets at 
the time of writing go to Appendix IV.  The ABRF datasets were chosen because 
multiple labs had submitted data, so varying levels of data quality could be considered, 
such as levels of contamination and sample handling. Capturing such variance in data 
quality was an important factor to include in this investigation, so decoys could be 
evaluated regardless of individual technique, data quality or mass resolution.   
 
 204 
 
Although the ABRF protein mix was originally intended to contain 49 proteins only, 
ABRF Proteomics Standards Research Group Bioinformatics Committee (sPRG BIC) 
confirmed the presence of further „bonus‟ proteins in the mix (Lane et al., 2007).  
Subsequently, a „master list‟95 of SWISSPROT confirmed protein constituents was 
published as a result of retrospective consensus analysis using diverse search strategies.  
For this thesis, all human proteins on the list were considered, including synonymous 
accession numbers, where necessary.  The total number of proteins was therefore 49 
plus associated synonyms totalling 64, plus 40 „bonus‟ proteins (total 104).  
Identifications of all these proteins were deemed to be true positives (TPs).  To perform 
the study, the author converted the accession numbers provided by the ABRF to 
Ensembl-compatible IDs (Appendix IV shows the list). 
 
The ABRF datasets were downloaded using the Tranche Java Downloader Application 
at ProteomeCommons96, and the metadata downloaded from www.abrf.org.  Sean 
Seymour (of ABRF) was contacted to fill in the gaps in the metadata, where necessary.  
If individual submitting laboratories provided multiple data files for the analysis of the 
protein mixture, then these files were merged into a single file and the number of 
spectra was counted and verified against the ABRF metadata file.  ReAdW, a free 
program available for download as part of the TPP software tools, and XCALIBUR 
(Thermo Scientific, Waltham, MA)  were  used  to  convert  .raw  data  to  .mgf  format,  
                                               
95 Available at www.abrf.org 
96 www.proteomecommons.org 
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where required.  The ten labs fulfilling the above format and metadata conditions were 
downloaded; their code numbers were: 00700, 10085, 12874, 14997, 17017, 22069, 25636, 
53178, 53908 and 72079. 
4.3.2 GAPP-APS pipeline produces high quality protein identifications 
The peptide and protein identification performance of diverse decoy database designs 
was evaluated using the GAPP pipeline (Shadforth et al., 2006), where (as mentioned in 
Chapter 3) primary scoring is performed by X!Tandem (Craig et al., 2004) followed by 
validation and protein inference using advanced APS (Shadforth et al., 2005b) (Figure 
34).     
   
For the explanation that follows, note that: an analysis „run‟ for GAPP is defined as a 
single MS/MS data submission, with a specific decoy search and a specific set of search 
parameters; a protein identification (or „hit‟) is any protein found in the target database 
that passes the APS threshold set by the decoy database search for that given analysis 
run; and a peptide „hit‟ is any peptide that was found in the target search database that 
corresponds to a protein that passed APS.   
 
X!Tandem first assigns a peptide sequence to an MS/MS spectrum in GAPP; the results 
are peptide sequences each with an X!Tandem score.  Proteins are inferred from these 
peptides, and validated with the advanced APS method.  There are two parts to the 
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advanced APS method, these are: calculating APS thresholds using a decoy database 
search, and sampling to determine a local maximum for selecting the best APS 
threshold to use (as shown in Figure 34). 
APS threshold and applying decoy database searches to GAPP 
GAPP calculates the sum of X!Tandem scores of the peptides that match to the protein, 
and divides this value by the number of peptides that match to the protein, thus taking 
the mean average.  This aims to account for the fact that the sum of many low scoring 
incorrect peptide identifications would result in an overall high total score for the 
protein overall, thus the protein would appear to be a correct identification when it was 
not; a deleterious situation for an automated search.  Thus, peptide assignments to 
proteins with an APS score below an APS threshold are discarded.  This threshold is 
derived ab initio by setting it to the maximum APS score from the decoy database search 
for the data in question.   
 
GAPP pipeline‟s default decoy is a reversed version of the target.  To create this decoy 
database, all the amino acid sequences in the Ensembl protein database were literally 
reversed.  The assumption is that the reverse DB covers enough of the possible random 
sequences to be reliable, which is a credible assumption, but remains to be proven.  
Despite the uncertainty however, this APS approach in GAPP has been demonstrated to 
perform well when compared to Sequest, Mascot, PeptideProphet, X!Tandem and 
others (Shadforth et al., 2006). 
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Threshold sampling in advanced APS 
„i‟ is a quality filtering value applied to determine which APS score is best to apply as 
the filtering threshold.  The APS values for each run are computed several times at 
different increments of i, and the APS value for i that results in the most identifications 
is chosen.  Note that APS is the protein level measure, and i is at the peptide level.  For 
example, the algorithm proceeds as follows:  
Step 1:  For i = 0, if X!Tandem score for the peptide > i, calculate the protein‟s APS score, 
store the number of peptides and proteins.   
Step 2:  For i = 5, if X!Tandem score for the peptide > i, calculate the protein‟s APS score, 
store the number of peptides and proteins...etc.   
This is repeated in steps for i in increments of 5, up to 50.  The final result is a table of 
values (Table 17) for each value of i, which is stored in the GAPP DB schema. 
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Table 17 APS_score_info table from the GAPP database schema 
Column Description Example data 
entry 
unique_id Unique number of the run, auto-incremented for each data 
submission to GAPP pipeline 
1 
single_pass Number of protein identifications that pass the APS threshold 
with a single peptide assigned  
5 
multi_pass Number of protein identifications that pass the APS threshold 
with multiple peptide assignments 
4 
total_pass Sum of single_pass and multi_pass values.  The total number 
of protein identifications that the pass APS threshold. 
9 
single_thresh The APS score required for proteins with a single peptide 
identification (equal to the maximum APS found for proteins 
matched to a single peptide in the decoy database search) 
76.21 
multi_thresh The APS score required for proteins with multiple peptide 
identifications (equal to the maximum APS found for proteins 
matched to multiple peptides in the decoy database search) 
6.96 
qual_filter i value (incremented in steps of 5) 10 
 
The APS threshold that is applied for a given run is the one that maximises the total 
number of identifications: the highest „total_pass‟ (Table 17).  However, if there are two 
values of i with the maximum number of protein identifications for the same run, then 
the value of i that has a higher number of multiple-peptide protein identifications is 
applied.   
 
In summary, i serves to remove noise (low scoring peptides) in a parametric way by 
sampling the best APS threshold empirically.  This approach increases confidence 
without losing true positive identifications by finding a local maximum for each search.       
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GAPP processing capabilities and X!Tandem search parameters 
For the decoy database analysis in this chapter, processing was carried out on a Linux-
based Beowulf cluster of 16 3.2GHz dual core nodes. In total 1,440 individual search 
runs were performed, excluding initial testing.  The author estimates that this would 
have taken approximately 90 days to compute using a single processor. Computing 
power is an important limiting factor in terms of the number of different combinations 
of algorithms, search parameters and data that can be considered when comparing 
decoys in this way.  For this study, the author collated the spectra to submit to GAPP. 
Luca Bianco created a script to automate the submission process so the pipeline could 
be run overnight, taking the spectra from a specified file directory.   
4.3.3 Search parameters were applied according to the ABRF metadata 
All datasets were processed with the following X!Tandem search parameters: missed 
cleavages up to 2, carbamidomethyl as a variable modification (because the metadata 
stated IAA97 treatment had been used across all labs) and charge state up to 3+.  The 
mass tolerances were set to reflect the MS instrument used by the individual submitter 
(Table 18), with five search parameter sets in total. Unfortunately, as for the majority of 
publicly available MS/MS datasets, the mass accuracies derived from calibration were 
not reported in the  accompanying  metadata, so   the   parameter   sets  were  chosen  to  
                                               
97 Iodoacetamide (IAA) is an alkylating sulphhydryl reagent that is used to prepare peptides for MS.  It prevents 
disulphide bonds forming between cysteines.  It produces peptides with carbamidomethyl modifications, so the mass 
shift of these must be accounted for in automated searches.    
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represent the approximate resolution known to be achieved by the given instrument 
type (Table 18).  
 
Table 18 The mass tolerance parameters used for each dataset.  The tolerances reflect the average resolution 
achieved by the instrument setup 
Parameter set 
no. 
Instrument 
type 
Mass tolerance 
(Da) 
Fragment 
tolerance (Da) 
ABRF submitter 
code 
1 HCT 1.5 0.8 22069 
2 LCQ 2 1 72079 
3 LTQ 1.5 0.8 00700 
4 LTQ-FT 0.3 0.7 12874 
    17017 
    25636 
    53908 
5 QTOF 0.5 0.5 10085 
    14997 
    53178 
 
Ensembl (31st May 2007, homo_sapiens.ncbi36.45.pep.all.fa), which contains all the 
proteins known to be in the sPRG2006 mixture, was used as the target sequence 
database for generating the decoy databases.  
4.3.4 Two search strategies were applied 
The claim of superiority of the target-decoy composite strategy is ubiquitous in the 
literature (Higdon et al., 2005, Haas et al., 2006, Reidegeld et al., 2006, Klammer and 
MacCoss, 2006, Balgley et al., 2007, Falkner et al., 2007, Elias and Gygi, 2007, Reidegeld et 
al., 2008).  Despite this, the search method still remains a controversial topic, since 
separate searches are believed to result in more conservative FPRs, because there is no 
competition with the high quality matches for the best scores.  As a result, decoy hits 
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may receive elevated scores, so matches to the target have to achieve even greater scores 
to pass the higher threshold (Elias and Gygi, 2007). 
 
This study performed searches in both ways: firstly, by searching the target and decoy 
database in parallel so that each database was searched independently from the other, 
and secondly, using the target and decoy as a composite with the forward search by 
appending an additional identifier to the decoy entries.  The Perl script to append this 
tag to each accession number was implemented by Luca Bianco.   
4.3.5 Nine decoy database designs were investigated 
Nine different decoy database designs were tested, four of which were generated at the 
protein level using the most popular published techniques and five, not previously 
described, which were produced at the peptide level (Figure 35). 
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Figure 35 Taxonomy of decoy databases (a) Denotes novel methods of decoy generation implemented in this 
study.  REV: reversed proteome; PRD: uniformly distributed amino acid composition decoy; RND: weighted 
amino acid composition decoy; SHF: shuffle decoy database; MC: decoy where the mass of peptides are 
conserved; pep: denotes a peptide level version of the decoy database as described above; „_c‟ denotes decoys 
appended to the target proteome; „_s‟ denotes decoys that are searched separately in parallel to the target 
proteome.  
 
The main decoy database designs that have been described previously include reversed 
proteome (Moore et al., 2002, Peng et al., 2003, Cargile et al., 2004, Kapp et al., 2005, Qian 
et al., 2005, Shadforth et al., 2005b, Reidegeld et al., 2006, Balgley et al., 2007, Reidegeld et 
al., 2008), shuffled sequence decoys (Stephan et al., 2006, Reidegeld et al., 2006, Klammer 
and MacCoss, 2006, Reidegeld et al., 2008) and randomised decoys (Elias and Gygi, 
2007, Reidegeld et al., 2008).  Reverse database searches are the most popular decoy 
employed to reduce FPs, primarily because they do not require a distribution to be 
determined, since the reverse proteome is deterministically computed.  By reversing 
each protein, amino acid composition and protein length are preserved, so the statistical 
properties of the target are maintained.   
 
Shuffle-type operations can also be performed to create decoy databases, where a 
shuffle is essentially a randomisation process performed within given constraints or 
rules.  The operation may be performed in several ways, for example, where all amino 
acids of the original protein have been shuffled to random positions using functionality 
of proprietary decoy database builder software, such as DecoyDB (Reidegeld et al., 2006, 
Reidegeld et al., 2008).  The final alternative is randomising sequences using an amino 
acid distribution reflecting the entire target proteome. 
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The properties of the decoy databases employed in this study are summarised in Table 
19.  For each decoy, excluding reverse sequence decoys, ten instances were generated so 
that the average distribution of identifications could be calculated.  This was required 
because the randomisation process produced differences in each decoy‟s composition 
each time the program to generate it was executed.     
  
Table 19 Summary of the database properties of the decoys. a - note that proteome length is preserved when 
protein (or peptide) length is preserved. b - in the case of (K/R)P this may be shuffled to create additional 
K/R not followed by P, which is a tryptic cleavage site. 
 
 
 
 
Decoy 
design 
Protein 
and 
peptide  
length 
preserved
a
 
Amino acid 
composition 
preserved in 
each protein 
Amino acid 
composition 
preserved in 
whole 
proteome 
Tryptic 
cleavage 
sites 
preserved 
Protein 
mass 
preserved 
Tryptic 
peptide mass 
preserved 
REV Yes  Yes Yes  No Yes  No  
PRD Yes No No No No  No  
RND Yes No Approx. No No  No  
SHF Yes Yes  Yes No Yes No  
pREV Yes Yes Yes Yes but may 
be more 
Yes Yes but may 
be more
 b
  
pPRD Yes No No Yes but may 
be more 
No  Yes but may 
be more
 b
  
pRND Yes No No Yes but may 
be more 
No  Yes but may 
be more
 b
  
pSHF Yes Yes Yes Yes but may 
be more
b
  
Yes  Yes, unless
b
 
MC No  No No  Yes, but 
may be 
more 
Yes Yes  
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For the reversed proteome (REV) each protein sequence was reversed, meaning that the 
N-terminus of a protein became the C-terminus, and vice versa. Cleavage sites were not 
conserved with this method.   
 
For the uniformly distributed amino acid composition decoy (PRD) the algorithm found 
the size of a protein then created another of identical length by randomly selecting 
amino acids. A uniform probability distribution was used to choose the amino acid to 
add to the polypeptide chain. In this way, all residues had equal probability (1/20) of 
being placed in each position of the decoy protein. The protein length is the only feature 
preserved by this method.   
 
For the weighted amino acid composition decoy (RND) a pre-computation step was 
performed to determine the amino acid distribution of the whole proteome. For each 
protein to be randomised, the size was used to generate a new protein by randomly 
selecting amino acids with a probability distribution depending on the distribution of 
each amino acid within the whole proteome. The [0,1] interval was divided in 20 sub-
intervals, whose length depended on the frequency of the distribution of each amino 
acid in the proteome. A random number from a normal distribution between 0 and 1 
was chosen to decide the amino acid to add to the polypeptide chain under 
construction. This method maintained the protein size and the proteome‟s amino acid 
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distribution, but cleavage sites and amino acid distribution at the protein level were not 
conserved.   
 
In the shuffle decoy database (SHF), the positions of amino acids within a protein were 
randomly changed. This conserved the protein length as well as the amino acid 
composition. The swapping of residues‟ positions could, however, affect cleavage sites, 
which are not protected by this operation.   
 
The peptide level decoys included pREV, pPRD, pRND, pSHF and MC.  To generate 
these, a pre-computation step was required to digest each protein in silico into tryptic 
peptide sequences. Then, a post-computation step reassembled all digested peptides 
into proteins. In the post-computation step, care was taken to conserve all cleavage 
sites.   The reverse peptide decoy (pREV) was similar to the REV decoy but was 
performed at the peptide level, whereby the reverse of each tryptic peptide was 
computed. This preserved the protein length and the amino acid composition. The 
number and composition of cleavage sites was at least as large as it was in the original 
protein.   
 
For the uniformly distributed amino acid composition decoy at the peptide level 
(pPRD), each peptide was substituted by a new sequence having the same length and 
amino acids from a uniform random distribution.  As for the other peptide level decoys,  
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the cleavage sites were used to determine peptide lengths prior to randomisation.  This 
approach maintains protein length but not amino acid composition. The number and 
composition of cleavage sites was at least as large as in the original protein.   
 
In the weighted amino acid composition decoy at the peptide level (pRND) each 
peptide was substituted by another with the same length. All amino acids were 
randomly chosen from a distribution depending on the frequency of amino acids in the 
proteome.  This preserved protein length but not the amino acid composition of 
peptides. The number of cleavage sites was at least as large as in the original protein.   
 
For the peptide shuffle decoy (pSHF) amino acids were randomly shuffled in each 
peptide sequence using the same approach as for SHF.  This preserved protein length 
and the amino acid composition of peptides. The frequency of cleavage sites was at least 
as often as in the original protein.   
 
Finally, for the mass-conserved decoy (MC), the mass of each tryptic peptide that 
constituted a protein was computed and a new, randomly generated, peptide having 
the same mass (plus/minus a tolerance, in this case fixed to 0.5 Da) was substituted for 
the original in the newly generated protein.  This method preserved the mass of 
digested peptides but varied the amino acid composition and the protein length.    
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Palindromic sequences were not removed, neither were any target sequences found in 
the decoy by chance.  This is because it has been shown that palindromic peptides 
account for a negligible proportion of the proteome (Elias and Gygi, 2007) and the 
probability of obtaining an identical sequence by chance is small (1/20)l, where l is 
sequence length. 
For this part of the work, the author designed the selected decoy models, and 
performed conceptual design of the algorithms to create them in conjunction with Luca 
Bianco, who coded the final programs to generate the decoy database instances: a 
program written in C for the mass conservation decoy and Perl scripts for the others.     
4.3.6 Decoy database performance was measured using FPR 
False positive rate (FPR), FP/(FP + TP), was used as the principal measure of decoy 
performance.  This is because it captures the identification performance of each search, 
taking into account both correct and incorrect identifications.  FPR could be determined 
because a standard protein mixture was analysed (Higdon et al., 2005).  FPR was 
calculated at both the protein and peptide levels, however the focus of the analysis was 
predominantly on protein identification performance. 
There is ambiguity in the community as to the definition and usage of the term „False 
Positive Rate‟ (FPR) versus „False Discovery Rate‟ (FDR).  In the literature there are 
instances where FPR and FDR have been used interchangeably, for example in Elias and 
Gygi‟s paper (Elias and Gygi, 2007), where FPR was defined as FP/(FP + TP) (as in this 
thesis) and in (Jones et al., 2008a) where the same measurement is referred to as FDR.  
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Further complications arise still, for example, where FDR is defined as the percentage of 
PSMs (peptide-spectrum matches) that are incorrect by some authors, such as (Käll et 
al., 2008), and can be applied when datasets of unknown composition have been used 
(Blackler et al., 2006, Reidegeld et al., 2008).   Also FDR - for separate target decoy 
searches - may be calculated as the number of decoy peptides identified, divided by the 
number of target peptides identified (Choi and Nesvizhskii, 2008a, Tabb, 2008).  The 
purpose of FDR in this case is to give an indication of the percentage of incorrect 
peptide identifications that have been accepted as correct by passing a user-defined 
threshold.  In this study, however, FDR, by this definition, did not need to be 
determined, because a standard dataset of known composition was employed, so FPR 
sufficed – as calculated as FP/(FP + TP), where the TPs list was available.   
4.3.7 Statistical analysis included factorial ANOVA 
ANOVA was performed on the mean FPR values to determine if there was a 
statistically significant difference in performance across the decoy designs.  It was 
performed with three factors using Genstat (VSN International Ltd., UK), the factors 
being: i) decoy design (nine as shown in Table 19), ii) search strategy (composite and 
separate) and iii) instrument (five MS setups as shown in Table 18).  The aim was to 
determine which, if any, decoy design was significantly better than the others and also 
to investigate the effect of search strategy and instrument type on FPR - to put any 
difference between decoys into context.  To establish significant differences, pair-wise 
comparisons of least significant difference (LSD) values were made.  For instrument 
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type, the number of replicates was not uniform so LSDs had to be compared taking into 
account the replicate number for each case.  Bespoke scripts were written by the author 
to import data into Matlab (Mathworks, Natick, MA) and Genstat for these analyses. 
 
In addition to ANOVA, box whisker plots were generated to graphically illustrate the 
differences in protein identification performance across different labs and decoys.  Such 
a plot shows the robustness of each decoy design, demonstrating the variability 
between the ten individual instances.  These plots were generated using Matlab scripts 
written by the author.  Additional graphs were created using Excel.   
 
To explore the effect of decoy design on identification performance further, the author 
designed a database to capture several other metrics at the time of search.  These 
properties were designed to give further, detailed understanding into the aetiology of 
the differences in decoy design performance, and included: 
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 Number of protein identifications (TP, FP and decoy database) 
 Number of peptide identifications (TP, FP and decoy database) 
 Number of peptides found per protein identification (TP, FP and decoy database) 
 Number of peptides matched with seven or fewer amino acids (TP, FP and decoy 
database).  Seven amino acids is the number reported by Elias and Gygi at which peptide 
redundancy between target and reverse decoy deteriorates (Elias and Gygi, 2007). 
 Average length of peptide identifications (TP, FP and decoy database) 
 Number of assigned peptides identical in sequence across target and decoy 
 False positive rate at the peptide level 
 False positive rate at the protein level 
 APS score threshold for single peptide identifications 
 APS score threshold for multiple peptide identifications 
 
For each decoy database (except the reverse decoys) there were ten values for each 
metric in this list, these represented the ten instances.  The author implemented the 
MySQL database to capture these metrics, and Luca Bianco wrote the intermediary 
script between GAPP and this metrics database.  The author manually queried specific 
values, such as APS thresholds, from the metrics database schema. 
4.4 Results 
4.4.1 FPRs summary 
Mean FPRs were reported between zero and 5.6 percent for peptide level 
identifications, and zero and 17.9 percent for the protein level identifications.  Actual 
numbers of FPs and TPs used in the calculations are provided in Table 20.  The separate 
  
222 
search strategy generally performed better, producing lower FPRs over the majority of 
decoy designs (Figure 36 and Table 20).     
 
 
 
 
Figure 36 Mean protein identification FPR by decoy design and search strategy.  Separate searches are 
generally more accurate.  The majority of decoys produced a lower FPR when searched independently of the 
target database, the only exception being pRND which resulted in lower FPR when searched in composite 
with the target.  pREV searched in composite with the target appears to be the optimal method, followed 
closely by pSHF in both composite and separate.  Bars represent the standard error.  Decoy/method LSD 5% 
= 2.86  
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Table 20 Mean true positives and false positives across all data submitters and decoy search types.   
(a) TP proteins   (grand mean = 32.1, standard deviation = 13.1 )  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) FP proteins  (grand mean = 1.80, standard deviation = 2.61) 
Submitter REV_c PRD_c RND_c SHF_c pREV_c pPRD_c pRND_c pSHF_c MC_c REV_s PRD_s RND_s SHF_s pREV_s pPRD_s pRND_s pSHF_s MC_s 
22069 3 3.5 3.2 2.6 0 2.5 1.8 1.7 4.3 3 2 2.4 2.2 0 1.5 2.3 1.5 2.3 
72079 8 14.1 9.4 9.8 3 11.2 7.6 6.9 12.7 2 10.3 9.6 8.5 3 9.7 9.8 8.2 7.8 
00700 1 2.6 1.3 0.2 1 1.6 0.3 0.3 3 0 1.6 2.1 1.3 2 2.2 2.3 1 2.2 
12874 0 0.2 0 0.1 0 0 0 0 0.3 1 0.1 0.3 0.2 1 0.6 0.7 0.1 0.2 
17017 2 4.4 1.8 1.6 2 2.7 1.6 1.2 4.7 6 1.6 1.7 2.2 1 2 2.1 1.7 2.2 
25636 1 1.1 0.8 1 1 1.2 0.3 1.2 1.2 0 0.8 0.4 0 0 0.3 0 0.1 0.1 
53908 1 1.4 0.5 0.6 0 0.6 0.1 0.6 0.9 2 0.6 0.9 0.4 0 0.3 0.5 0 0.5 
10085 1 0.8 0.9 0.6 0 0.6 0.3 0.6 1 0 0.5 0.7 0.8 1 0.5 0.6 0.3 0.7 
14997 3 1 0.8 0.8 0 1 0.2 0.9 1 1 0.4 0.1 0.8 1 0.5 0.5 0.2 0.4 
53178 1 1.4 0.3 0.6 1 0.8 0.4 0.5 1.5 1 0.7 0.3 0.7 1 0.5 1 0.5 0.7 
 
Submitter REV_c PRD_c RND_c SHF_c pREV_c pPRD_c pRND_c pSHF_c MC_c REV_s PRD_s RND_s SHF_s pREV_s pPRD_s pRND_s pSHF_s 
MC_
s 
22069 34 34.4 34.8 34.3 33 33.8 33.6 33.6 35.2 34 33.1 33.4 32.8 33 33 33.8 32.9 33.5 
72079 61 64.5 63.3 62.4 62 63.2 62.2 63 64.1 58 63.1 62.1 61.7 62 61.9 62 62.1 61.7 
00700 20 22.7 20.4 19.8 20 21 19.7 19.8 22.5 19 22 22.9 21.1 24 23 23.1 20.9 21.7 
12874 36 35.8 35.2 35.7 36 35.3 35.8 35.9 36 36 35.8 35.7 36 36 35.2 36 35.9 36 
17017 34 33.7 33.3 33.8 32 33.6 33 33.3 33.8 34 33.5 33.6 33.4 34 33.4 33.6 33.6 33.4 
25636 10 9.5 8.4 8.7 7 8.5 7.8 9 8.9 9 10 9.5 8.8 8 9.1 7.8 8.9 8.6 
53908 28 27.1 26.2 26.3 24 26.8 26.1 25.9 27.1 27 26.4 26 26.4 26 26.3 26.7 26.4 26.7 
10085 37 37.2 37 37 37 37 37 37.1 37.1 37 37 36.9 36.8 37 36.8 36.9 37 37 
14997 37 36.4 36.7 36.8 36 36.5 36.6 36.4 36.7 36 36 35.5 36.7 36 36.1 35.9 35.4 36 
53178 25 27.1 24.9 25.5 26 26 25.6 25.1 26.5 26 25.5 25.3 25.8 27 25.8 26.3 25.7 25.9 
  
224 
The grand mean FPR across all 180 means (10 data submitters x 9 decoy designs x 2 
search strategies) at the protein level was only 4.56 percent (standard error 0.31), and at 
the peptide level only 1.34 percent (standard error 0.10).   
4.4.2 Recommendation for decoy design based on protein level FPR 
The ANOVA F probability values were under 0.05 for each of the three factors for the 
protein level FPR mean values: 0.030 for decoy design, 0.021 for search strategy and 
<0.001 for MS instrument setup, respectively.  This was an exciting result indicating that 
there were significant differences between the FPRs across the decoy designs, and that 
the FPRs obtained by separate searches were significantly different to FPRs obtained by 
composite searches over the datasets tested.  Importantly, the interaction F values 
showed no statistically significant interactions between the three factors at the protein 
level, with all values exceeding 0.05, meaning that the decoy effects on FPR were 
reproducible across the different search methods and instrument types.  This is 
important as it indicates that the relative performance of the decoys across the samples 
analysed in the study is independent of the MS instrument or search strategy employed.  
Finally, inspection of the residuals showed that the average FPRs fitted the normal 
distribution, so the underlying assumptions required for ANOVA were valid. 
 
To determine which decoy design performed best, the LSDs at 5% from the ANOVA 
analysis were compared to the mean FPR values (Table 21).   The LSD at 5% is the 
absolute value by which two means must differ to be deemed significantly different 
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with 95% confidence.  The comparison shows that pREV, pSHF and pRND were 
significantly better in terms of protein FPR than MC and PRD.   pREV was also 
significantly superior to REV and pPRD.  There was, however, no single „winner‟ decoy 
database that was significantly better than all the rest; however, the results are suitable 
to make the recommendation that peptide level reverse be used routinely for automated 
searches using the APS method.  This is because pREV is as good as the other decoy 
designs, significantly better than MC, PRD, pPRD and REV, but, perhaps more 
importantly, in practical terms it is easier to generate and use than pSHF or pRND (the 
other contenders) because it does not require multiple database instances to be 
generated to derive a robust result.   
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Table 21 Significant differences between decoy designs for protein identification false positive rate (FPR).  
The underlined values are the pairs that demonstrate statistical significance.  To determine significant 
differences the least significant difference (LSD) value at 5% was compared to the mean FPRs.   The LSD at 
5% is the absolute value by which two means must differ to be deemed significantly different with 95% 
confidence.    pREV, pSHF and pRND are significantly better in terms of protein FPR than MC and PRD, 
and SHF is significantly better than MC.  pREV is also significantly better than pPRD and REV.  it is 
therefore the recommended decoy design for protein identification because it is as good as the other decoy 
designs, significantly better than those mentioned and is easier to generate than other randomised decoys, 
because it does not require multiple instances to be run to derive a reliable result.   LSD at 5% = 2.022 
 
Decoy design  MC pPRD PRD pREV pRND pSHF REV RND SHF 
 Mean FPR  6.01 5.06 6.03 2.91 3.72 3.49 4.95 4.68 4.22 
MC 6.01 x 0.95 0.02 3.1 2.29 2.52 1.06 1.33 1.79 
pPRD 5.06  x 0.97 2.15 1.34 1.57 0.11 0.38 0.84 
PRD 6.03   x 3.12 2.31 2.54 1.08 1.35 1.81 
pREV 2.91    x 0.81 0.58 2.04 1.77 1.31 
pRND 3.72     x 0.23 1.23 0.96 0.5 
pSHF 3.49      x 1.46 1.19 0.73 
REV 4.95       x 0.27 0.73 
RND 4.68        x 0.46 
SHF 4.22         x 
 
 
The ANOVA provides a Boolean result on significant difference, but to further explore 
the variability in decoy design the box whisker plot is useful (Figure 37, continued in 
the Appendix IV).  This plot shows that certain decoy generation methods produce 
more reproducible performance than others.  This variation further affirms the 
recommendation of a reverse decoy design, where standard deviation is always zero. 
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Figure 37 Box whisker plot to illustrate the distribution of protein level false positive rates (FPRs) across 
the ten database instances for each decoy design.  Each color represents an individual ABRF data-
submitting laboratory.  The horizontal line is the mean of the ten database instances, the box around the 
line shows one standard deviation above and below the mean, the whiskers show two standard deviations 
from the mean and the filled dots are the maximum and minimum individual FPR values obtained for the 
given decoy.  The first nine decoys on the x-axis were searched in composite with the target and the last 
nine separate to the target.  A representative of each instrument type is shown, for the remaining three 
labs (53908, 14997 and 17017) see the Appendix IV.   
 
The coefficient of variation (CV) value for protein FPR means in this study was 
70.6%, which is why small differences between decoy designs could not be detected 
as significant by the ANOVA.  This is also the reason for the relatively large LSD 
values – with FPRs having to be very different to be classed as significantly different 
(Table 21).  However, the data volume and scope was sufficient in this study to make 
statistically significant, meaningful recommendations, hence sub 0.05 F values were 
reported. 
4.4.3 Recommendation for search strategy based on protein level FPR 
For search strategy, the ANOVA generated an LSD (5%) for FPR at the protein level 
of 0.953.  The difference between the composite and separate means, 5.12 and 4.00, 
respectively, was 1.12, therefore composite and separate search methods were 
significantly different across the datasets included in this study – with separate 
being the significantly superior method.  The recommendation, therefore, is that 
separate searches should be used, which is in contrast to the multiple studies using 
datasets from samples of unknown composition that recommend composite 
searches, such as (Elias and Gygi, 2007, Reidegeld et al., 2008).   
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4.4.4 Recommendations based on peptide level FPRs  
For peptide level FPRs, F values were not below 0.05 for decoy and search method: 
0.077 and 0.178, respectively.  Machine type, however, did show the expected 
significant difference at the peptide level (F value <0.001).  Unlike the protein level 
FPR, the peptide FPR values also showed interactions between search strategy and 
instrument (F value <0.001).  The meaning of this interaction is very difficult to 
interpret, however more pertinent to this study is the fact that there were no 
interactions between decoy design and search strategy, and no interactions between 
decoy design and instrument.   
 
In contrast to the protein level, there was no statistically significant difference 
between composite and separate search strategies at the peptide level, although the 
mean overall peptide FPR was lower for the separate search data (1.2) than the 
composite (1.4).  Finally, the CV value for peptide FPR means was 79.5 percent, 
which is higher than the protein level.  
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4.5 Discussion 
In this study, the FPRs at the peptide level were lower than the protein level.  This is 
to be expected, because the peptide hits are identifications corresponding to actual 
matches between the database and m/z values, whereas protein identifications are 
inferred from peptide level data, and the process of inference is subject to additional 
error and ambiguity.   
4.5.1 APS threshold explains the differences in FPR between the 
different decoy database designs 
To understand the reasons for the lack of a clear „winning‟ decoy design, and to see 
why pREV, pSHF and pRND were significantly better than MC and PRD, various 
metrics were examined across the different decoy designs.   The APS threshold was 
the metric that best explained these observations. Figure 38 (a) illustrates average 
single-peptide APS threshold for four of the ABRF data submitters (across the ten 
instances of each decoy design), and Figure 38 (b) the same only for multiple peptide 
APS thresholds.  Arguably, the single threshold is the most important threshold to 
examine because the results showed that the average number of peptides required to 
make a false positive identification was one, compared to true positives which on 
average found multiple peptides to assign to the protein (data shown in Appendix 
IV).  It shows that across the four labs shown pREV, pSHF and pRND have some of 
the highest APS thresholds compared to the other decoys, and explains why these 
three had significantly better FPRs than MC and PRD (Table 21).  MC and PRD 
routinely had lower APS thresholds compared to pREV, pRND and pSHF, so these 
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decoys permitted more low-scoring FP identifications to pass, thus producing higher 
FPRs as a consequence.   
 
Figure 38 also shows that the best decoy was not always the same (in terms of 
threshold) across the different datasets.  Lab 17017, for example, showed pREV had 
the highest, whereas 25636 showed pRND had the highest for single peptide APS 
thresholds.  This study, however, looked holistically across ten different datasets and 
the statistical analysis showed no significant interactions meaning that overall the 
decoys behaved reproducibly across the datasets – despite this sample perhaps 
indicating otherwise. 
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(a) 
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 (b)  
 
 
Figure 38 Average APS score thresholds across the diverse decoy designs for (a) single-peptide protein 
identifications and (b) multiple-peptide protein identifications.  Four of the ten ABRF submitting labs are 
shown and were chosen to represent a suitable range of candidates, including data from different 
instruments and across different ranges of FPs (72079, high FPs; 12874, low FPs; 17017 and 25636 mid-
range FPs).  The remaining three labs (00700, 14997 and 22069) are shown in Appendix IV. The bars 
show the standard error above and below the mean; reverse decoys have zero variation so have zero 
error.  The thresholds are plotted to establish the underlying reasons for the differences in decoy 
database performance; in particular, to understand why pREV, pRND and pSHF were significantly 
better than MC and PRD.  The figure shows average peptide score (APS) thresholds, where APS is 
calculated as the sum of the individual peptide X!Tandem scores divided by the number of peptides for 
the given protein identification.  This figure illustrates average single-peptide APS threshold (across the 
ten instances of each decoy design).  The single threshold (in (a)) is particularly important because the 
results showed that the average number of peptides required to make a FP identification was one or less 
(remembering there are ten instances of each decoy design some of which had no FPs), compared to true 
positives which on average found multiple peptides to assign to the protein (see the Appendix IV for these 
data).     
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Finally, Figure 38 clearly shows that separate searches achieve higher (thus more 
stringent) APS thresholds.  This is because the decoy hits are not in direct 
competition with high quality matches when searched independently, so can achieve 
elevated APS scores (Elias and Gygi, 2007).  Lastly, pREV and pSHF conserve both 
peptide and amino acid composition (see Table 19 earlier), this could be an 
additional contributory factor for these decoys performing significantly better than 
MC and PRD.   
 
Other metrics that explained some of the observations were: (1) total number of 
peptide hits (Figure 39), which showed that more hits are made against the decoy 
databases when searched in parallel, as opposed to composite; and (2) average 
length of peptides used in identifications (Figure 40), which showed that on average 
false identifications are made using shorter peptides compared to those for true 
identifications.  This data also indicates that the decoy databases represented 
acceptable null models, because peptides of very similar length to TPs were found in 
the decoys.  
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Figure 39 Understanding differences between decoy designs by examining the number of peptides found by each individual decoy design.  The horizontal line is the 
mean of the ten database instances, the box around the line shows one standard deviation above and below the mean, the whiskers show two standard deviations 
from the mean and the filled dots are the maximum and minimum individual FPR values obtained for the given decoy.  The first decoys on the x-axis were searched 
in composite with the target and the last nine in parallel.  More peptides are found in separate searches because there is less competition for matches.  This is also 
why there is a more conservative hit rate with the separate search because with more peptides found by the decoy, there is more likely to be a higher maximum 
APS (hence higher APS threshold) in the decoy meaning more peptides hits are filtered out.  (The remaining two labs are plotted separately because the values 
overlap).   
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The remaining metrics that were considered included the mean number of assigned 
peptides that were identical between the target and decoy- this was virtually zero 
(grand mean 0.018); and the number of assigned peptides of seven amino acids or 
less, which showed that on average only one or fewer (0.83) peptides under seven 
residues was hit in the TP protein space and only 0.13 in the FP space across all 
decoys and labs. 
Figure 40 Mean peptide lengths found across ten instances of each decoy type.  The bars show the standard 
error above and below the mean.  False positives are generally attributed to shorter peptide matches. 
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4.5.2 Identification performance was comparable with the original ABRF 
study 
Comparison with the results reported in the original ABRF analysis poster98 have to 
be limited to the 49 core proteins because the „bonus‟ constituents were only 
identified subsequently (Lane et al., 2007).   The comparison showed that on the 
whole, GAPP identified similar numbers of the original TPs and FPs, although this 
varied according to lab.  For example, lab 72079 originally reported 47 TPs and 5 FPs, 
but using pREV in separate (the now recommended decoy database search strategy) 
with GAPP, it achieved 41 TPs and 3 FPs, and for lab 14997, originally 36 TPs and 
zero FPs were reported, but GAPP achieved 32 TPs and 1FP.  This is an encouraging 
outcome, as the ABRF data submitters were able to leverage their expertise through 
manual interpretation, whereas the results in this chapter were generated 
automatically.   
4.5.3 Differences in FPR between data submitters was caused by 
individual sample handling 
Given that the combination of a decoy database and APS scoring is often purported 
to eliminate FPs, it may seem surprising that FPs were not totally eliminated; the 
grand mean average number of FPs over all analyses was 1.8 FPs. A list of all FPs 
observed across the ten labs for (one instance of) all decoys was collated and 
analysed by the author;  none corresponded to the cRAP (“cee-RAP”) – the Common 
                                               
98 Andrews et al., 2006, ABRF-sPRG2006 study: a proteomics standard, see 
http://www.abrf.org/ResearchGroups/ProteomicsStandardsResearchGroup/EPosters/ABRFsPRGStudy2006post
er.pdf 
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Repository of Adventitious Proteins99 -  list of contaminants, however, four possible 
contaminant proteins were identified (shown in red in Table 22).  These 
contaminants were not the most ubiquitous FPs.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 22 False positive (FP) protein descriptions taken from results of a single instance of each decoy 
design.  There are 49 FPs in total.  Rows in bold are FPs with no functional descriptions.  In red are the 
FPs believed to be common contaminants introduced during sample handling.   
 
                                               
99 This is a list of sequences in fasta format for the most common contaminant proteins in proteomics. It 
contains proteins from multiple species and includes common laboratory, dust and contact-related proteins, as 
well as molecular weight or mass spectrometry quantitation standard proteins.   
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Ensembl identifier Description 
ENSG00000049618 
 
AT-rich interactive domain-containing protein 1B (ARID domain- containing 
protein 1B) (Osa homolog 2) (hOsa2) (p250R) (BRG1-binding protein 
hELD/OSA1) (BRG1-associated factor 250b) (BAF250B).  
ENSG00000065883 Cell division cycle 2-like protein kinase 5 (EC 2.7.11.22) (CDC2- related 
protein kinase 5) (Cholinesterase-related cell division controller).  
ENSG00000073712 Pleckstrin homology domain-containing family C member 1 (Kindlin-2) 
(Mitogen-inducible gene 2 protein) (Mig-2).  
ENSG00000075914 Exosome complex exonuclease RRP42 (EC 3.1.13.-) (Ribosomal RNA- 
processing protein 42) (Exosome component 7) (p8).  
ENSG00000078487 Zinc finger CW-type PWWP domain protein 1.  
ENSG00000096654 Zinc finger protein 184 
ENSG00000104133 Spatacsin (Spastic paraplegia 11 protein) (Colorectal carcinoma- associated 
protein).  
ENSG00000108557 Retinoic acid-induced protein 1.  
ENSG00000116254 Chromodomain helicase-DNA-binding protein 5 (EC 3.6.1.-) (ATP- 
dependent helicase CHD5) (CHD-5).  
ENSG00000119812 Protein FAM98A.  
ENSG00000121495 Retrotransposed gene: no description available 
ENSG00000122034 Transcription factor IIIA (Factor A) (TFIIIA).  
ENSG00000128731 Probable E3 ubiquitin-protein ligase HERC2 (EC 6.3.2.-) (HECT domain and 
RCC1-like domain-containing protein 2). 
ENSG00000128881 Tau-tubulin kinase 2 (EC 2.7.11.1).  
ENSG00000136327 Homeobox protein Nkx-2.8 (Homeobox protein NK-2 homolog H).  
ENSG00000138379 Growth/differentiation factor 8 precursor (GDF-8) (Myostatin).  
ENSG00000141837 
 
Voltage-dependent P/Q-type calcium channel subunit alpha-1A (Voltage- 
gated calcium channel subunit alpha Cav2.1) (Calcium channel, L type, 
alpha-1 polypeptide isoform 4) (Brain calcium channel I) (BI).  
ENSG00000141968 Proto-oncogene vav. 
ENSG00000143520 Filaggrin family member 2  
ENSG00000143702 Centrosomal protein of 170 kDa (KARP-1-binding protein) (KARP1-binding 
protein).  
ENSG00000146872 Serine/threonine-protein kinase tousled-like 2 (EC 2.7.11.1) (Tousled- like 
kinase 2) (PKU-alpha).  
ENSG00000148842 Metal transporter CNNM2 (Cyclin-M2) (Ancient conserved domain- 
containing protein 2) 
ENSG00000152670 Probable ATP-dependent RNA helicase DDX4 (EC 3.6.1.-) (DEAD box 
protein 4) (VASA homolog).  
ENSG00000153201 
 
E3 SUMO-protein ligase RanBP2 (Ran-binding protein 2) (Nuclear pore 
complex protein Nup358) (Nucleoporin Nup358) (358 kDa nucleoporin) 
(p270).  
ENSG00000156222 
 
Sodium/nucleoside cotransporter 1 (Na(+)/nucleoside cotransporter 1) 
(Sodium-coupled nucleoside transporter 1) (Concentrative nucleoside 
transporter 1) (CNT 1) (hCNT1).  
ENSG00000161849 Keratin type II cuticular Hb4 (Type II hair keratin Hb4) (Keratin-84) (K84).  
ENSG00000162896 
 
Polymeric-immunoglobulin receptor precursor (Poly-Ig receptor) (PIGR) 
(Hepatocellular carcinoma-associated protein TB6) [Contains: Secretory 
component].  
ENSG00000163214 Putative ATP-dependent RNA helicase DHX57 (EC 3.6.1.-) (DEAH box 
protein 57).  
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In virtually all cases, a FP was seen by multiple decoys, but by only one lab, 
implying that the FP was derived from individual sample handling or 
instrumental/protocol error on a one-off basis (Figure 41 and Figure 42).       
 
 
ENSG00000164574 
 
Polypeptide N-acetylgalactosaminyltransferase 10 (EC 2.4.1.41) (Protein-
UDP acetylgalactosaminyltransferase 10) (UDP- GalNAc:polypeptide N-
acetylgalactosaminyltransferase 10) (Polypeptide GalNAc transferase 10) 
(GalNAc-T10) (pp-GaNTase 10). 
ENSG00000166508 DNA replication licensing factor MCM7 (CDC47 homolog) (P1.1-MCM3). 
ENSG00000168924 Leucine zipper-EF-hand-containing transmembrane protein 1, mitochondrial 
precursor.  
ENSG00000169509 Protein NICE-1.  
ENSG00000170748 Testis-specific heterogeneous nuclear ribonucleoprotein G-T (hnRNP G- T).  
ENSG00000171433 Glyoxalase domain containing 5  
ENSG00000171444 Colorectal mutant cancer protein (Protein MCC).  
ENSG00000175756 Aurora kinase A-interacting protein (AURKA-interacting protein).  
ENSG00000175920 Protein Dok-7 (Downstream of tyrosine kinase 7).  
ENSG00000176825 No longer in the Ensembl database 
ENSG00000177843 No longer in the Ensembl database 
ENSG00000179981 Teashirt homolog 1 (Serologically defined colon cancer antigen 3) (Antigen 
NY-CO-33).  
ENSG00000180043 Pseudogene: no description available 
ENSG00000186543 CDNA FLJ41343 fis, clone BRAWH2001973.  
ENSG00000188013 Meis1, myeloid ecotropic viral integration site 1 homolog 3 isoform 2 
ENSG00000188153 Collagen alpha-5(IV) chain precursor.  
ENSG00000188483 Immediate early response 5-like  
ENSG00000189182 Keratin, type II cytoskeletal 1b (Keratin-77).  
ENSG00000197582 Glutathione peroxidase 1 (EC 1.11.1.9) (GSHPx-1) (GPx-1) (Cellular 
glutathione peroxidase).  
ENSG00000197594 
 
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (E- 
NPP 1) (Phosphodiesterase I/nucleotide pyrophosphatase 1) (Plasma-cell 
membrane glycoprotein PC-1) [Includes: Alkaline phosphodiesterase I (EC 
3.1.4.1); Nucleotide pyrophosphatase 
ENSG00000198854 Skin-specific protein 32. 
 243 
 
 
Figure 41 The distribution of FP protein identifications across specific Ensembl gene accession numbers, showing the breakdown by decoy type.  The theoretical 
maximum is 10 for each coordinate on the graph, because each position shows the number of different data submitters, where the FP was found for decoy.  The 
data shown is derived from examination of one instance (out of the ten performed). 
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Figure 42 The distribution of false positive protein identifications across specific Ensembl gene accession numbers showing the breakdown by data submitter.  The 
theoretical maximum is 18 for each coordinate on the graph, because each position represents FP observe across 18 different decoy types for decoy instance 1.  The 
data shown is derived from examination of one instance (out of the ten performed). 
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Tau-tubulin kinase 2 (ENSG00000128881), for example, was observed by 16 decoy 
designs for lab 17017 (LTQ-FT).  Furthermore, lab 72079 (LCQ) had the most FPs by 
a large margin, suggesting generally poor sample handling; this observation was 
consistent with the original ABRF study (Andrews et al., 2006).   
 
Significant differences in FPR were detected between instrument types, except for 
LTQ and HCT, which did not report a significant difference (both being ion traps) 
(Table 23 and Figure 43).   
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Table 23 Three-way ANOVA analysis.  Given the number of replicates available (a), the least significant 
differences were found (b), and applied to determine whether significant differences had been observed 
(c).  It showed that there were statistically significant differences between the mean protein FPR values 
achieved by the instrument types tested (underlined and bold).  The only exception was LTQ/ HCT, 
which did not report a significant difference in FPR.  This is to be expected, since  LTQ and HCT are 
both ion trap instruments, and both have the same mass tolerances applied for the protein identification 
search.   
 
(a) 
 HCT LCQ LTQ LTQ-
FT 
QTOF 
No. of 
replicates 
18 18 18 72 54 
 
 
(b) 
  18 to 18 18 to 54 18 to 72 54 to 72 72 to 72 
LSD at 5%  2.131 between 2.131 and 1.685 1.685 between 1.066 and 1.685 1.066 
 
 
(c) 
 
 
 
        
Instrument type   HCT LCQ LTQ LTQ-FT QTOF 
   Mean FPR (prot) 6.04 11.7 6.05 3.84 2.16 
HCT 6.04 x 5.66 0.01 2.2 3.88 
LCQ 11.7  x 5.65 7.86 9.54 
LTQ 6.05   x 2.21 3.89 
LTQ-FT 3.84    x 1.68 
QTOF 2.16     x 
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Figure 43 False positive rate by decoy design showing the effect of instrument type.  Separate and 
composite runs are considered together.  HCT, LCQ and LTQ were represented by only one replicate for 
each run type, whereas LTQ-FT was represented by four labs and QTOF by three.  The highest 
resolution instrument, the LTQ-FT did not result in the lowest FPR; although the lack of multiple 
submissions from a QTOF make its superiority inconclusive. 
 
It should also be noted that only one replicate was present for HCT, LCQ and LTQ.  
The box whisker plots illustrate the large variation in FPR (Figure 37), which is to be 
expected since not only the instrument differs, but also the experience and skill of 
the practitioner.   
4.6 Conclusions and recommendations to increase confidence in 
automated searches 
Given the work presented, the peptide level reverse decoy searched independently 
from the target may be recommended as a suitable alternative to reduce FPs in 
automated searches.  The research offers science-based evidence that may prove 
useful for guiding proteomic data reporting policies.  For example, the recently 
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released “Paris Guidelines” specify that FPR should be estimated for large scale MS 
studies using randomised decoy database searches when reporting the findings in 
publications (Bradshaw et al., 2006, Tabb, 2008).  The work here suggests which 
randomised decoy should be applied. This research also provides a specific example 
of how publicly available MS/MS datasets may be exploited for novel studies by the 
community.    However, it should be noted that although experimental variance has 
been covered by use of the ABRF datasets, a specific pipeline was employed for the 
analysis. As such, the author cannot claim that the observed pattern of decoy 
performance will definitely be seen in all proteomics workflows.  Thus, an 
investigation with other pipelines, using the presented methodology, would 
represent valuable work.  In particular, it is most likely that the findings will be 
reproducible across pipelines that employ search engines set to accept only one 
peptide identification per spectrum, as was the case for X!Tandem.  X!Tandem did not 
allow second, third or fourth (etc.) ranked peptides to be found as „hits‟; only one 
peptide was successfully identified per spectrum – the top ranking peptide.  This is a 
critical point, because without competition for this top hit position, differences in 
performance between decoys would most probably have been negligible.   In this 
study, however, separate searches produced lower FPRs than with the composite 
because there was competitive pressure for the highest score.  Mascot, for example, 
can be set to accept only the top scoring peptide per spectrum in this way.                      
A research article has been written by the author describing the investigation 
performed in this chapter.  It has been published in the Journal of Proteome 
Research (see Appendix IV). 
  
249 
4.7 Additional future work 
4.7.1 Testing further standard datasets  
To further confirm the conclusions made in this chapter, it is proposed that an 
additional standard MS/MS dataset be applied to the GAPP/ decoy database 
analysis.    There are several candidate datasets that could be applied; Appendix IV 
lists the alternatives.  This work would exploit the existing framework for analysis, 
with the decoy databases already being generated and Matlab scripts requiring 
minimal recoding.   
4.7.2 Apply peptide level reverse decoy database in the public GAPP 
pipeline 
Now that the peptide level reverse decoy database is recommended for GAPP, this 
decoy should become the default database for the public GAPP system.  At the 
moment, the protein level reverse is still in use.  Ideally, there should be an option 
for users to select their decoy database of choice, at the time of data submission.  The 
scripts for generating the decoy database instances could be applied to the website to 
achieve this. 
4.7.3 Investigation into theoretical FPRs would make the study more 
useful for non-standard datasets 
FPR was the primary measure for protein identification performance.  This is a 
useful metric, but there are other approaches that could improve the thoroughness 
of the work.  For example, one of the reviewers of the decoy design manuscript 
suggested that theoretical FPR should be varied to make the results more applicable 
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to non-standard datasets.  The proposed work would involve calculating theoretical 
FPR - using “classical” approaches (Elias and Gygi, 2007) (Jones et al., 2008a) using 
FPR = 2 * decoy hits / (decoy + target hits), or similar variants, and comparing these 
values to the real FPRs already obtained. This would mean dropping the APS 
threshold value to take in more “hits”, and calculating theoretical FPRs at 1%, 5%, 
10% for example (in the study already performed all results were based on a single 
nominal 0% threshold).   This additional experiment would be possible because the 
APS data was stored for all GAPP analysis runs performed in the original study, so 
the APS threshold can be varied incrementally when querying out the results to 
obtain plus or minus the actual APS score used as the theoretical 0% FPR threshold.   
This work would be informative, because: 
 It would highlight the differences a user would obtain from searches where they do not know the 
identifications a priori; as is normally the case. For example, if a search is run versus Ensembl 
database at a nominal FPR of 5% (measured from decoy hits being FPs) then what would be the real 
FPR?  
 It may highlight further the differences observed between decoy designs, and could confirm the initial 
findings of the original work.  
 It would evaluate performance at a variety of thresholds, as is the norm for ROC analysis.  
Importantly, there are potential dangers in drawing inference from a single threshold, as was the case 
in the original study. 
 
In addition, it is proposed that posterior error probabilities (PEPs) could be 
estimated (Käll et al., 2008), as this approach can be thought of as a measure of local 
FDR for specific proteins rather tham the dataset as a whole.  This metric could be 
calculated as part of the re-analysis of the data presented, and could confirm the 
findings that the reverse peptide decoy is the recommended choice. 
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5 MRMaid, the web-based tool for designing multiple 
reaction monitoring (MRM) transitions 
 
 
 
 
 
 
MRMaid, the web-based tool for 
designing multiple reaction  
monitoring (MRM) transitions 
 
 
 
 
 
 
“For a scientist, all of this is clear, but for a computer it isn‟t” 
Henning Hermjakob, EMBL annual report 2007-08 
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5.1 Summary 
Multiple reaction monitoring (MRM) exploits MS/MS to quantify selected proteins 
of interest, such as those previously identified in differential studies. Using this 
technique, the specificity of precursor-to-product ion transitions is harnessed for 
quantitative analysis of multiple proteins in a single sample.    
 
The design of transitions is critical for the success of MRM experiments, but 
predicting signal intensity of peptides and fragmentation patterns ab initio is 
challenging given existing methods.  This chapter delivers a new tool, MRMaid 
(pronounced “mermaid”), which offers a novel alternative to streamline the design 
of MRM transitions, and is aimed at the lab-based proteomics researcher.  By 
exploiting available knowledge of the MRM technique, and using publicly available 
software programming resources (such as LAMP and PICR), this new tool offers fast 
and reliable transition design, negating the need for theoretical prediction of 
fragmentation and removing the need to undertake prior „discovery‟ MS studies.   
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5.2 Basic characteristics of an SRM assay  
For SRM, a peptide precursor ion that is pre-selected undergoes a CID reaction in 
MS/MS, generating fragments referred to as product ions.  If the chosen pair of 
precursor and product ion m/z signals is distinct from other m/z signals in the MS 
run, then it is suitable for monitoring.  If this precursor represents a proteotypic 
peptide (PTP) – one that is unique to the protein of origin and usually visible in 
MS/MS – then this transition is not only distinguishable from others, but it is a 
characteristic signature for the protein of interest.  Thus, by introducing a heavy 
surrogate of the native peptide into the reaction, the quantity of the protein target 
may be accurately determined.  Moreover, many peptides may be monitored this 
way, one after another; hence MRM is a method suitable for multiplexing where 
several targets may be quantified in the same experiment.   
5.3 There is no best practice for designing SRM transitions 
The critical part of performing SRM is designing suitable transitions to monitor the 
protein(s) of interest.  In early studies, there was no alternative but to perform 
empirical „discovery‟ MS/MS studies to design SRM transitions (Table 24).  And 
even by the early 2000s, no widely accepted best practice had emerged for transition 
design, and the level of detail given for the selection of candidates was variable in 
the literature.   
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Paper Year Study Transition design criteria and/or method Software used for S/MRM transition 
design 
(Barr et al., 1996) 1996 SRM Peptides chosen because they responded well in FAB-MS. No 
(Barnidge et al., 2003) 2003 SRM Peptide chosen by optimising for signal intensity in MS . No 
(Gerber et al., 2003) 2003 MRM including  
PTM detection 
Peptides chosen based on amino acid sequence and the protease used. No  
(Zhang et al., 2004) 2004 Distinguished 
protein isoforms 
using MRM 
Chose two signature peptides based on the four most intense MS/MS TIC peaks for 
each isoform. 
No 
(Kuhn et al., 2004) 2004 MRM No information given. No 
(Beynon et al., 2005) 2005 QconCat Peptides chosen if: did not contain C; were unique in sequence with respect to the 
other peptides monitored; mass 1000-2000 Da (for MALDI) ; gave strong signal in 
MS; and had R at terminus. 
No, but software was used to predict 
the gene sequence for the construct. 
(Unwin et al., 2005) 2005 MRM for PTM 
detection (MIDAS) 
Manual calculation and software script developed by Applied Biosystems. MRM 
Builder software generated precursor-to-product ion transitions and CEs for 
phosphopeptides.  MS used the results to perform sequential scan cycles and select 
suitable peptides. 
Software script developed by Applied 
Biosystems 
MRM Builder software for pre-
MIDAS workflow 
(Cox et al., 2005) 2005 MRM including 
PTM detection 
Used prototype software with protein sequence and LC conditions as inputs.  
Performed in silico digest and calculated the m/z of the precursor and fragment ions.  
Definition of „appropriate‟ not explicit, but it had to contain S/T or Y.  It calculated 
Q1 and Q3 m/z values for various charge states and fragment ions.  The software 
created multiple possible transitions for the given protein of interest. 
„Research-grade‟ version of software 
from the Applied Research group at 
MDS Sciex 
(Ciccimaro et al., 2006) 2006 MRM for PTM 
detection 
Most intense precursor ion and product ion chosen.  Applied MIDAS approach for 
prediction and data acquisition. 
MIDAS software 
(Anderson and Hunter, 
2006) 
2006 MRM Predicted tryptic peptides , found corresponding Swissprot annotation, found 
physico-chemical parameters of each (composition, mass, Hopp-Woods 
hydrophobicity annotation (Hopp and Woods, 1981)), predicted RT (Krokhin et al., 
2004).  Determined likelihood of detection of each peptide using a published plasma 
data and calculated each protein: (no. of hits for peptide)/(no. of hits for most freq 
detected peptide for that protein) and  index of protein quality by positively 
weighting: P, KP, RP, DP and negatively weighting: C, W, M, chymotrypsin sites, 
detrimental Swissprot features and mass less than 800 and more than 2000.  Length 
set at 8-24 amino acids.  Used GPMDB to selected peptides from frequently detected 
proteins.   
Used in silico techniques including 
software tools to predict physico-
chemical properties.  Used GPMDB 
repository to confirm proteotypic 
peptides from MS results (Craig et 
al., 2004).  No integrated software 
program used. 
(Wolf-Yadlin et al., 2007) 2007 MRM for PTM, 
used iTRAQ 
labeling not radio-
isotope labels 
Performed discovery study.  Considered peptide m/z and charge state, the 
characteristic b- and y-ions and CE required.   
No  
(Stahl-Zeng et al., 2007) 2007 MRM using 
elution time 
constraints to 
maximise number 
of transitions 
Used criteria of the proteotypic species (as defined by Peptideatlas) including that the 
peptide ionises well in the range of the MS instrument and is unambiguously 
associated to a single protein. 
Used bespoke software modifications 
for instrument control and data 
acquisition in the MRM study. 
Table 24 Overview of empirical methods for SRM transition design applied in the literature to date. 
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Paper Year Study Transition design criteria and/or method Software used for S/MRM 
transition design 
     
(Kay et al., 2007) 2007 MRM Some transitions taken from papers, others chosen using criteria: most intense 
y-ions, two product ions were monitored, extracted chromatograms for 
peptides of interest and used  HPLC peaks at identical RT for the two 
transitions.  When HPLC peaks were summed signal-to-noise ratio was 
required to be a minimum of five. 
No 
(Keshishian et al., 
2007) 
2007 MRM Factors considered were: observed or predicted RT, MW, and charge state.  
Preference was given to moderately hydrophobic peptides likely to produce 
triply or doubly charged ions in detectable mass range. 
No 
(Lenz et al., 2007) 2007 MRM Decision was based on collision energy (in Q2), specific m/z and dwell time 
required. 
No 
(Lange et al., 2008) 2008 MRM Predicted transitions using TIQAM. TIQAM  
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5.3.1 Summary of existing transition design software 
Despite the lack of consensus, various commercial, vendor-specific software 
packages for MRM transition design are available, including, for example MIDAS™ 
(MRM-initiated detection and sequencing) Workflow Designer software (ABI, Foster 
City, CA), which calculates theoretical peptides and corresponding transitions, then 
builds the MIDAS acquisition method (Unwin et al., 2005), whereby a coupled Q-
TRAP (ABI) iteratively cycles through scans and to select suitable peptides.  Thermo 
Scientific‟s (Waltham, MA) contribution has been presented to user groups but was 
not available for purchase at the time of writing. It takes data from SIEVE, the 
Automated Label-Free Differential Expression Software, computes ions generated, 
relates those back to the sequence and then imposes filters similar to those in 
MRMaid (see later section). 
 
In 2007, however, when the author was developing MRMaid, there were no publicly 
available software programs to predict suitable transitions.  In 2008, at the same time 
as MRMaid was released, TIQAM (Targeted Identification for Quantitative Analysis 
by MRM) (Lange et al., 2008) was published by the Institute of Systems Biology, 
Seattle.  This was the first tool to mine a public MS repository, PeptideAtlas (Deutsch 
et al., 2008), for peptides based on the number of previous observations.  It 
fundamentally differs from the approach taken by MRMaid, because it requires the 
user to experimentally acquire MS/MS data to isolate suitable candidates from the 
list of possible transitions, whereas MRMaid is able to indicate which peptides in the 
shortlist are most suitable using its novel transition scoring algorithm. MRMaid is 
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also a web-based tool whereas TIQAM is designed to be installed locally, requiring 
setup of a local database.  
 
In summary, at the time of development there were limited options available for 
MRM practitioners requiring transition design support without involving 
acquisition of MS/MS data for the prediction process.  In this chapter, a publicly 
accessible MS vendor-independent program, called MRMaid, is presented, which 
provides transition design support to assist the expansion in use of the MRM 
method.  
5.4 Methods 
5.4.1 An overview of the MRMaid system 
MRMaid‟s method for transition design relies on the combination of two sources of  
information: firstly, on prior knowledge of the kind of precursor peptides that 
generally perform better in MS/MS, and secondly, on mining the data in a 
proteomic data repository, GAPP (Shadforth et al., 2006), to determine which 
precursor and corresponding fragment ions have appeared regularly for the given 
protein of interest.  The hydrophobicity and reverse phase RT of each peptide 
candidate are calculated so suitable transitions may be selected and ordered.  
Finally, as with all approaches for transition design, the shortlist of the best 
transition candidates must be validated using a suitable MS instrument.      
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The GAPP database is populated with data from public resources and data 
submitted directly by users, as described previously in this thesis.  Peptide 
candidates for MRM are mined from this data source by applying the principle of 
proteotypicality (Mallick et al., 2007), whereby peptides that map unambiguously to 
a single protein are first mined from the database.     
 
To design an MRM experiment, several SRM transitions are monitored in a single 
assay.  For this purpose, MRMaid allows comparison of individual SRM transition 
candidates using estimated RT and hydrophobicity values, this way transitions may 
be selected to avoid co-elution of peptides.  The proposed peptide candidates can be 
compared by downloading the page of MRMaid results and comparing RT and 
transition score (TS) values.  This process is explained below, and ultimately allows 
users to design the optimal bespoke MRM experiment for their specific target 
proteins.  
 
To indicate reliability of the transitions, metrics of reproducibility are calculated for 
the candidate product ions.  An indication of reproducibility is required because 
GAPP is a public system, and as such, accepts data from any source if the format and 
metadata requirements are met.  Reliability is ensured in two discrete ways: firstly, 
peptide precursor (and subsequent fragment) candidates are presented to the user 
with the number of times they have been observed in GAPP for the protein of 
interest.  Secondly, the individual product ions are assessed in terms of signal 
intensity reproducibility: an average of signal intensity for the relevant m/z peaks is 
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calculated across all applicable experiments, as well as the variance and standard 
deviation values.  These descriptive statistics indicate the reproducibility of the 
fragment ions for a given precursor, and hence, point to the number of times one 
would expect to have to run the MRM experiment to observe a good result for the 
transition.   
5.4.2 Software implementation 
MRMaid (Figure 44) is a program written in Perl and PHP that interrogates the 
GAPP database for suitable transitions for a given protein sequence.  The protein 
target is input by the user as a database accession number, such as an Ensembl, 
Swissprot or IPI number.  Many database accession numbers are supported thanks 
to integration of the EBI‟s PICR service (Côté et al., 2007).    
 
The steps in the algorithm for transition design include the following:  
(a) All PTPs for the protein are retrieved 
(b) PTPs are filtered by criteria defined by the user 
(c) MS/MS data for the protein is retrieved, descriptive statistics are calculated and y- 
and b-ions are assigned for each peptide using the mass tolerance window provided 
by the original data submitter 
(d) TS value is computed for each peptide and is used to rank the transitions 
(e) RT and hydrophobicity are computed for each peptide 
 
The following sections explain the MRMaid workflow (Figure 44) in more detail.  
The algorithm is novel and was conceptualised and formulated by the author.  With 
help and direction from the author, Vanessa Ottone (visiting student) implemented 
the function to assign b- and y-ions using mass data. 
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Figure 44 The process of transition design in MRMaid.  Transition score is used to rank the resulting 
transition predictions. x is a value that can be adjusted according to users‟ requirements, in the web 
release it is one. 
 
Luca Bianco implemented the PHP script for the MRMaid website homepage, using 
Darren Oakley‟s original GAPP style-sheet.  He also implemented the PHP program 
(using the GD library) to draw the spectral graphics.         
5.4.3 MRMaid has filters to determine optimal transition candidates 
Users may choose from a series of filtering options to constrain the prediction of 
transitions (Table 25).  These filters take the form of a list of check boxes, drop down 
menus and text boxes on the homepage.  They can be found below the box where the 
user enters the accession number for the protein target.  The filters were chosen 
through targeted questioning of experts in the MRM approach and the use of 
prototypes for live demonstration. The author organised meetings and lead the 
sessions with expert practitioners from Quotient BioResearch Ltd., a contract 
research organisation, and the University of Cambridge.  The reasoning given for 
inclusion of the criteria suggested by the experts is described below and is 
summarised in Table 25.  All peptides that pass the relevant filtering steps enter the 
transition scoring phase, which is necessary to rank the candidates. 
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Table 25 Optional filters that may be used to constrain the search for MRM transitions using MRMaid 
Filter criterion Description 
Peptide observation 
redundancy 
Peptide must have been seen in x% of all observations of the query 
protein in GAPP database 
Internal cleavage Peptides with K or R, unless followed by P 
Instrument type Constrains to MS/MS data retrieved for the instrument set up 
selected 
Omit N and Q N and Q can be deamidated resulting in m/z reproducibility issues 
Peptide length Short peptides (<7 or 8 amino acids) are unlikely to be unique to the 
target, and very long peptides will be out of mass range 
Omit M and C Often covalently modified affecting m/z 
Omit Q and E Can spontaneously cyclise to form pyroglutamate 
Accept only P-
containing peptides 
Produces a very high abundance peak – suitable when a single 
product ion is sufficient, such as in low complexity samples 
Omit P at any position Swamps tandem spectrum, selected when multiple transitions per 
target are required, such as in high complexity samples like serum 
Omit P1 (P adjacent to 
the C-terminus) 
Can produce non-specific product y-ion 
 
Omit P2 (P second 
position from C-
terminus) 
Can produce non-specific product y-ion 
 
m/z cut off (user 
specifies a value, x) 
Selects only fragment ion m/z > x, where x is a percentage of the 
precursor m/z 
  
Users may define the proportion of times a peptide has been observed for the target 
protein in GAPP database.  In this way, the frequency of peptide identifications in 
the repository may be used as a measure of transition reliability for the protein.  For 
example, if users enter „50‟ then this means that the peptide candidate(s) presented 
in green in the peptide results table (see Figure 45) are assigned in at least 50% of 
occasions when the protein target was successfully identified in GAPP, so these are 
the best candidates to choose.  The higher the value entered, the more stringent the 
prediction. 
 
As a default, peptides with internal cleavage sites (namely peptides with K or R, 
unless followed by P) are omitted to prevent selection of peptides that may be 
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irregularly cleaved.  This is a necessary feature since the efficiency of trypsin is 
known to be only (approximately) 70 percent (Yen et al., 2006, Falth et al., 2007). 
 
Another important consideration for users intending to perform MRM is whether 
MS/MS evidence is available for their particular MS instrument.  Each instrument is 
known to have a different set of preferred PTPs (Mallick et al., 2007), therefore, to 
account for this phenomenon, GAPP database‟s MS instrument information may be 
incorporated as a filter into the querying process.  A drop-down menu to select the 
type of instrument is provided on the homepage. 
 
Protein expression can vary significantly between tissue types.  To try to account for 
this, the type of biological sample can also be specified as a filter in the search for 
transitions.  In serum, this is particularly useful, since its levels of protein expression 
and sample complexity can present unique challenges for the transition design.  The 
ability to choose transitions based upon experiments performed on the same type of 
sample increases the likelihood of selection of successful candidates. 
 
In addition to constraining experiment-specific factors, information on the sequence 
of the peptide may also be used in the filtering process.  For example, N and Q may 
be deselected, because these residues can be deamidated resulting in fragment ion 
m/z irregularities and problems with reproducibility.  This is a problem because the 
m/z of fragment ions must be as consistent, and hence reliable, as possible.  Opting to  
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omit peptides containing Q or E at the N-terminus is also possible in MRMaid, 
because these residues can spontaneously cyclise to form pyroglutamate.  Likewise, 
P is an important residue to consider when designing transitions.  Peptides 
containing P may be considered favourable, because they generally produce MS/MS 
peaks of high intensity.  This is because proline‟s 3D structure promotes 
fragmentation, often producing a single greater abundance fragment ion that 
„swamps‟ the remainder of the tandem mass spectrum.  However, this single signal 
may not be sufficient to identify the protein with adequate specificity, particularly in 
complex samples.    For this reason, users may opt to omit or allow candidate 
peptides containing P.  The location of P in the peptide primary sequence is also 
important.  P, which is adjacent to the C-terminus (P1) or in the second position from 
the C terminus (P2), is generally not desirable in MRM.  This is because a very short, 
non-specific product y-ion is produced, which is unsuitable for monitoring.  Users 
may, therefore, opt to omit P1 and P2-containing peptides from their results.   
 
Peptide sequence can also affect the probability of covalent modification.  M and C 
are often modified residues, so if they are omitted it makes it possible to constrain 
the candidates to those where mass should not vary.  Naturally, if all possible amino 
acids that fall into this category were omitted, the filter would be too strict, however 
by negatively weighting these residues in the TS calculation it provides a more 
suitable method (see the next section for more detail).  Typical modifications like 
carbomido-methylation are, however, worth considering in peptides for monitoring, 
as there are examples in the literature, such as for Apolipoprotein A2 (Kay et al., 
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2007) where they have been present in transitions, so for this users may choose a 
filter in this list to omit them. 
 
A further filter option is peptide length.  Users may constrain this because very short 
peptides (<7-8 residues) are unlikely to be unique, and peptides longer than 
approximately 20 to 25 residues are unsuitable for MRM because they may exceed 
acceptable mass range.  For all MRMaid searches, mass range for the peptide (MS 
mode) is restricted to 500-1600 m/z.  This range is routinely used for monitoring 
tryptic peptides, so peptide candidates beyond this range are omitted by default. 
 
b- and y-ions are common fragment ions produced in tandem MS.  To restrict 
transitions to peptides that produce suitable y- or b-ions for monitoring, two 
approaches are employed in MRMaid.  Firstly, y-ions (shown in red) and b-ions (in 
blue), with the charge states, are highlighted in the resulting spectrum graphic and 
results table (an example is shown in Figure 45).   
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Figure 45 MRMaid has three main views for the candidate transitions.  This shows screenshots of 
elements of the interface for transitions predicted for transthyretin (ENSG00000118271).  The first (top) 
is the list of peptide candidates ordered by transition score (TS). „m/z to monitor‟ is the range within 
which the product ion masses fall.  The peptide sequences are hyperlinks, when a user clicks on 
„GSPAINVAVHVFR‟, for example, the product ion results are displayed (centre) and a list of schematic 
spectra (bottom) that represent the underlying data in GAPP DB that was used for the predictions.  The 
„Export in TSV‟ link (top) allows users to download all the peptide and product ion data for the target. 
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y- and b- ion assignment is achieved by dynamic computation using the accepted 
rules of fragmentation (Zhang et al., 2005), and where the theoretical m/z values (for 
monoistopic and average mass - as required) are compared to those observed in the 
underlying MS/MS data.  The mass tolerance window is applied to ensure the 
resolution of the data is accounted for in the assignment; for this, the range specific 
to each experiment in GAPP is used, and not the maximum over all relevant 
observations in the search.  In an extremely small number of cases, this window 
prevents unambiguous assignment of a peak to a single b- or y-ion.  In this case, the 
ion is not counted as b- or y- and is instead grouped into the „other ion type‟ 
category (shown in black).    
 
The second approach to ensure MRMaid suggests suitable fragment peaks is by 
using m/z cut-off; an approach that is demonstrated in the literature (Anderson and 
Hunter, 2006, Keshishian et al., 2007).  This facilitates selection of fragments with m/z 
greater than the precursor m/z.  If desired, only MS/MS fragment masses that are x 
percent or more of the mass of the precursor will be recommended by MRMaid, 
where x is specified by the user.  For example, if x is 100%, then only fragment ions 
having a mass higher than the precursor ion will be selected.  This ensures that 
fragments in the higher end of the m/z spectrum will be considered and accounts for 
the effect of the mass filtering step that is applied between MS and MS/MS modes.  
This approach has the knock-on effect of increasing the chances of producing a more 
reliable and specific fragment candidate, because the specificity of a transition 
greatly increases when looking at a product ion that is higher m/z than the precursor 
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ion. Note that there is no limit to the number of fragment ions that can be suggested 
to the user – only the underlying data restricts this.   
5.4.4 MRMaid takes a novel approach to transition ranking 
MRMaid‟s transition score (TS) provides a quantitative measure of predicted 
performance in MRM to candidate transitions that are retrieved by mining the GAPP 
database and by aggregating the results.  Implementation of a series of Boolean 
filtering steps (as in the filters described above) was one available options for this 
part of the process.  However, this would not reflect the approach taken by experts, 
and would have made it impossible to judge relative favourability of candidate 
transitions.  Therefore, TS is calculated as the weighted sum of several key 
characteristics of the spectral data (each denoted as a letter: q, c, r, s, p and n), giving 
a quantitative measure of expected performance in MRM (Table 26).  The relative 
weights applied (50, 8, 7, 6, 1 and 1, respectively) were determined by combining 
authors‟ experience with researching the literature and discussions with practising 
MRM experts.  Note that all values are normalised to a range between zero and one, 
such that each coefficient has consistent scale. 
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Table 26 Derivation of Transition Score (TS) coefficients.  TS is used to rank the predicted transitions in 
MRMaid.  It is calculated as the sum of the coefficients, each relating to efficiency in MRM. Each 
coefficient is derived by multiplying the value by the weighting. 
Transition score  
coefficient 
Description Relative 
weighting 
MS/MS suitability (q) Assesses MS/MS spectrum for suitability in MRM by 
assessing m/z values of y-ions 
50 
Peptide coverage (c) Favors fragment ions that represent a greater 
proportion of the precursor peptide sequence 
8 
Mass range (r) Constrains acceptable MS/MS mode mass range 7 
Precursor charge state 
(s) 
Doubly and triply charge peptides are favored 6 
Positively weighted 
residue content (p) 
H, K and R 1 
Negatively weighted 
residue content (n) 
Y,S,T,C and M 1 
 
 
The MS/MS suitability score (q) positively weights precursor peptides that 
demonstrate a suitable profiles of y-ions for MRM.  A suitable y-ion profile is one 
where there are several y-ions at the high m/z range of the MS/MS spectrum.  y-ions 
with a 1+ charge state were chosen for this because these generally have higher m/z 
than b-ions, so are a suitable indicator to determine the quality of a spectrum for 
MRM.  They are also the ions that are routinely used, as demonstrated, for example, 
in Anderson and Hunter‟s paper (Anderson and Hunter, 2006) where virtually all 
experimentally confirmed transitions were y-ions: see Table 27, where selected 
transitions from this article are used to validate MRMaid performance.  Furthermore, 
b-ions are less suitable than y-ions because they are susceptible to cyclisation, which 
can result in fragment ions of unexpected sequence (Harrison et al., 2006).  Therefore, 
the q coefficient, and hence overall TS value, is designed to favor spectra showing 
evidence of multiple y-ions and  is achieved by considering three key factors for each 
precursor peptide sequence that passes the initial filtering stage for the protein of 
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interest.  First: the highest m/z value of the MS/MS spectrum that is a y-ion with 1+ 
charge (
max)/( zm ); second: the number of peaks of the spectrum that are y-ions with 
1+ charge (npeaks); and third: the standard deviation of m/z values of peaks of the 
spectrum that are y-ions with 1+ charge (stdpeaks).  Standard deviation is calculated in 
the usual way (Equation 1), where pe ak szm )/(  is the individual m/z value of a y-ion 
with 1+ charge in the MS/MS spectrum, and 
p e a k szm )/( is the mean m/z value of all 
the individual y-ions with 1+ charge for the given spectrum, for the peptide in 
question. 
 
Equation 1 Calculating standard deviation, which is used to calculate the coefficient q in MRMaid‟s 
transition score 
 
p e a k sst d  
1
)/()/(
2
peaks
peakspeaks
n
zmzm
 
The rationale for using the three factors above is the following: if it is possible for a 
peptide to fragment into n different y-ions, then the MS/MS metric for suitability in 
MRM should favour spectra with evidence of larger y-ions (those having higher m/z 
values), as well as a higher number of y-ions in total. Since, in general, the whole 
complement of theoretically possible y-ions, for a given peptide, are not produced, 
instead spectra with a smaller standard deviation of m/z values belonging to 
identified y-ions must be favoured.  
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The three elements, above, are combined to assign higher scores to spectra carrying 
evidence of the heaviest y-ion, as well as the greater number of y-ions.  If two or 
more spectra are equal according to these first two criteria, the one identifying a 
higher number of heavier y-ions gets a higher score.    Thus, given a spectrum for a 
peptide sequence in the GAPP database, its interim score 
rk  (r denoting „real‟) is 
calculated as shown in Equation 2.  
 
Equation 2 Calculating the interim score kr as part of coefficient q   
rk  
peaks
peaks
std
nzm
1
)/( m ax
 
After this, using the peptide sequence, a theoretical interim score tk  (t for 
„theoretical‟) is similarly calculated, but this time considering the total complement 
of theoretical y-ions (with 1+ charge state) for the sequence, using the rules of CID 
fragmentation (Zhang et al., 2005).  To finish, the MS/MS suitability score (q) is 
computed as a ratio between the real and theoretical interim scores (Equation 3), 
thus, q is normalised to a scale between zero and one, as is the case of all other 
coefficients in TS. 
 
Equation 3 MS/MS suitability score (q) is computed as a ratio between the real and theoretical interim 
scores 
t
r
k
k
q
 
In summary, q provides a quantitative scale of MS/MS suitability to each peptide 
based on the MS/MS spectral evidence, and is weighted most heavily because it is 
quantifying actual experimental data.        
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Peptide coverage (c) refers to the proportion of the target peptide that is represented 
by the product ions for the transition.  Product ions that have greater m/z are 
preferable, because they represent  a greater proportion of the original peptide in the 
spectrum and, therefore, increase the specificity of the transition.  Peptides with 
fragments within the mass range for MS/MS mode (r) of 500-1600 m/z are positively 
weighted, for reasons mentioned earlier. 
 
Most tryptic peptides are doubly charged cations, with one charge originating from 
the primary amine terminus and one from the K or R residue side chain at the C-
terminus. Precursor charge state (s) is important for MRM because doubly or triply 
charged precursor peptides are favoured, due to the mass filtering stage.  Doubly 
and triply charged precursors, therefore, achieve a coefficient higher than singly 
charged peptides, such as those derived from unspecific protein cleavage.  Charge 
state for each precursor peptide is known, because this information is available in 
GAPP‟s input peak lists (currently .mgf, .pkl or mzXML).  Fragment ions with a 
single charge are preferred in MS/MS mode; information on charge state is 
displayed as b- and y-ion labels on the peaks, so the user can select singly charged 
peaks for monitoring. 
 
Weighting of specific residue content (coefficients p and n) allows more refined 
ranking to be performed on the  candidate  output list.  Positively - charged  residues  
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have been demonstrated to increase fragmentation and hence visibility in MS, so are 
positively weighted (Mallick et al., 2007).  Y, S and T, like C and M, may be post-
translationally modified, so are negatively weighted. 
5.4.5 Transitions can be scored in the absence of MS/MS evidence 
TS may also be calculated in the absence of MS/MS data.  In this situation, it is 
computed with q omitted and the user is informed on the results page.  This 
calculation involves digestion of the protein and application of user-defined filters as 
in the usual MRMaid mode.  Clearly, candidates predicted in the absence of MS/MS 
evidence are less robust, because predicted peptides cannot be statistically measured 
for reliability across experimental datasets, and less comprehensive, because 
candidate MS/MS fragment ions cannot be suggested.    However, an indication of 
which peptides should be monitored is welcome functionality, since the alternative 
is deciding on transitions manually, which would be tedious for large proteins, and 
particularly problematic when many proteins are to be analysed.     
5.4.6 Results can be downloaded from MRMaid 
In the final output, MRMaid provides a tabulated list of ranked transition 
candidates, which are intended for validation using the MS instrument.   This 
validation is necessary because it is not possible to select a single in silico-derived 
transition, without experimental confirmation, as shown by existing software 
options, such as MIDAS workflow designer.  The results table may be exported as 
tab-separated values (TSV) for import into a spreadsheet package for local analysis 
and archiving.  Also, as described previously, schematic spectra are displayed to 
highlight the y- and b-ions suggested for monitoring. 
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5.4.7 Retention time is calculated using a linear model 
Elution time data is commonly used in combination with MS/MS to support 
transition design for MRM experiments (Stahl-Zeng et al., 2007, Wolf-Yadlin et al., 
2007, Keshishian et al., 2007).  RT is used in the discovery phase to decide which 
peptides to monitor - on the basis of peak separation and, once transitions are 
chosen, it allows transition ordering (Wolf-Yadlin et al., 2007) and provides 
confirmation that the peptide species expected is the one actually being monitored 
(Stahl-Zeng et al., 2007, Keshishian et al., 2007, Kay et al., 2007).  Management of 
elution time also maximises the number of transitions that can be performed, 
without overly compromising on sensitivity (Stahl-Zeng et al., 2007).  
 
Implementation of RT was necessary for MRMaid to become an MRM, rather than 
an SRM, design tool.  By having RT indicators to compare across all candidate 
transitions, the order of transitions in a multiplexed experiment can be planned.  The 
problem in achieving this is that GAPP is dependent on data sources in the public 
domain and RT information is rarely captured in publicly available datasets.  In the 
absence of this data, RT is predicted using a linear peptide RT algorithm, which 
holds true for peptides up to approximately 20 residues (Krokhin et al., 2004).  This 
was acceptable since MRM peptides are typically no more than 24 amino acids.  The 
procedure involves summation of residue coefficients then correction for the length 
of the peptide and factors relating to the procedure and setup of the column.  There 
are eight different options for reverse phase column setup provided by MRMaid for 
this process, each of which can be selected by the user using a drop-down menu.   
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There is a default option available, namely, a microflow method (4µl/min) applying 
a gradient of 1-80% ACN over 60min (1.32% ACN/min) using a 150µmx150mm 
Vydac® 218 TP C18 bead column (5µm).  It is recommended that the user selects the 
specific setup that reflects his/her own RP chromatography procedure.  Therefore, 
there is a warning printed on the results page when the default option is selected, to 
remind users that they should choose a specific setup wherever possible.  RT 
prediction is programmed in a modular fashion, so that as improved RT models 
become available, new algorithms may be integrated into MRMaid.  The author 
implemented the RT prediction program in conjunction with Vanessa Ottone. 
5.5 Results 
5.5.1 Man versus MRMaid: testing MRMaid’s performance  
To demonstrate MRMaid‟s ability to predict MRM transitions, a selection of 
transitions that had been experimentally validated were obtained by the author and 
compared to the results generated by the MRMaid program.  Table 27 shows the 
comparison with transitions from Anderson and Hunter (Anderson and Hunter, 
2006), and Table 28 transitions provided by Chris Barton of Quotient Bioresearch.   
 
The author obtained diverse datasets from Human Proteinpedia, PeptideAtlas and 
Tranche and analysed and stored them using GAPP.  The data included serum-
based identifications required for the test cases.  In addition, four MS/MS datasets 
for horse serum proteins were obtained and submitted to GAPP pipeline (with 
appropriate  search  parameters  based  on  the   metadata):   these  were  two  whole  
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plasma samples, and two samples depleted of highly abundant proteins using ACN-
depletion, taken from eight horses see (Barton et al., 2009) for details.  The data, in 
total, represented 100 runs in QQQ-MS/MS.        
 
 
 
 
 
 
 
 
 
 
 
 
Table 27 MRMaid performance versus experimentally verified transitions (Anderson and Hunter, 2006).  
The results shown are derived from MRMaid searches using the default search parameters, namely, no 
internal cleavage sites, 80% of the precursor mass and 50% of total observations.  Peptides which did not 
meet the criterion of 50% of total observations criterion (shown as red rows in the table of results) were 
still considered, due to current quantity of available MS/MS reference data.  An „observation‟ in this case 
is an identification made using a single MS/MS dataset that was submitted to GAPP. Results are derived 
from searches performed on 26
th
 August, 2008.  Values are rounded to one decimal place in the table but 
MRMaid shows up to three in the results on the website.  Key: (a) these values may be shown as a range 
to account for the mass tolerance of fragment ions entered by the user when the MS/MS data was 
submitted to GAPP; (b) relative intensity refers to the fact that signal intensity is normalised by the 
GAPP analysis pipeline.  When spectra are uploaded for protein identification, the y-dimension of each 
spectrum is normalised to 100.  This means that for all the spectra in the GAPP database, which are 
mined by the MRMaid program, there is a maximum y value of 100.  This is also reflected in the 
graphical MS/MS spectra displayed on the MRMaid product ion results page.  The intensity values differ 
for each individual peak in each experiment submitted to GAPP, therefore the mean over all observations 
is given for each particular ion species, for example, y8.  It is possible to successfully monitor product ions 
at low abundance, as long as there is no overlap with other peaks: generally there is less likely to be 
overlap at the very high m/z end of the spectrum, therefore the higher the m/z, the lower the abundance 
that can be successfully tolerated.  
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Table 28 MRMaid performance using horse serum transitions.  Settings applied were: species horse, default RT setting, 8-24 aa length, 80%, 50%.  * - denotes that 
the peptide was predicted by MRMaid, but there was insufficient data to predict the product ion (performed 18
th
 May, 2009).  
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5.5.2 Retention time prediction is accurate 
Compared to empirically-derived RTs (in Table 28), MRMaid‟s RT predictions from 
sequence alone are encouragingly accurate.  The retention times measured for 
nineteen peptides were compared to the RTs predicted using Krokhin and co-
workers algorithm (Krokhin et al., 2004), as implemented in MRMaid (Figure 46).   
 
 
Figure 46 Observed versus predicted retention time for selected transitions shows that MRMaid's 
retention time prediction is accurate 
 
The R2 value was 0.75 (to two decimal places), indicating that the RT estimates 
suggested by MRMaid were very likely to be adequate for avoiding co-elution when 
planning a MRM experiments. 
282
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5.5.3 MRMaid has comprehensive documentation and user support 
The author prepared resources to help users, and has made them available via the 
MRMaid website (see Figure 47 for a summary).  These include: videos to introduce 
the aims of the system; demonstration „walk-through‟ videos filmed using (a trial 
version of) Adobe CaptivateTM 3; a glossary of terms; a user guide; and a link to the 
paper published in Molecular Cellular Proteomics Journal.  Furthermore, interactive 
help „bubbles‟ were integrated into the homepage, where users select the filters and 
enter details for their searches.  The user guide including screenshots, glossary and 
journal paper can be found in Appendix V.  In addition, a practical guide to using 
the MRMaid software has also been accepted for publication as a book chapter by 
Humana Press (2010), see Appendix V.        
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Figure 47 Summary of the MRMaid user documentation and help resources taken as screenshots from www.mrmaid.info (26
th
 August, 2009) 
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5.6 Discussion  
5.6.1 MRMaid can design transitions with multiple product ions 
MRMaid is essentially an SRM design tool which can be used for MRM design by 
combining the results of several SRMs in a single spreadsheet.  As explained above, 
a protein accession number is entered via the interface and candidates are predicted.  
The results may be downloaded, which include both product and precursor ion data, 
then following this, the next protein to be targeted is entered.  Candidates are 
generated by MRMaid and downloaded, as before.  This process is repeated until all 
the spreadsheet data has been captured.  Finally, using TS, number of observations 
and RT, the candidates may be ordered for experimental validation in MS/MS, 
before purchasing synthetic surrogates or designing an expression construct (see 
Figure 48).   
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 Figure 48 The process for applying MRMaid to multiple reaction monitoring (for multiple protein targets) 
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Recommendations and tips to assist users in optimal candidate selection are 
provided in the interactive help documentation. 
5.6.2 MRMaid can design multiple transitions for targeting proteins in 
complex samples 
MRMaid is particularly suitable for designing transitions with multiple product ions.  
A shortlist of multiple peptide candidates is provided for each target, so two or three 
of these can be selected for validation.  For each of these, a list of many different 
product ions is provided, each with metrics to indicate their reproducibility and 
reliability.  At this stage users may select several of the best product ions.  In this 
way, MRMaid supports multiple product ion selection for each peptide.  This allows 
monitoring of a target even in very complex samples: by having several ions to act as 
signposts for the protein in MS/MS, it can make it possible to confirm its presence in 
spite of high levels of noise.   
 
Moreover, by allowing users to apply a sample type filter at time of search, such as 
serum, transition design for complex samples is further supported, because this 
strategy increases the likelihood that a candidate will be selected that has been 
proven to work even amongst associated sample noise. 
5.7 Conclusions 
MRMaid is a modular, web-based tool built around the GAPP DB framework, 
providing a web-based solution for fast and reliable transition design.  Candidate 
transitions are ranked based on a novel transition scoring system, and users may 
 288 
 
refine the results by selecting optional stringency criteria.  Comparison with 
published transitions showed that MRMaid successfully predicted the peptide and 
product ion pairs in the majority of cases with appropriate retention time estimates.  
 
It is web-based with an intuitive user interface and does not require computer 
expertise to use - avoiding download and complicated processes for setup locally.  It 
also supports diverse MS instruments and RP chromatography conditions, so has 
flexibility to be useful to a large number of users. 
   
MRMaid is a tool for designing MRM transitions and is intended to support the 
proteomics community by exploiting public data resources and prior knowledge of 
the MRM technique.  MRMaid eliminates the need for time-consuming preliminary 
studies by delivering ranked candidate transitions based on an existing repository of 
experimental data – meaning that far fewer transitions need to be validated before a 
suitable candidate is found.  The software is freely available as an executable 
application on the web at www.mrmaid.info and is a major deliverable for this 
EngD. 
 
As with any automated workflow, no human judgment could be applied to interpret 
the results; only widely applicable rules could be used. Despite this, the MRMaid 
results presented demonstrate that accurate peptide-product ion transition 
predictions can be made when MS/MS data is available for querying.  Estimation of 
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RT is also of high enough accuracy to be useful for ordering transitions and avoiding 
co-elution.   
 
As the data content of the Genome Annotating Proteomic Pipeline repository 
increases, the coverage and reliability of MRMaid are set to increase further.  In 
conclusion, MRMaid represents an effective first step towards the future of 
integrated software applications for the design of quantitative proteomic 
experiments. 
 
In the wider context for proteomics research, MRMaid is a fitting example of a tool 
that contributes to transformations in knowledge (McNally, 2008).  Specialised 
disciplinary skills and expertise from lab-based MRM practitioners were built into 
MRMaid in a process that now enables novices and other relatively unskilled 
personnel to perform what previously was a ground-breaking, expert procedure – 
namely designing targeted assays for several targets.  This philosophy is an accepted 
way that modern science, including proteomics, progresses in the „knowledge 
economy‟.     
5.8 Suggested developments for MRMaid releases in the future 
5.8.1 Transition candidate ranking using a star rating 
The MRMaid transition ranking system could be improved by linking MRMaid with 
MRMaid  database,  a  repository   of   published   transitions  (see  Chapter  6).    The  
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principle is to rank the transitions by a star rating or as „gold‟, „silver‟ or „bronze‟, 
depending on the level of MS evidence for the transition candidate in question, by 
MRMaid calling the MRMaid-DB during processing.  The transition candidates 
could be ordered into three categories, for example: 
 Gold transitions: when a published, validated transition from a journal publication is 
available in MRMaid-DB for the target protein 
 Silver: when the transition candidate is supported by MS/MS data in GAPP database  
 Bronze: when the transition candidate is supported by a theoretical prediction only, i.e. 
when MS/MS evidence or a published transition is absent  
The benefit of this would be to make it even clearer to the user which candidate is 
the best, increasing the likelihood of reproducibility. 
5.8.2 Batch mode for submitting protein targets 
MRMaid can predict transitions for only one protein target at a time.  Newer 
additions to the field, such as MaRiMba (Sherwood et al., 2009), support batch 
submission of proteins, so that transitions for several proteins may be determined 
simultaneously, saving the user time inputting and interpreting the outputs of 
searches.  Support for batch submission of targets would therefore improve the 
MRMaid program.   
5.8.3 Protein sequence as input 
Collaborators at Quotient Bioresearch and the University of Cambridge have 
suggested that MRMaid would be greatly improved if it could accept protein 
sequences as inputs, not just protein accession numbers.  In this way, users can skip 
the time needed to find the protein ID and there is  less  chance  of  an  erroneous  ID  
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being used.  As in Skyline (Prakash et al., 2009) - a recent addition to the array of 
transition design tools -  protein or peptide sequences can be input directly by the 
user and filters are applied to decide which peptides are most suitable, given „rules‟ 
of transition design (similar to the MRMaid approach); no accession numbers are 
needed. 
5.8.4 Interspecies mode for predicting transitions  
Generally, MS/MS data for some species, such as human and yeast, is more readily 
available compared to other species used in biology research, such as the rat, horse, 
dog or hamster, for example.  Having a facility in MRMaid to predict transitions for 
less well-supported species may prove useful in the future.  This would require 
extrapolation from the data that is available.  In genomics, for example, the 
interspecies approach can be applied to microarray analysis, to analyse CHO cell 
lines using mouse arrays, for example (Ernst et al., 2006).  However, it remains to be 
seen how this approach may be applied for data-driven, cross-species transition 
design.  Although cross-species identification for MS using PMF has been 
demonstrated (Lester et al., 2002), the problem of leveraging data from one species to 
design transitions to target a protein in another has yet to be addressed at all in the 
literature.  If MRMaid could be modified to offer this service, it would be unique, 
and from communications with collaborators, such as researchers at Quotient 
BioResearch who design MRM assays to target horse proteins, it would add value to 
the field, potentially helping many research groups.   
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Having protein sequences as inputs per se (as described in the previous future work 
item) would be compatible with the implementation of interspecies transition 
prediction in MRMaid.  By searching for any transition candidates that have suitable 
spectra for a given peptide sequence (regardless of which species database the target 
protein pertains to) would mean candidates could be searched for in an unbiased 
way – with species not constraining the search. 
5.8.5 PSI-compliance of MRMaid 
A standard format for storing and sharing transition data, TraML, is almost 
complete.  Ideally, MRMaid should be modified to make it possible to export the 
transition candidates it predicts in a fashion compliant with the new standards.  If 
this is not possible, because MRMaid does not have the minimal data required for 
the final agreed version, then MRMaid should at least be modified to export the 
transitions in a format compatible with MS instruments, so that the candidates can 
be directly programmed into the instrument ready for validation and/or 
quantitation; this way researcher avoid having to convert the list from MRMaid 
manually.    
5.8.6 Porting data to MRMaid via GAPP 
In essence, MRMaid is a data-mining algorithm for retrieving transitions from a 
database of spectra.  The predictions it can make are only as good as the data quality 
and content of the repository it mines.  Ideally, therefore, MRMaid should be 
adapted to work as a universal „front-end‟ program that can interrogate a suitable 
„back-end‟ MS/MS data repository.  For example, data from other public 
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repositories, such as PRIDE, GPMDB or Tranche, could be ported to the MRMaid 
server, or indeed a configurable, generic version of MRMaid could be coded to sit on 
top of these public databases.  GAPP DB is too limited and is less likely to continue 
to grow at a fast rate as the other offerings, such as PRIDE.   
 
Moreover, the generic, configurable version of MRMaid could be implemented as a 
commercial software product for mining customers‟ in-house MS/MS data 
repositories, and also mine public datasets as well (at the same time), if desired.   
This would satisfy the unmet need for companies, such as OBT (mentioned earlier), 
who wish to have a completely private facility for predicting transitions with 
MRMaid.  
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6 MRMaid-DB: a repository for published MRM transitions 
 
 
 
 
 
 
 
MRMaid-DB: a repository for  
published MRM transitions 
 
 
 
 
 
 
 
 
 
 
“Once an SRM assay for a protein is established, 
it becomes universally useful and exportable” 
From Picotti et al., 2008 
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6.1 Summary 
The thesis so far has focused on repositories for disseminating proteomic MS data 
and identifications.  In this chapter, a new type of repository is developed, namely a 
public database for storage and dissemination of published and experimentally 
validated transitions.  It is designed for researchers seeking to quantify proteins 
using the increasingly popular technique of SRM, providing a structured system for 
published transitions, which otherwise would remain in publications in disparate 
forms, being difficult to systematically search.  The database is unique compared to 
the only other offering in this space (MRMAtlas), because it directly couples 
transitions to the research paper from which they came, and permits users to submit 
their own transitions as they publish them.         
 
Together, MRMaid (described in the previous chapter) and MRMaid-DB (described 
here) provide a two-pronged approach to address the lack of computational 
resources for the SRM practitioner.  For example, when there are no published 
transitions, users may use MRMaid to design new ones, and when there are 
validated transitions in the literature, they can interrogate MRMaid-DB to retrieve 
them.    
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6.2   6.2  Introduction 
The key to selected reaction monitoring (SRM) is finding the best peptide-to-product 
ion transitions to monitor.  The MRMaid database (MRMaid-DB), presented in this 
chapter, is a new online database for capturing SRM transitions from published 
research papers to save practitioners time when searching for transitions that have 
been previously validated.  It contains all the information needed to reproduce the 
transitions, such as information on the sample matrix, HPLC, and MS 
instrumentation used, and also includes details of the manuscript of origin.  
Transitions are submitted using simple web-based data entry forms, meaning 
researchers have a simple way to increase access to their transitions, and in turn, 
may increase the citations for their research papers.  
 
To use a crude analogy, MRMaid-DB may be compared to a second-hand shop, 
where researchers can bring their own SRMs and search for new ones as they need 
them, only the „goods‟ are all free.  However, MRMaid-DB does not contain a 
haphazard mixture of good, average and poor quality transitions, but instead only 
contains high quality, experimentally validated transitions; each one having been 
published in peer-reviewed journal articles.  Each SRM entry is checked manually 
upon entry, and the product ion type and mass are cross-checked against the peptide 
sequence to ensure accuracy.  In MRMaid-DB, the previous „owners‟ of each 
transition are available -as journal titles and author names- and users can quickly 
determine if a transition will fit in and suit their own lab because all protocol, sample 
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handling and mass spectrometry details are available.  MRMaid-DB‟s „shop window‟ 
is based on the Biomart framework, using colour schemes and „look and feel‟ 
consistent with the MRMaid/ GAPP family of software.    
6.3 An introduction to MRMaid-DB 
The key to performing successful SRM studies is finding the best peptide-to-product 
ion transitions to monitor.  To find the best transitions, researchers can perform 
empirical validation themselves in the laboratory, or exploit the new tools for 
transition design that have emerged during this EngD (Walsh et al., 2009, Martin et 
al., 2008, Lange et al., 2008, Prakash et al., 2009, Mead et al., 2009, Sherwood et al., 
2009).  The most reliable transitions, however, are those that have already been 
experimentally validated and peer-reviewed by others. Yet the problem with using 
these is the lack of a common reporting format, and the absence of a central resource 
for published transitions, meaning researchers must scour the literature manually 
taking time and effort. The aim in producing MRMaid-DB, therefore, was to solve 
this problem by providing a freely accessible collection of the majority of available 
empirically-confirmed transitions, described in proteomics literature to date.  
Furthermore, it is a scalable, structured database system to support the continued 
growth in generation of SRM data in the community.       
6.3.1 Existing repositories for SRM transition data 
The only other SRM transition data resource on the web at the time of writing was 
MRM Atlas (Picotti et al., 2008).  In the MRM Atlas paper, this group reinforced the 
idea that storing validated transitions is a scientifically worthwhile effort, because 
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they demonstrated that transitions may be reproduced across different QQQ-MS 
instruments (Picotti et al., 2008) with minimal „tweaking‟, such as collision energy 
adjustment.  MRM Atlas is built on the SBEAMS framework (Marzolf et al., 2006), 
and contains ready-to-use peptide-to-product ion transitions for approximately 1,500 
S. cerevisiae proteins (equivalent to 21% of the yeast proteome) (Picotti et al., 2008).  
Information stored includes protein sequence; precursor charge; Q1 m/z; Q3 m/z; 
intensity; ion type; collision energy; hydrophobicity; observed retention time; 
number of peptide observations; annotator (name of individual/lab or „best‟); and a 
hyperlink to a „consensus‟ spectrum (representative pattern of product ions for the 
peptide by averaging many observations).  MRM Atlas is searchable via 
PeptideAtlas, or may be queried via its own interface (see (Picotti et al., 2008) for an 
example).  Furthermore, using a new data visualisation option, SRM assays in MRM 
Atlas can be accessed by clicking on protein targets in metabolic pathway diagrams.   
 
MRMaid-DB is distinct from MRM Atlas in several ways: firstly, it contains 
transitions and the infrastructure to support transitions for multiple species: 
currently there are optimised transitions for monitoring proteins from horse, yeast, 
cow, mouse and human.  It is also unique in providing a quick and easy method of 
uploading transition data online, and includes paper manuscript details, so users can 
extract all the transitions from a given article in one search. 
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At the time of writing, plans were presented for a new resource: the PeptideAtlas 
Transitions Resource (PATR)100.  It is not available yet, but demonstrates the topical 
and fast-moving nature of this field of research.   
6.4 Method and implementation 
6.4.1 MRMaid-DB Data Content 
A typical transition has the following core information: a protein target, peptide 
sequence (including any PTMs), precursor m/z; product ion m/z; and observed 
peptide retention time.  MRMaid-DB stores this core information, but in addition, it 
stores detailed auxilliary information for reproducing the transition accurately.   
 
The database scope was set by the author by capturing user requirements for SRM 
assays from lab-based practitioners.  Once a list of data-fields had been formulated, 
the items were cross-checked with nine research papers (Gerber et al., 2003, Kuhn et 
al., 2004, Zhang et al., 2004, Cox et al., 2005, Anderson and Hunter, 2006, Stahl-Zeng 
et al., 2007, Kay et al., 2007, McKay et al., 2007, Keshishian et al., 2007) that included 
SRM assays to see if the desired data items were usually reported in peer-reviewed 
papers (without needing to contact the authors).  For the majority of the items on the 
list the data was routinely available, although some decoding and knowledge of the 
field was required to extract the information, such as decoding the descriptions of 
the RP-HPLC protocols, for example.   
                                               
100 Deutsch et al., ASMS conference 2009, Philadelphia USA, poster presentation 
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Detailed information is captured so that users can easily identify the most suitable 
transition for their particular workflows; data-items include sample processing, 
biological matrix, and RP-HPLC-MS setup parameters.  All of these factors can affect 
the reliability of detection of the precursor/product ions, so by making these 
available users have the best possible chance of reproducing the selected assay(s) in 
their own labs.  Moreover, if the transitions were validated for a given sample type, 
it follows that they should be reproducible for the same sample type if variables are 
kept constant.  Indeed, by specifying the details of biological matrix in MRMaid-DB, 
it ensures that the orders of magnitude and interference can be accounted for when 
users‟ samples, settings, and platform match those of the validated transition(s) in 
the database.   
6.4.2 The MRMaid-DB transitions database schema 
The established data fields were encoded into a non-redundant database schema, 
designed by the author.  A database does not need to be a faithful representation of 
reality (see Figure 49 for the steps used), because it is not a simulation or model.  
Rather, it is a more pragmatic solution, whereby only the features are included that 
are absolutely necessary for the purpose of the system to be fulfilled.  As an analogy, 
a database is a play, which depicts a real-life story, but only picks out events that are 
necessary for the audience to get the message to be conveyed.  The entities in 
MRMaid-DB and the relationships between them have, therefore, been chosen with 
just two things in mind: does the user need this information?, and is the data 
available in journal papers? 
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Figure 49 The methodology used to create the MRMaid-DB transitions database.  PK is primary key, FK 
is foreign key. 
 
 
The database schema was created in Fabforce.net DB Designer 4 for Windows, a free 
database design suite.  Using this package, the tables and relationships were entered 
and the schema could be exported to a „create database‟ SQL script automatically.   
 
The MRM transition schema includes 16 tables, ten of which are look-up tables 
(Figure 50).  One-to-many relationships exist between the tables; for example, in the 
look-up table „journal‟, one journal contains many individual papers, so is a one-to-
many relationship.  Likewise, each paper in the „paper‟ table can contain many 
transitions so paper to transition table is also one-to-many.    
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Figure 50 MRM transitions MySQL database schema   
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The tables were initially populated in batch with data taken manually from the nine 
papers (those mentioned earlier) by creating a comma delimited file of the data (see 
Appendix VI) and uploading it table by table.  Tables were populated using 
PHPMyAdmin, a web-based software that is part of the Easy PHP (2.0.0.0) 
installation bundle.   
 
In some cases, papers used protein IDs such as Swissprot or IPI for the protein 
targets, for which there were multiple Ensembl gene ID equivalents; for example, 
IPI00303963 (Complement C2 precursor) which is cross-referenced (by PICR, 
accessed 10th June, 2009) to ENSG00000166278, ENSG00000204364 and 
ENSG00000206372.  To cope with this, all Ensembl gene IDs were included in the 
data entry for the first instance of MRMaid-DB. 
6.4.3 MRMaid-DB is based on the Biomart framework which offers 
flexible and federated querying  
The type of database front-end to use for populating and querying the database was 
selected next.  The database was implemented in MySQL, which is a widely used 
database framework that is compatible with several database „skins‟.  The author 
investigated several alternatives that were free and compatible with MySQL 
databases101.  These were: 
 
                                               
101 Intermine (www.intermine.org) was considered but it is compatible with postgreSQL, not MySQL. 
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1. DadaBik102, a free PHP-based front-end that is customisable and can support 
searching, inserting and updating of database records.  DadaBik was tested (see 
Figure 51) but was ruled out because multiple primary keys could not be supported. 
2. Xataface103, a flexible front-end that automatically generates web forms and search 
menus.  It offers customised features and functionality via configuration files, 
templates, and plug-ins. Xataface was ruled out because it was excessively rich in 
features and flexibility, a simpler solution was preferred. 
3. Biomart104, this interface is familiar to biologists, because existing databases in 
biology research use it.  It offers very powerful, flexible querying and is supported by 
its creators, who offer implementation support by email.   
4. Code a solution from scratch using PHP, as was done for GAPP database’s website.  
This would require coding all possible queries in SQL statements manually into web-
forms, taking more time but having the possibility to make the site totally bespoke.  
This option was ruled out, because time was better spent on novel aspects of the 
system, not coding an interface from scratch - a routine task in IT. 
  
                                               
102 www.dadabik.org 
103 http://xataface.com 
104 www.biomart.org 
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Figure 51 Dadabik was tested as a possible solution for 
web-based querying and data entry to the transition 
database 
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Biomart was chosen, because it offered superior implementation support and scope 
to federate queries with existing EBI Biomarts, advantages which were valuable for 
this project and are explained later.  Furthermore, the database in this chapter was 
developed at the end of the EngD, so a solution had to be selected that could be 
implemented quickly, given the time constraints.  Biomart offered the quickest route 
to have a working prototype compared to the other options. 
 
Biomart does however, have limitations; for example, it is less flexible than coding 
from scratch, because the interface is configurable only within the parameters 
offered by the system. Moreover, the author could not incorporate interactive help 
pop-ups in the interface or other functionality.  It was also not possible to „drill 
down‟ into results, where one query is run, the results displayed, and then these 
results queried further by the user.   
6.4.4 Implementing an instance of Biomart  
Pre-requisites for running Biomart version 0.7 on the web were: 
 Martj-0.7: notably this includes Martbuilder and Marteditor, all the configuration 
files, such as header.tt, and other files to manage the appearance of the Mart 
interface.  
 LAMP (Linux Apache MySQL and PHP) configuration: both the Biomart per se, and 
the other pages of the MRMaid-DB website were web-based, so must be set up to 
run on a server. 
 Biomart Perl: available via Perl package manager (PPM)   
 Correct configuration of XML files, such as the registry files 
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Once the MRMaid-DB schema was created in MySQL, the database was transformed 
into a Biomart database, using the Martbuilder (Figure 52).    A Biomart database is a 
database with greater redundancy, so queries can be executed quickly via the 
finished Mart query interface.  
 
 
Figure 52 The MRM transition database (a MySQL database) shown in Martbuilder.  The MySQL 
database was transformed to a Biomart using Martbuilder software. 
 
Martbuilder transformed the MySQL transitions database (16 tables) into a large 
redundant table („main‟) table, and one other („dm‟) table that stores the display 
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parameters for specifying the interface appearance (which is populated by exporting 
information from Marteditor, this is explained later).   
 
The Biomart „main‟ table is based on the transition table, because it is the central 
table in the original MySQL schema (Figure 53).  The new mart version of the 
database is exported as a „create SQL‟ script (Figure 53, window inset), hence the 
Biomart is also encoded as SQL, so is also a MySQL database, like to original, but has 
only two tables instead of 16.   
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Figure 53 Martbuilder transforms the MySQL transitions database (16 tables) into a large redundant 
table this „main‟ table is based on the transition table because it is the central table in the original 
MySQL schema.   
 
Next, the Biomart MySQL database was imported into Marteditor (Figure 54).  
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Figure 54 Marteditor software was used to tune the Biomart interface parameters, including the 
attributes and filters displayed 
 
In Marteditor, one can configure the interface displayed to the user, specifying the 
attributes and filters, for example; this system of „filters‟ and „attributes‟ is now 
explained briefly. 
      
The Biomart query interface is a database front-end that has standard features: it has 
filters - criteria on which the results are filtered/constrained (a protein ID, for 
example) and attributes - the data items that the user wishes to have returned from 
the search (the peptide, m/z values and collision energy, for example).   Biomart 
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allows any combination of filters and attributes to be selected simultaneously, 
offering the maximum level of query flexibility to users.   
 
Theoretically, any of the data-fields in the Biomart could be applied as filters or 
attributes in the interface, if this was specified in Marteditor.  The author has chosen 
only the filters and attributes deemed pertinent to the needs of users of MRMaid-DB 
(shown in Figure 55).  The assumptions for this selection were based on discussions 
between the author and expert MRM practitioners.  There is a worked example of 
using filters and attributes in Case Study 1 in the results section of this chapter.   
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Figure 55 Filters and attributes in the MRMaid-DB transitions Biomart.  The ellipses indicate the five main data categories in the Biomart 
query interface.  The boxes show the data-fields available in the schema.  Shaded boxes indicate data-fields that are compulsory when 
submitting transition data.  The boxes with a heavy line are the data-fields that can be applied as filters when searching the Biomart, the 
other boxes are just attributes 
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The parameters entered into Marteditor for the filters and attributes must all refer to 
the new Biomart database column names and table names, not those of the original 
database and must be compatible with the other configuration files.  Once these are 
set, the settings are „exported‟, which means they are added automatically by the 
Marteditor program to the „dm‟ table of the transition Biomart MySQL database.   
6.4.5 Federating the MRM transitions Biomart with Ensembl Biomart 
The MRM transition Biomart was federated with the Ensembl Biomart, an existing 
database provided by the EBI, by joining the Ensembl gene ID column.  Using this 
setup, the two Biomarts can be queried simultaneously.  The advantage of this is that 
the most up-to-date descriptions for targets may be retrieved from the EBI servers, 
rather than retrieving descriptions or names of targets from a local version of 
Ensembl, which may become out-of-date.  There are five logical sections to the 
transition Biomart: transition, protein, protocol, matrix, and paper (Figure 55).  Each 
section has several data-fields, as per the original schema.  Only linking fields, such 
as foreign keys are not displayed to users.    
 
To get the Ensembl Biomart options to display correctly, the settings had to be 
specified in the registry XML file.  The complete set of Biomart configuration files are 
in Appendix V.  Configuring Biomart was not trivial, since the written 
documentation did not have explicit instructions on how to do it.  The author sought 
advice and practical help for setting up the system, including the federated 
querying, directly from the Biomart developers.   
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6.4.6 Submitting transition data to MRMaid-DB 
The website allows any registered user to submit SRM assays, which are then 
manually curated by the administrator (for now, the author) and inserted into the 
database (Figure 56).   
 
As soon as the submission is approved, the data becomes immediately available via 
the public interface by execution of two PHP programs: the first moves data from the 
temporary user submission database, to the MySQL database, and the second 
transforms the updated MySQL database to a Biomart MySQL database, compatible 
with the query interface of the website (Figure 56).  These two PHP programs were 
coded by Luca Bianco.   
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Figure 56 The process of data submission to MRMaid-DB 
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The data submission process (and hence the temporary user submission database) 
were designed by the author on the basis of how practitioners perform and publish 
MRM studies.   Multiple transitions can be performed given a single experimental 
protocol, and multiple transitions may be published for single protocol/workflow; 
thus, to save users time when submitting transitions this idea was applied.  For 
example, users must only submit biological matrix, protocol, and manuscript 
information once, save the information as a list of settings, and give the list a name.  
These settings can then be applied when submitting transition data on subsequent 
visits to the site (see Case Study 3 in the results section).  The temporary user 
submission database (Figure 57) stores the submissions in this logical format as an 
intermediate stage before entry into MRMaid-DB proper.  The data entry system was 
conceptualised and designed by the author, but to save time for the author (who was 
extracting and submitting transitions from papers for the first release of MRMaid-DB 
at the time), Luca Bianco encoded the items into a MySQL schema, ready for use on 
the MRMaid-DB website.   
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Figure 57 Data submission database tables for the MRMaid-DB website.  Dotted arrows show the website interfaces for the corresponding MySQL tables.  
The solid lines indicate links between database tables in the schema.   
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To test the submission process, selected transitions from a recent paper (Barton et al., 
2009) were entered by Chris Barton (the author of that paper), via the completed 
MRMaid-DB web interface.  His submission tested the process shown in Figure 56, 
and helped to ensure that the data entry was intuitive for an external user.  His 
comments were applied to improve the interface.  Screen shots of the whole data 
submission process are available in the user guide in Appendix VI.   
6.4.7 Exporting data from MRMaid-DB 
When a query is executed, the attributes selected by the user are presented in a 
single results table, which can be exported in HTML, CSV, TSV or XLS formats.  The 
results can be refined to show distinct rows of data by selecting a check box in the 
results display panel.  This export functionality is standard for Biomart.    
6.4.8 Designing the MRMaid-DB website look and feel 
MRMaid-DB is a comprehensive website, not just a Biomart query interface.  Biomart 
has been applied by other groups.  One offering (see http://paramecium.cgm.cnrs-
gif.fr) was used as an example of how to create a coherent website around a Biomart 
query interface.  There is a homepage, help area and information about the creators 
for users to browse.   
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6.5 Results  
6.5.1 Examples of MRMaid-DB use cases 
The following case studies give detailed walk-throughs for the most typical 
procedures performed using MRMaid-DB.  The author has also produced a user 
guide, which is available in Appendix VI, which also includes example workflows.   
Case study 1: Retrieving a list of transitions for a protein target 
In this scenario, a list of validated transitions is retrieved for a specific protein target, 
namely human apolipoprotein A-II (ENSG00000158874).  The filter must be selected 
first, this is the field on which data retrieval is to be restricted; in this case, it is the 
protein identifier.  To begin, the user clicks „Browse Mart‟, chooses the „MRM 
transition database‟, clicks „filters‟ on the left toolbar, and expands the „Filter by 
protein‟ section. The Ensembl ID of interest is then pasted into the „Ensembl ID for 
target‟ text box - the adjacent box must also be checked to indicate this filter is active.  
The Ensembl ID now appears on the left toolbar.   
 
Next, the attributes are selected, which are the data-fields to be retrieved for this 
protein.  The user clicks „Attributes‟ in the left toolbar to see the available lists of 
attributes. For SRM transitions, useful information includes the protein target (in this 
case the name and ID), peptide, precursor m/z (Q1), product ion m/z (Q3), peptide 
retention time, collision energy and dwell time.  These features are now selected by 
the user as attributes, by checking the relevant boxes.   
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The protein name (description), which is desired for the output list, is not available 
in the attribute form shown (for transition Biomart); it must instead be selected from 
the Ensembl Biomart.  To do this, the user clicks the second „Dataset‟ link in the left 
toolbar and chooses in the drop-down menu the dataset for Homo sapiens (NCBI36); 
this is because the target in this example is human, so the dataset must be selected 
depending on the species in the query.  To confirm the user‟s selection, the database 
name is now shown in the toolbar.  Next, the user clicks „Attributes‟ for the Ensembl 
Biomart, and expands „Gene‟.  Ensembl Gene ID and Ensembl Transcript ID are 
checked by default.  The user unchecks these and selects instead description (and/or 
Ensembl Protein ID, not used in this example); again the selections now appear in 
the left toolbar.   
 
The filters and attributes are now in place, so to retrieve the transitions the user 
clicks the results button above the toolbar, which executes the search.  The results 
show the transitions retrieved (screenshot in Figure 58) with the table including data 
from both the transition and Ensembl Biomarts.  To export these results, the user 
selects the download option from the drop-down menu above the table and hits 
„Go‟. 
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Figure 58 Screenshot of results from a federated query using MRMaid-DB for apolipoprotein A-II.  The 
first seven columns are from the MRM transition Biomart, and the final column is from the Ensembl 
Homo Sapiens (NCBI36) Biomart database.  The asterisk (*) in the peptide sequence indicates a 
modification on the previous residue. „-1‟ is entered for numerical fields when the data is not available in 
the manuscript („null‟ if a non-numerical field).  The tool bar on the left displays the filters and attributes 
selected for the search; the first dataset refers to the MRM transition Biomart, and the second dataset 
refers to the Ensembl Biomart.  For both peptides shown, there are two possible transitions.  
Simultaneous monitoring of multiple transitions that identify the same peptide can increase selectivity of 
the SRM assay; MRMaid-DB can store multiple transitions pertaining to the same peptide and protein, 
for this purpose.     
 
Case study 2: Retrieving all the transitions from a particular 
manuscript 
A frequently cited paper is Anderson and Hunter‟s investigation, where human 
plasma proteins were monitored using SRM (Anderson and Hunter, 2006).  This case 
study shows how to retrieve all the validated transitions from this particular article.  
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To begin, the user selects as filters for the transition database: first author „Anderson 
NL‟; journal „Molecular Cellular Proteomics‟; and volume „5‟ (volume is optional in 
this case).  Next the user selects the attributes: Ensembl gene ID; peptide; precursor 
m/z (Q1); product ion m/z (Q3); and retention time.  As explained in case 1, selecting 
„description‟ in the Ensembl Biomart gene attributes is the way to retrieve the target 
name, if required.  To count the number of transitions for this paper, the user clicks 
the „count‟ button above the left toolbar.  This shows that there are 119 transitions 
that meet the filter search criteria (displayed below the count button).  To retrieve 
the transition data for these, the user clicks the „results‟ button.  A list of the 
transitions and protein descriptions is displayed, and can be exported.              
Case study 3: Submitting transition data to MRMaid-DB 
For users to start submitting transition data from their own manuscripts, they must 
first register and log in via the „Submit data‟ area of the website.  Once logged in, a 
submission status bar appears on the left to indicate the number of transitions 
submitted and approved for this specific user.  To begin submission, information on 
the experimental set-up must be entered and saved (as „SRM settings‟).  Clickable 
help bubbles (blue question marks) are positioned next to some of the data-fields in 
the data entry form: these give a brief explanation of the type of data required, with 
specific examples.  During the data entry process, if the data required is not available 
in the drop-down menu options then users must check the „Not there?‟ box and 
write in their desired entry in the text box at the end of the section (labelled „Any 
problems…?‟).  In this case, the administrator will  enter the  user‟s  request  into  the  
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relevant lookup table of the schema, making it available for future submissions.  This 
feature is required because comprehensive controlled vocabularies were not 
available for all aspects of the MRMaid database, such as HPLC column models and 
mobile phase compositions.   
 
Once the form is complete, the settings can be saved.  If there any data entry issues, 
these are highlighted in red when the user attempts to submit the form.  The data 
fields that are flagged can be amended and the form submitted again, without losing 
the settings already entered.   
 
To submit individual transitions, the user selects the link on the left.  The settings 
that were entered and saved earlier are now selected by the user in the drop-down 
menu.  Once selected, the transition data entry form is filled in by the user.  The 
protein target must have an Ensembl accession number; if the user has another type 
of accession number it must first be converted to Ensembl.  To convert the accession 
number, the user can click on the PICR icon; this takes him/her to a tool that cross-
references database accession numbers and can convert lists of various IDs in batch 
mode (Côté et al., 2007).   
 
After completing the form, the user clicks „Submit transition‟ to send the data to the 
database administrator for approval.  Once approved, the transitions enter the 
Biomart immediately and are available to all users. 
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6.6 Discussion 
There is currently no officially sanctioned standard for reporting SRM transitions in 
research papers and repositories.  HUPO-PSI and Institute of Systems Biology are 
currently coordinating efforts to develop a standard XML-based format for storage 
and exchange of SRM transitions, called transitions markup language (TraML).  The 
first draft was posted on the HUPO-PSI website105 on May 2nd, 2009.  The overlap 
between the proposed TraML standard format (as in August 2009) and MRMaid-DB 
has been examined (Table 29). 
 
 
 
 
 
 
 
 
 
 
 
                                               
105 www.psidev.info 
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 Transitions Markup Language (TraML) MRMaid Database  
Data-fields 
specified as 
compulsory 
TraML, version: TraML format version used 
CV, URI: uniform resource identifier for the controlled vocabulary 
CV, fullName: name of the controlled vocabulary 
CV, id: identifier for the controlled vocabulary 
CV, version: version of the controlled vocabulary 
contact, id: contact person for referencing 
publication, id: identifier for the publication 
instrument, id: identifier for the MS instrument 
software, id: identifier for  referencing the  software 
software, version:  version of the software used to generate transitions 
protein, id: identifier for the protein target 
protein, name: name of the protein target 
cvParam, accession: accession number for the controlled vocabulary 
cvParam, cvRef: reference to the controlled vocabulary parameters 
cvParam, name: name of the controlled vocabulary 
peptide, id: identifier for the peptide 
peptide, modifiedSequence and unmodifiedSequence: peptide sequence with 
and without modified amino acids 
compound, id: identifier for the compound to be monitored by SRM 
precursor, mz: Q1 m/z 
product, mz: Q3 m/z 
prediction, softwareRef: reference to the software for transition prediction 
prediction, transitionSource: how the transition predictions were made (e.g. 
using a consensus spectrum search) 
configuration, instrumentRef: reference to instrument configuration for 
validation or optimisation of transitions 
validation, transitionSource: how the transition(s) was validated 
Ensembl gene ID (for the target) 
Peptide sequence 
Q1 m/z 
Q3 m/z 
First author (of the paper) 
Title (of the paper) 
Transition 
targets  
Different biomolecules  Peptides only (and validated in peer-reviewed papers) 
Signal intensity 
data 
Signal intensity, intensity rank, and relative intensities  No intensity information 
Redundancy Some redundancy  if all elements are filled in, such as Q1 m/z which can be 
specified in Element <transition> and Element <precursor> 
Redundancy is avoided by storing the SRM settings only once for each type of 
setup, and reusing this for the individual transition submissions. 
Sequence 
information 
Whole protein sequences and peptides  Protein IDs and peptide sequences 
Product ion 
data 
Ion series and ordinal separately: „y‟ and „6‟, respectively. Product ion type as „y7‟, for example. 
PTMs and 
heavy peptides 
PTMs or heavy residues are written as square brackets in the modified peptide 
sequence. 
PTMs are specified by an asterisk in the sequence and a text field with the name 
of the modification(s).  Heavy residues are described in the isoform / variant data-
field 
Table 29 A comparison of the data captured by TraML versus MRMaid-DB.  The comparison shown here is based on the TraML early draft (Version 
0.2.0.0) released on May 13, 2009. 
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Publication 
details 
Published articles from which the transitions are derived can be captured, as 
Pubmed IDs, for example.  
More detail on the paper, including the Pubmed ID or DOI, as well as journal 
name, title, mini abstract, volume, start page, etc. 
Contact details  All contact names of people who produced the transitions First author of the paper article  
Transition 
design / 
analysis 
software  
Name and version of the software used to design the transitions.  Also the 
„transition source‟ (how the transitions were selected) 
No software or transition selection information  
Peptide 
retention time 
Predicted or actual RT data Observed RT only 
Protein name/ 
description 
Protein description is in TraML (in Element <protein>) Transition data Biomart database is federated with the EBI‟s Ensembl Biomart 
for several species (currently human, mouse, dog, cow, horse, and yeast). The 
description/name of the target ID must be retrieved from the Ensembl Biomart. 
Coefficient of 
variance 
- Captures coefficient of variance in % for each transition from the published 
paper manuscript. 
Ranking 
transitions 
Transitions ranked in recommended order by the experimentalist For each protein in each paper the transition is indicated as the best (y) or not the 
best (n) or unknown (0), if not specified in the research paper. 
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Although TraML and MRMaid are very different (the former is a data standard, 
whereas the latter is a database) it is worth comparing their data models, because it 
would make sense to support TraML import/export within MRMaid when TraML 
becomes stable. Currently, MRMaid-DB export is in a simple spreadsheet format, 
although results can be extracted as XML via the Biomart API. 
 
TraML contains the specifications for representing SRM transitions for monitoring 
different types of compounds via mass spectrometry, not just proteins and peptides, 
plus signal intensity information, and experiment/sample information encoded 
using ontological terms.  This contrasts with MRMaid-DB which, being dedicated 
specifically to proteins / peptides, captures only a subset of the data included in the 
TraML specification. Furthermore, MRMaid-DB also takes a pragmatic approach to 
data entry, allowing free text entry for fields for which ontologies have yet to be 
developed, such as for specific RP-HPLC conditions.  
 
At the moment there is no relevant MIAPE (The Minimum Information About a 
Proteomics Experiment) module for this area of proteomics, so TraML and MRMaid-
DB enforce their own rules regarding compulsory data fields. Again, MRMaid-DB 
currently takes the more pragmatic approach, requiring only a subset of the data 
considered compulsory in TraML (Table 29). 
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6.7 Conclusions 
MRMaid-DB is a scalable compendium of high quality, validated transitions 
available at www.mrmaid-db.info.  It provides a freely accessible online framework 
to store and disseminate transitions as they become available in the literature.  This 
has the potential to save users valuable time when designing SRM experiments, and 
to increase citations for those authors submitting their transitions to the database. 
 
Along with TraML and MRM Atlas, MRMaid-DB acts as a useful template for 
researchers looking for guidance on what to include in their SRM publications in the 
future.  Indeed, in the same way that prototype software applications act as a useful 
tool for communication between users and developers, these new developments will 
hopefully stimulate researchers to discuss and decide which aspects of experimental 
information are most important for reproducing SRM assays in practice. 
6.8 Future work 
6.8.1 Data content of MRMaid-DB 
For the purposes of this thesis, the novel work was development of the data 
management system, not database population.  At the time of release, MRMaid-DB 
contained only 272 individual SRM transitions, which is sufficient for a prototype 
system but does not reflect all of the published transitions in the public domain at 
that time.  MRMAtlas, the only other system for storing MRM transitions, is limited 
to yeast at present, but despite this has thousands of transitions already.  Immediate 
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future work, therefore, should be population of MRMaid-DB with newly published 
transitions.   
6.8.2 MRMaid-DB should become compatible with standards  
MRMaid-DB could be made TraML-compatible (hence PSI-compliant), once the 
standards are finalised.  This was not possible at the time of writing this EngD, 
because the standard was not ready for release, however, as demonstrated in Table 
29 there are already data-fields in common.  For example, a parser program could be 
produced to allow export of entries from MRMaid-DB in TraML format for the data-
fields available. 
6.8.3 Automated quality control at point of data entry 
Each SRM entry is checked manually by the author to verify that product ion type 
and mass are correct using both the research article and also web-based m/z 
calculators to ensure fidelity of the data entered.  This is a process which could, at 
least in part, be automated.  In MRMaid, for example, there is already a function to 
calculate the b- and y-ion complement of a peptide sequence.  Using this code, the 
mass of the peptide entered could be automatically checked against the m/z values 
(and ion type) entered by the user into the form.      
  
  
 332 
 
 
  
 333 
 
7 Conclusion 
 
 
 
 
 
 
 
 
 
Conclusion 
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This project contributes to the body of knowledge in proteomic bioinformatics on 
several levels.  Firstly the field of „proteomic bioinformatics‟ was characterised in 
terms of its commercial presence (Chapter 2), and as an array of publicly available 
repositories and software resources (Chapter 3).  There is no research available in the 
public domain regarding the management of proteomic bioinformatics, so it is 
believed that the work presented in Chapter 2 adds significant value to the field.  
The immediate future plan for the material is to re-format it into a teaching case for 
the MBA course, for example via the European Case Clearing House106.  The 
business history could also be written up separately as an article for Enterprise & 
Society: The International Journal of Business History.  The review of the latest 
developments in public repositories, Chapter 3, offers a further notable contribution 
to the field, because the public repositories are constantly changing in functionality 
and content.  A review in a single document is thus valuable to both lab-based 
proteomics practitioners, who wish to upload their datasets or mine existing ones, 
and for proteomic bioinformaticians, wishing to have an overview of existing 
resources to avoid repetition of effort and to design tools to plug gaps in the 
resources currently available.   
 
In Part II, the long standing question of which decoy database should be used to 
reduce FPs in automated identification workflows was answered.  A systematic 
investigation of diverse decoy database designs was carried out using GAPP, 
                                               
106 A not-for-profit organisation that provides a collection of case studies and papers for teaching purposes for 
management training. 
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revealing that the recommended decoy database design is peptide level reverse, 
searched independently from the target database.  This work was a „brute force‟ 
empirical approach and offers a practical way to reduce the risk of pursuing false 
protein leads in biological/pharmaceutical research.  Naturally, by taking the 
recommended approach, which stringently filters out FPs, it may happen that true 
identifications are also filtered out thus not providing the full picture of the proteins 
present in a sample.  In this scenario, the investigator can be sure that what is 
identified was present, but will not know what is absent from the list – this is 
favourable in a pharmaceutical setting, for example, when researchers must be 
certain that the protein was present.  The work also has potential to affect reporting 
policies for high-throughput proteomics, for example, by providing science-based 
evidence on which kinds of randomised decoy searches should be applied for 
reporting false identification rates in journal papers (Bradshaw et al., 2006, Tabb, 
2008).  Future work to examine the decoy database performance on different datasets 
and pipelines will help to confirm the recommendations made from this study.    
 
Chapter 4 also provided a tangible example of how novel research may be 
performed by exploiting datasets made public in a proteomics repository on the 
internet, such as those reviewed in Chapter 3.  Mitchell Waldrop, a journalist at 
Scientific American, posed the question in April 2008 “...is posting results online for all 
to see a great tool or a great risk?”107.  The author argues that the work presented shows 
                                               
107 From an article entitled ‘Science 2.0 Is open access science the future?’ 
 337 
 
that it is indeed worthwhile to make data freely available to the community via 
public proteomics repositories, such as Tranche at ProteomeCommons (as was used 
in Chapter 4).  In this case there are more benefits for making datasets available than 
risks, especially since datasets are, in any case, usually only made available after 
publication.   At present, one of the issues for proteomics data-sharing in this way is 
that there is currently more value placed on receiving citations for papers than there 
is value in having one‟s datasets re-applied and cited.  This situation is likely to be 
improved with projects such as MIBBI (Minimum Information for Biological and 
Biomedical Investigations) (Taylor et al., 2008).  As Chis Taylor - who runs the project 
- stresses, external referencing of datasets that are obtained via repositories is 
important to incentivise authors to submit their data to databases in the first place 
(personal communication, July 2009).  A formal system to make this possible is much 
needed.  Moreover, by making data available in repositories, it is good for science as 
a whole, because it means reviewers can determine if the data is as good as authors 
say before work is accepted for publication.  It also allows data to be re-used in new 
analyses, such as with new algorithms as they become available, and can lead to new 
tool development that is only possible when a critical mass of data is put together, 
such as consensus spectral searching, for example.   
In Part III a new tool (MRMaid) and database (MRMaid-DB) were developed to 
support MRM studies. These systems, unlike those in Part II, focused on quantitative 
proteomics,  an   area  of   proteomics   which  is  increasingly  important   permitting  
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detection of changes in the absolute quantities of proteins for use in systems biology 
and biomarker discovery and validation. Indeed, MRM is an effective technique for 
this purpose, but its limitation is that it is exclusively for targeted protein 
quantification; it must be hypothesis-driven. Other quantitative methods, such as 
label-free and those reviewed in Chapter 1 are required in situations where the 
proteins to target are not known - where there is no hypothesis to direct the 
quantification.   
Designing transitions for SRM assays from scratch, or locating existing transitions in 
research papers is time-consuming, and does not leverage existing knowledge and 
data resources.  MRMaid and MRMaid-DB offered new bioinformatics solutions to 
solve these problems.  Indeed, since releasing MRMaid, several new publicly 
available tools for transition design and optimisation have subsequently emerged.  
These new computational resources fall into two main types:  
(1) Web-based data-mining applications that sit between the user and a large public proteomics 
repository on the internet like MRMaid, they include The Global Proteome Machine’s MRM 
Worksheet (Walsh et al., 2009), and ESPPredictor (Fusaro et al., 2009) 
(2) Standalone packages to predict transition candidates, which are installed and executed 
locally, such as MRMer (Martin et al., 2008), Skyline (Prakash et al., 2009), and  MaRiMba 
(Sherwood et al., 2009).  This second group can exploit data from public repositories for the 
prediction process, for example via a web service or by applying specific spectral libraries.   
The array of new offerings demonstrates how quickly the MRM approach is gaining 
popularity.  Moreover, they highlight how appropriate the development of MRMaid 
was at the time.  Indeed, MRMaid (along with TIQAM) lead the field of MRM 
informatics, being the first freely available tools in the world for transition design.  
Indeed, MRMaid has already been cited by others in recent papers and reviews, for 
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example in the MaRiMba paper (Sherwood et al., 2009), and in a review article on 
MRM for clinical applications (Kim and Kim, 2009).  To further contribute to the 
state of the art in this field, the author has written a review of publicly available 
software for MRM informatics.  A review of these resources was desirable, since like 
repositories, the field is fast moving and researchers find it difficult to weigh up the 
capabilities and benefits of each offering.   The review has been accepted by 
Proteomics journal and will be published as part of the HUPO conference 
proceedings edition of Proteomics in 2010 (see Appendix VII).   
Also, MRMaid-DB has implications for the new standard format, TraML, for 
reporting transition data in the community.  The process that the author went 
through to obtain all of the data items required to reproduce transitions is the same 
process that the HUPO-PSI work group are going through now.  Therefore, it may 
be argued that by comparing the data-fields captured by MRMaid-DB with TraML, 
the MRMaid-DB schema may serve to validate the new standard going forward.     
In summary, the outlook for MRMaid and MRMaid-DB is promising.  Indeed, a new 
proposal is being put together in Autumn 2009 to obtain funding108 to, among other 
things, integrate the MRMaid algorithm and its transition scoring, as well as the 
MRMaid-DB schema, into PRIDE database at the EBI.  PRIDE is the only major 
public proteomics repository still to provide transition design functionality.  
Applying MRMaid in this way would provide a way to achieve longevity of support 
and continued global reach for the resources developed on this EngD.  In general, a 
                                               
108From the bioinformatics and biological resources (BBR) fund from the BBSRC (Biotechnology and 
Biological Sciences Research Council).     
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major issue for tools like MRMaid is that they never progress from the level of 
„prototype‟ to a robust application, and down-time on small-scale development 
servers is inevitable.  By incorporating the MRM tool and database into PRIDE, 
which has professional support and regular sources of funding, there is the best 
chance of delivering benefits to users on a continued basis.  Moreover, as part of the 
EBI‟s toolbox, there is greater likelihood that the proposed future improvements to 
MRMaid will go ahead (such as those mentioned at the end of Chapter 5).   
Finally, it is likely that once SOPs are in place for the MRM approach, such as those 
that will be delivered by CPTAC, MRM will form a major part of the proteomics 
toolbox in both research environments and clinics.  This means that sources of 
reliable transition candidates, such as MRMaid and MRMaid-DB, will become 
increasingly important in the future. 
7.1 Wider opportunities for future work 
To conclude, some further areas of research work are suggested to build on the 
achievements of this thesis.   
7.1.1 Decoy database design options 
The decoy databases created in Chapter 4 were based on randomising protein 
sequence databases based on known mathematical techniques, such as shuffling or 
reversing.  There are other approaches to this randomisation that could be applied; 
for example, in proteins there are recurring biological motifs, the sequences are not 
completely random strings.  New approaches to design decoy databases can take the 
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information on biological sequence motifs into account for decoy database creation, 
such as in a study that applied pattern recognition approaches and a Monte Carlo 
sampling algorithm (Feng et al., 2007).  If the statistical properties of the target are to 
be accurately mirrored in the decoy, then short repeating domains should also be 
accounted for in the decoy design.  This avenue should be explored, and may lead to 
improved FPRs. 
7.1.2 Refactoring of the systems: GAPP and MRMaid  
Future work should include re-coding of GAPP and MRMaid from scratch, because 
there are several aspects that need to be improved.  The original release of GAPP 
(Shadforth, 2005) was not well-documented and written in Perl.  Issues with it 
include speed, presence of bugs in the code, and that the input and output formats 
are not PSI standards-compliant.  Perhaps more importantly, however, is that the 
GAPP framework is based on Ensembl gene identifiers, hence MRMaid had to be 
based on these.  Ensembl genes are not useful for protein isoforms, since each gene 
has a single ID even if several isoform variants exist.  For MRMaid in particular this 
is a problem, because ideally users need to be able to monitor specific variants by 
MRM. 
 
To make all of these changes in a piecemeal fashion would be a difficult task, and it 
would be more time-efficient to implement complete refactoring of the system, with 
the focus on delivering modularity and extensibility in the new version.  Indeed, this 
would allow GAPP to become a robust application, not a prototype as it effectively  
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is now.  Furthermore, a stand-alone version could be created at the same time and 
commercialisation explored.   
7.1.3 Automated data harvesting 
As explained in this thesis, there is a growing body of MS data available in public 
repositories.  It is suggested, therefore, that changes be made to GAPP to allow 
harvesting of data from two major proteomic repositories, PRIDE and Tranche.  One 
of the major pieces of work for the author in Chapter 5 was making sure enough 
spectral data was in GAPP DB, so MRMaid could make meaningful transition 
predictions.  To improve MRMaid, therefore, more data needs to be made available 
to it via GAPP DB.  To implement data-harvesting is not a simple operation because 
the minimum set of metadata will be required as search parameters for X!Tandem; 
hence, a middleware interface is required to connect to the repositories every time 
new data becomes available.  The multiplicity of file formats for the spectra is also an 
issue to be accounted for, although it is hoped that HUPO-PSI‟s mzML will become 
the widely-adopted format of choice for MS/MS datasets in the near future.     
 
The danger of taking data from multiple distributed sources is that some of it may be 
erroneous, or of poor quality.  It is therefore important that some form of quality 
assessment be made on data presented to GAPP via automated harvesting.  Various 
techniques to assess and improve spectral quality have already been described, for 
example in (Flikka et al., 2006).  Filters could be used to eliminate poor quality data 
prior to submission.  In addition, post - processing  could be  developed  to remove 
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errant identifications; for example, a rule-based expert system could apply 
knowledge of MS fragmentation chemistry taken from experts to identify and 
remove erroneous identifications, such as through knowledge of fragmentation 
chemistries and the limits of detection of MS.   
7.1.4 Facility to execute different search engines in GAPP 
To improve the data and identifications available to MRMaid further, and to make 
the score for optimising decoy database designs wider, it is suggested that GAPP 
pipeline be extended to include peptide scoring from others search engines in 
addition to X!Tandem including, for example, OMSSA and Mascot (for which the 
user would need to link GAPP to their Mascot server). This will also allow consensus 
scoring, whereby results from multiple search engines are combined to increase 
confidence, thus only identifications validated by searching various approaches 
would be stored in GAPP DB.  It would also provide scope to combine the results of 
the different search engines into a single score, such as FDRScore as described in 
(Jones et al., 2008a).  Of course, Mascot is a commercially licensed software product 
so cannot be integrated into the open source distribution of GAPP, or made freely 
available as a part of the web-based installation of GAPP. However, users could 
„farm out‟ processing to their own in-house Mascot server, if they have one. Mascot 
is a widely used and accepted search engine, particularly in the UK, so it would be a 
valuable addition for the purposes of testing decoy designs and for MRMaid. 
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7.2 Final word: proteomics gear-heads are here to stay 
Biologists may feel frustrated by bioinformatics, believing that „black boxes‟ (tools) 
developed by „gear-heads‟ (bioinformaticians) do not represent „real biology‟ 
research; rather a complicated means to an end.  A recent sociology workshop 
explored this point; McNally - who lead it - found that biologists saw the growth in 
proteomic bioinformatics (the „gear-head moment‟) merely as a transient stage in the 
history of biology research, and they “look forward to the day when the gear-heads move 
aside to make room for biology to return to its rightful position centre stage and resume the 
„real‟ job of science, which is addressing biological questions and meeting urgent social 
needs” (McNally, 2008).       
 
McNally‟s findings do not, however, reflect the reception the author has received for 
the work presented in this thesis.  In fact, the author would argue that each piece of 
research presented here was designed specifically to assist lab-based researcher‟s 
endeavours by providing a means for researchers to leverage expertise and data 
from others, and to increase access and recognition to their own and others‟ work.  
Given the explosion in data volume, it is also hard to agree that proteomic 
bioinformatics research represents a short transient stage.   
 
In reality, it is likely that even more sophisticated „black boxes‟ will be needed to 
federate disparate data for the systems biology models of the future.  It is more likely 
that the „real biology‟ of the future will have computing as its central, novel focus, no 
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longer with the focus on the actual process of biological data capture, but rather the 
analysis afterwards.  Evidence of this shift is already here: the CEO of the BBSRC, for 
example, concedes that increasing amounts of text and data are likely to change the 
entire epistemology of much of science109. Indeed, it appears that the proteomics 
gear-heads are here to stay and the future of proteomics, and biology in general, 
needs them.  
 
  
                                               
109 Taken from Professor Douglas Kell's blog at the BBSRC website (http://blogs.bbsrc.ac.uk/), ‘Computational 
infrastructure for modern biology’ posted on 21st September, 2009. 
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Appendix I Figure 1 A summary of software tools to interchange proteomics data formats (Source: ISB 
ProteomeCenter) 
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Appendix I Table 1 Short courses/ workshops attended during the EngD 
Course Course content 
Research planning and report writing  Scientific report writing, data analysis and 
interpretation skills 
Techniques to aid innovation  Design/realisation process, IP rights, statistical 
experiment design, new manufacturing processes 
GRAD summer school  Personal development,  teamwork, facilitation skills 
and confidence 
Technology change and 
environmental assessment  
Auditing methods for environmental impact 
Learning team approach course  Team-building, leadership, inter-personal skills, 
problem-solving 
Intelligent systems  Architecture, knowledge engineering and control, 
languages used in expert systems, Bayesian 
interference, fuzzy logic and decision support systems 
including clinical applications 
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Appendix I Table 2 Conferences, Presentations and Posters for the EngD
Date Title of EngD work presented Presentation 
type 
Conference or meeting name Location Materials in 
appendix CD 
21-25/07/07 Novel bioinformatics tools for cross-species data 
analysis 
Poster 15
th
 International conference on Intelligent Systems for 
Molecular Biology, and 6
th
 European Conference on 
Computational Biology 
Vienna, Austria No 
19/11/07 - - 6
th
 Annual Proteomics Day 
and Second BSPR London Regional meeting 
London, UK - 
6-7/05/08 Using Bioinformatics to Increase Speed and Reduce 
Uncertainty in Protein Biomarker Discovery 
Oral and 
paper 
Cranfield Multi-Strand Conference Cranfield, UK Paper 
18-19/06/08 Bridging the GAPP Oral  Proteomics Method Forum Dundee, 
Scotland 
No 
8-10/07/08 Fast and reliable MRM transition design Oral  British Society of Proteome Research (BSPR) / European 
Bioinformatics Institute (EBI) Conference [Proteomics: 
From technology to new biology] 
Hinxton, UK No 
22-26/09/08 Applying community standard MS/MS datasets to 
evaluate proteomic data analysis pipeline 
performance 
Poster  7
th
 European Conference on Computational Biology Cagliari, 
Sardinia, Italy 
Poster 
01/12/08 
 
- - The Seventh Annual Proteomics Day, and Third BSPR 
London Regional meeting 
 
London, UK - 
20/05/08 Man versus MRMaid: can a computer program 
design transitions as well as a Quotient scientist? 
Oral  Quotient BioResearch Ltd. lunchtime seminar Fordham, 
Newmarket, UK 
No 
27/06/09-
02/07/09 
MRMaid: automating the design of multiple 
reaction monitoring (MRM) experiments using 
expert knowledge and MS/MS data-mining 
Poster  17
th
 International conference on Intelligent Systems for 
Molecular Biology, and 8
th
 European Conference on 
Computational Biology 
Stockholm, 
Sweden 
Poster 
14-16/07/09 Which decoy database gives the lowest false positive 
rate in automated searches using a proteomics 
pipeline? 
Poster  British Society of Proteome Research (BSPR) / European 
Bioinformatics Institute (EBI) Conference [Multiscale 
proteomics: from cells to organisms] 
Hinxton, UK Poster 
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 Appendix I Table 3 Professional memberships of the author, as a result of expertise gained on the EngD 
programme 
 
 
 
 
 
 
  
Date joined Organisation 
2009 The American Chemical Society 
2007 The International Society for Computational Biology 
2007 The British Society for Proteome Research  
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Appendix II Table 1 BBSRC proteomic MS grants awarded between 1999 and 2008.  The colours indicate linked grants, such as follow on grants.  Asterisk 
indicates grants which also include additional proteomics approaches (in addition to MS) 
Year Start date Grant Proposal details Recipient 
Establishmen
t 
1999 11/01/1999 £119,898 Software tools for complex mixture analysis of proteome proteins hubbard manchester 
2000 01/04/2000 £460,964 
Making the most of a genome sequence: the application of global transcriptome and proteome analysis 
to Streptomyces coelicolor A3(2)* smith manchester 
2001 01/08/2001 £197,912 
Realising a qualitative increase in the capacity of proteomics by statistical image analysis of 2D 
electrophoresis gels graham manchester 
2004 01/05/2004 £376,187 ISPIDER - a pilot grid for integrative proteomics apweiler EBI 
2004 01/07/2004 £360,181 
Developing PEDRo as a standard tool for the capture, representation, analysis, and dissemination of 
proteomics data oliver cambridge 
2004 01/10/2004 £202,883 ISPIDER - a pilot grid for integrative proteomics martin birkbeck 
2004 25/10/2004 £363,821 ISPIDER - a pilot grid for integrative proteomics hubbard manchester 
2004 15/11/2004 £230,130 Application of field programmable gate arrays to eliminate bottlenecks in near-instrument proteomics beynon liverpool 
2004 22/11/2004 £129,699 A Grid-Based System for Cataloguing the Human Proteome from Distributed Mass Spectrometry Data bessant cranfield 
2005 01/04/2005 £222,889 ISPIDER - a pilot Grid for integrative proteomics jones UCL 
2005 01/09/2005 £20,000 
Development and Dissemination of e-Protein: A distributed pipeline for proteome annotation using 
GRID technology jones UCL 
2005 01/09/2005 £19,965 
Development and Dissemination of e-Protein - a Distributed Annotation Pipeline for Proteome 
annotation using Grid technology sternberg imperial 
2005 01/12/2005 £150,193 Computing Equipment for Bioinformatics * sternberg imperial 
2006 01/05/2006 £444,800 EMBOSS: European Molecular Biology Open Software Suite * Rice EMBL 
2006 01/10/2006 £50,205 ProteomeHarvest - Excel/XML Bridge for User-friendly Proteomics Data Collection Apweiler EBI-EMBL 
2007 01/04/2007 £92,274 Further Development of the Genome Annotating Proteomic Pipeline bessant cranfield 
2007 01/05/2007 £156,781 A Multi-Processor Linux Farm for Bioinformatics and Functional Genomics * lovell manchester 
2007 07/05/2007 £99,103 Informatics tools for analysis of quantitative proteomics data hubbard manchester 
2008 14/01/2008 £186,111 Rapid proteome profiling using positional signature peptides hubbard manchester 
2008 01/03/2008 £48,383 Database on demand - creating customized sequence databases for efficient protein identification apweiler EBI-EMBL 
2008 14/03/2008 £71,545 FPGA supercomputing technology for high-throughput identification and quantitation in proteomics beynon liverpool 
2008 15/03/2008 £356,480 FPGA supercomputing technology for high-throughput identification and quantitation in proteomics coca sheffield 
2008 01/06/2008 £217,459 Rapid proteome profiling using positional signature peptides beynon liverpool 
2008 01/07/2008 £103,094 X-tracker: a generic quantitation tool for MS-based proteomics bessant cranfield 
2008 18/09/2008 £99,876 
Computational methods to enable construcution of 3D models of protein complexes by integrating mass 
spectrometry and biochemical data robinson cambridge 
      
 Total £4,780,833    
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Appendix II Figure 1 Breakdown of public funding awarded for proteomic bioinformatics research in 
England between 1999 and 2008. 
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Appendix II Figure 2 Hits for GPMDB as an indicator of activity in proteomics research across the world 
during June 2009 
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Paper 1 of the EngD  
- Mead, J.A. and Shadforth, I.P. (2007) Bringing protein identification to the masses. Institute of Biology 
Biologist 54:200-206 
paper1_ 2007_biologist.pdf 
Paper 2 of the EngD 
- Mead, J.A., Shadforth, I.P. and Bessant C. (2007) Public proteomic MS repositories and pipelines: 
available tools and biological applications Proteomics 7(16): 2769-86 
paper2_ 2007_proteomics.pdf 
Paper 3 of the EngD  
- Mead, J.A., Bianco,L. and Bessant C. (2009) Recent developments in public proteomic MS repositories and 
pipelines. Proteomics 9(4):861-81 
paper3_ 2009_proteomics.pdf 
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Paper 4 of the EngD  
- Bianco,L.,Mead J.A. and Bessant,C.(2009) Comparison of novel decoy database designs for optimizing 
protein identification searches using ABRF sPRG2006 standard MS/MS datasets Journal of Proteome 
Research 8(4):1782–1791 
paper4_ 2009_jpr.pdf 
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 Appendix IV Figure 1 Work breakdown for the research work completed in Chapter 4 
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Appendix IV Figure 2 The remaining three labs from the box 
whisker plots in Chapter 4.  The plot illustrate the 
distribution of protein level false positive rates (FPRs) across 
the ten database instances for each decoy design.  Each colour 
represents an individual ABRF data-submitting laboratory.  
The horizontal line is the mean of the ten database instances, 
the box around the line shows one standard deviation above 
and below the mean, the whiskers show two standard 
deviations from the mean and the filled dots are the 
maximum and minimum individual FPR values obtained for 
the given decoy.  The first nine decoys on the x-axis were 
searched in composite with the target and the last nine 
separate to the target.    
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(a) 
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 (b) 
 
Appendix IV Figure 3 Remaining graphs from Chapter 4. 
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Appendix IV Table 1 Examples of standard public MS/MS datasets and where to find them. 
Dataset 
name 
Reference 
article where 
available 
Description  Instrument 
used 
Data format Data download location  Metadata location 
ABRF 
sPRG2006 
Paper 
pending see 
www.abrf.or
g 
derived from a study 
involving anonymous 
analysis by multiple 
labs.  49 human 
proteins, plus human 
and non-human bonus 
protein list determined 
by the sPRG BIC2007 
consensus study 
Various 
including 
HCT, LCQ, 
LTQ,  
LTQ-FT, 
Q-TOF 
.pkl 
.mgf 
 native .raw 
http://www.proteomecommons.org/data/sh
ow.jsp?id=802 
 
 
http://www.abrf.org/index.cfm/group.sho
w/ProteomicsInformaticsResearchGroup.
53.htm 
ABRF 
iPRG2008 
www.abrf.or
g/iprg has 
slides and 
posters  
mouse liver differential 
expression using iTRAQ 
Various  .mgf  
native.raw 
mzData 
mzXML 
.dta 
http://www.abrf.org/index.cfm/group.show
/ProteomicsInformaticsResearchGroup.53.
htm 
 
 
http://www.abrf.org/index.cfm/group.sho
w/ProteomicsInformaticsResearchGroup.
53.htm 
 
Aurum (Falkner et 
al., 2007) 
over 250 known human 
proteins 
MALDI-
TOF/TOF 
.mgf 
.pkl  
.t2d 
http://www.proteomecommons.org/data/sh
ow.jsp?id=90 
„Aurum homepage‟ 
http://www.proteomecommons.org/archi
ve/1122567790437/index.html 
The ISB‟s 
standard 
protein 
mix 
(SPMDB) 
(Klimek et 
al., 2008) 
18 proteins 1.1million 
spectra including 150 
replicate runs.  The 
standard is used 
regularly for 
determining 
performance of in-house 
MS instruments 
Species include rabbit, 
bovine, human, B. 
licheniformis, chicken 
LTQ, 
 LCQ Deca,  
Q-TOF, 
QSTAR, 
XCT Ultra, 
ABI 4800, 
ABI 4700,      
LTQ-FT 
native .raw  
mzXML 
http://regis-
web.systemsbiology.net/PublicDatasets/ 
 
Very large dataset, hence suitable for 
training and validation 
Most useful information is in the 
accompanying publication  
SASHIMI  
17 protein 
standard 
None 17 tryptically digested 
proteins, multiple 
species including bovine, 
rabbit, E.coli, chicken, 
horse  and others 
Micromass  
Q-TOF 
Ultima   
mzXML http://sashimi.sourceforge.net/repository.h
tml 
 
 
http://sashimi.sourceforge.net/repository.
html 
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SASHIMI  
7 protein 
standard 
None 7 protein mix: - rabbit 
glycogen phosphorylase, 
E. Coli beta-
galactosidase, bovine 
serum albumin, myosin, 
chicken ovalbumin, 
bovine serotransferrin 
LCQ mzXML http://sashimi.sourceforge.net/repository.h
tml 
 
http://sashimi.sourceforge.net/repository.
html 
 
SASHIMI  
7 protein 
ICAT 
standard 
None Cleavable ICAT labelled 
7 protein mix: bovine 
catalase, bovine alpha-
lactalbumin, chicken 
ovalbumin, bovine 
serum albumin, horse 
myoglobin, bovine 
serotransferrin, rabbit 
glycogen phosphorylase 
LCQ mzXML http://sashimi.sourceforge.net/repository.h
tml 
 
http://sashimi.sourceforge.net/repository.
html 
 
Experimen
tal Protein 
Mixture 
(Keller et al., 
2002b) 
Tandem mass spectra 
for 14 LC/MS/MS runs 
of control mixture A and 
8 LC/MS/MS runs on 
control mixture B 
(explained in paper)  
Thermo ion 
trap 
native .raw, .dta http://www.systemsbiology.org/extra/prote
in_mixture.html 
Data is downloaded from a password  
protected website (access can be granted 
for both non-commercial and commercial 
upon application by email) 
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Appendix IV Table 2 The identifiers considered to be true positives in this study performed in Chapter 4.  
They are derived from all the human proteins in the published ABRF sPRG 'BIC final protein list' 
(downloaded from: 
http://www.abrf.org/index.cfm/group.show/ProteomicsInformaticsResearchGroup.53.htm).  These 
identifiers were generated from SWISSPROT accession numbers using the PICR program at the EBI 
(http://www.ebi.ac.uk/Tools/picr).   
ENSG00000012223 
ENSG00000015475 
ENSG00000017427 
ENSG00000083750 
ENSG00000084207 
ENSG00000090013 
ENSG00000090382 
ENSG00000091513 
ENSG00000091583 
ENSG00000096087 
ENSG00000096696 
ENSG00000100311 
ENSG00000100448 
ENSG00000100665 
ENSG00000102081 
ENSG00000103275 
ENSG00000104267 
ENSG00000104879 
ENSG00000105220 
ENSG00000106804 
ENSG00000109107 
ENSG00000112855 
ENSG00000116030 
ENSG00000117450 
ENSG00000117601 
ENSG00000117984 
ENSG00000119392 
ENSG00000121691 
ENSG00000121769 
ENSG00000124588 
ENSG00000125730 
ENSG00000129559 
ENSG00000132141 
ENSG00000132693 
ENSG00000133703 
ENSG00000133742 
ENSG00000134202 
ENSG00000136810 
ENSG00000138207 
ENSG00000138798 
ENSG00000139610 
ENSG00000142168 
ENSG00000143416 
ENSG00000143437 
ENSG00000143947 
ENSG00000148180 
ENSG00000149575 
ENSG00000149925 
ENSG00000150991 
ENSG00000155876 
ENSG00000163631 
ENSG00000163815 
ENSG00000164111 
ENSG00000166347 
ENSG00000166710 
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ENSG00000167244 
ENSG00000167531 
ENSG00000167768 
ENSG00000167815 
ENSG00000169429 
ENSG00000170035 
ENSG00000170142 
ENSG00000170315 
ENSG00000170442 
ENSG00000170445 
ENSG00000170465 
ENSG00000170523 
ENSG00000171345 
ENSG00000171346 
ENSG00000171401  
ENSG00000171403 
ENSG00000172115 
ENSG00000172232 
ENSG00000172379 
ENSG00000172867 
ENSG00000173636 
ENSG00000173801 
ENSG00000174156 
ENSG00000174697 
ENSG00000174775 
ENSG00000175063 
ENSG00000176919 
ENSG00000181019 
ENSG00000182247 
ENSG00000182793 
ENSG00000185479 
ENSG00000186081 
ENSG00000186395 
ENSG00000186442 
ENSG00000186831 
ENSG00000186832 
ENSG00000186847 
ENSG00000186868 
ENSG00000187681 
ENSG00000188170 
ENSG00000188536 
ENSG00000196084 
ENSG00000196262 
ENSG00000196565 
ENSG00000198125 
ENSG00000198618 
ENSG00000203786 
ENSG00000204319 
ENSG00000204490 
ENSG00000205420 
ENSG00000205426 
ENSG00000206172 
ENSG00000206328 
ENSG00000206439 
ENSG00000211592 
ENSG00000211679 
ENSG00000211890 
ENSG00000211895 
ENSG00000211896 
ENSG00000211899 
ENSG00000213281 
ENSG00000213931 
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Paper 5 of the EngD  
- Mead, J.A., Bianco,L., Ottone,V., Barton,C., Kay,R.G., Lilley,K.S., Bond,N. and Bessant,C. (2009) 
MRMaid: the web-based tool for design of multiple reaction monitoring (MRM) transitions, Mol Cell 
Proteomics 8(4): 696-705 
paper5_2009_mcp.pdf 
Paper 6 of the EngD  
- Mead,J.A., Bianco,L. and Bessant,C. (2009) Mining proteomic MS/MS data for MRM transitions. Methods 
in Mol. Biol.;604:187-99 
paper6_2009_humana.pdf 
MRMaid user guide 
mrmaid_userguide.pdf 
MRMaid glossary 
mrmaid_glossary.pdf 
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Appendix V Figure 1 Work breakdown for the research work completed in Chapter 5 
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Paper 7 of the EngD  
- Mead J.A., Bianco,L., Barton C. and Bessant,C (2010) MRMaid-DB: a compendium of published SRM 
transitions. Journal of Proteome Research 9(1):620-5 
paper7_ 2010_jpr.pdf 
MRMaid-DB user guide  
mrmaid_db_userguide.pdf 
Folder („biomart‟) contains all the files needed for the set up of the Biomart instance for MRMaid-DB.  
Important files include: 
Biomart registry file required to set up the MRMaid-DB Biomart query interface 
myRegistryTransitionEns.xml  
Data to populate the MRM MySQL database (16 tables) 
csv_mrmaid_db_data_population.txt  
SQL dump file of the populated database 
mrmaid_db_dump.sql 
Apache server configuration file  
httpd.conf 
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Appendix VI Figure 1 Work breakdown for the research work completed in Chapter 6 
 413 
 
Appendix VII 
 
 
 
 
 
 
 
 
 
Appendix VII 
  
 414 
 
  
 415 
 
Paper 8 of the EngD  
- Mead, J.A., Bianco,L. and Bessant C. (2010) Free computational resources for designing selected reaction 
monitoring (SRM) transitions. Proteomics  Jan 13
th
 2010. [Epub ahead of print] 
paper8_ 2010_proteomics.pdf 
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